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Chapter 1: 
General introduction 
 
1.1 Obesity 
According to the World Health Organization (WHO), obesity is the world’s 
most widespread chronic pathological conditions, to the point that it has been 
defined as a global epidemic1. In fact, in the past years, overweight and 
obesity have reached epidemic proportions, with 1,9 billion overweight adults, 
600 million obese adults and over 100 milion obese children2. Obesity is a 
complex condition that leads to the impairment of the quality of life, and acts 
as a risk factor for the development of other diseases, such as cardiovascular 
diseases, diabetes, and hypertension3,4. 
Obesity is characterized by the excessive accumulation of body fat in 
various districts of the body. The most used parameter to define the severity 
of obesity is the body mass index (BMI), obtained by dividing the weight of the 
person expressed in kilograms by the squared height expressed in meters. 
The value obtained will fall in a category defining a pathological condition, as 
follows: 
- BMI < 16,5: severely underweight 
- 16,5 < BMI > 18,4: underweight 
- 18,5 < BMI > 24,9: normal weight 
- 25 < BMI > 29,9: overweight 
- 30 < BMI > 34,9: obese I class (moderate obesity) 
- 35 < BMI > 39,8: obese II class (severe obesity) 
- BMI > 40: obese III class (very severely obese) 
However, even though it is the most used index to describe body mass and 
obesity, BMI does not take into account other factors that influence weight, 
such as gender, age, and the percentage of lean/fat mass. Therefore, this 
index is usually accompained by the measurment of abdominal 
circumference, since the accumulation of fat in the visceral area is correlated 
to cardiovascular and metabolic disorders5. 
Many factors contribute to the development of obesity, such as the 
uncontrolled consumption of foods rich in fats and sugars, sedentary lifestyle, 
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and genetic background6. Hence, obesity is considered a multifactorial 
pathological condition, that can be linked to a chronic disruption of energy 
balance, defined as the ratio between the energy assumed through food 
consumption and the energy expenditure (basal metabolism, body 
temperature maintenance, physical activity). Therefore, when energy intake 
exceeds the energy expenditure, the excessive energy can be stored as fat, 
laying the basis for the development of obesity7,8. Energy balance is controlled 
by multiple physiological mechanisms, that involve a plethora of signals that, 
from the periphery, communicate with the brain, and viceversa9. Many organs 
partake in this intricated interplay, such as adipose tissue (that acts as 
storage), liver (the center for lipid and glucose metabolism)10, and central 
nervous system (CNS), that acts as an integration center for all the signals 
conveyed from the periphery, that will result in a behavioral response11 (Fig. 
1.1). Therefore, when these mechanisms are altered they may result in the 
onset of a pathological condition, for instance anorexia (with a low intake of 
energy) or obesity (with an excessive intake of energy)12,13. 
During the past few years, an increasing number of evidence 
demonstrated that obesity is not only the result of disrupted physiological 
patterns, but also environmental, social, and behavioral factors play a crucial 
role in the regulation of energy balance and fat accumulation14. For instance, 
the availability of calorie-dense foods, such as snacks, the reduction of 
physical activity due to a sedentary lifestyle, together with unhealthy eating 
habits, are all considered as pivotal factors for the development of obesity15. 
To date, an improvement of lifestyle, the introduction of healthier eating 
habits, and an increase of physical activity are the most effective ways to 
prevent the onset of obesity and eating-related disorders16. However, since 
the European Association for the Study of Obesity (EASO) estimated that 3,3 
billion people will be overweight by 203014, novel pharmacological approaches 
that would allow to regulate the metabolic alterations associated to this 
pathology are needed, in particular to control overfeeding. Therefore, in the 
past years, research has focused on investigating the mechanisms involved in 
the control of feeding and energy balance, that has led to the discovery of a 
variety of signaling pathways17,18, that are organized in a complex network of 
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heterogeneous molecules19–24, among which N-acylethanolamines (NAEs)25–28 
and N-acylphosphatidylethanolamides29 (NAPEs) have gained a great deal of 
attention. 
 
Fig 1.1: The pathways by which gut hormones regulate energy homeostasis. Schematic 
representation of the main pathways of the gut-brain axis. (Kevin G. Murphy & Stephen R. 
Bloom, Gut hormones and the regulation of energy homeostasis, Nature volume 444, pages 
854–859) 
 
1.2 The gut-brain axis 
The consumption of a quantity of calories that is sufficient to satisfy the 
energetic requirements of the body is of extreme importance. In fact, 
organisms that are able to regulate the intake of food based on the 
necessities are evolutionarly selected30. The reduction of the caloric intake or 
the increase of the energetic consumption lead to the activation of orexiant 
signals, that stimulate food intake and body weight gain. On the other hand, 
fat accumulation and the increase of body weight induce the release of 
anorexiant mediators, that decrease the caloric intake and the exploitation of 
fat storage31. 
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The gastrointestinal (GI) tract is innervated by the autonomic nervous system 
(ANS), that is divided in the parasympathetic and sympathetic divisions. The 
main nerves of the former are the vagus and the pelvic nerves, that exert and 
inhibitory tone on the GI tract; the main nerves of latter are the splanchnic 
nerves that have an exitatory effect on the digestive system. 
Then, a third component of the ANS was added, composed of the net 
of neurons located in the myenteric plexus32, called enteric nervous system 
(ENS)33. In general, the parasympathetic efferent nervous fibers of the gut-
brain axis, in particular vagal and pelvic efferents, are the main ways through 
which the activity of the ENS is regulated by the CNS during the digestive 
phase, whereas the sympathetic (splanchnic) efferent neurons are involved in 
the regulation of nociception and stress response34. 
The afferent fibers of the gut-brain axis are mainly represented by 
vagal afferents and spinal nerves, for the parasympathetic and sympathetic 
components, respectively. They convey to the CNS the stimuli produced in 
the intestine, that can be mechanical (distention and contraction) or chemical, 
such as nutrients in the intestinal lumen, hormonal stimuli, neurotransmitters, 
neuromodulators, citokynes and other mediators of inflammation35.  
The ingestion of food exerts the release of hormones and peptidic 
mediators, the modulation of the gastrointestinal motility and of bilio-
pancreatic secretions36. 
Incretins, such as the glucagone-like peptide-1 (GLP-1), and other 
hormones, like the peptide YY (PYY) and oxyntomodulin (OXM), secreted in 
the small intestine, inhibit the cephalic phase of digestion through vagal 
stimulation37,38. Moreover, other intestinal hormones, such as colecystokinin 
(CCK) and the gastric inhibitory peptide (GIP) inhibit gastric motility both by 
relaxing the fundus of the stomach and stimulating the contraction of the 
pylorus. These actions slow down gastric emptiyng, increase the duration of 
the digestion and of satiety, that, altogether, reduce caloric intake36,39. 
Since the vagus nerve innervates the majority of the GI tract, it plays a 
pivotal role in the regulation of the energy intake, hunger and satiety40. In fact, 
the pharmacological or surgical lesion of the vagus reduces the amount of 
food consumed in a meal and increases meal duration38,41. Moreover, it has 
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been demonstrated that a low frequency stimulation of the vagus induces a 
reduction of food intake38. However, the manipulation of the vagus nerve is 
paricularly difficult due to the anatomic connections between vagal, 
sympathetic and ENS fibers38. 
Circulating nutrients, that reflect the levels of nutrients in the periphery, 
are detected by the area postrema (AP), a circumventricular organ that lacks 
a functional blood-brain barrier (BBB) located on the floor of the fourth 
ventricle42, that, in turn, activates other nuclei in the brainstem41. In response 
to these stimuli, the brainstem, thanks to the activity of vagal efferent fibers, 
plays a crucial role in the control of the ENS, thus modulating many functions 
of the GI tract, and in the activation of neural circuits in the hypothalamus to 
reduce food intake. In particular, vagal afferents convey informations from the 
periphery to the nucleus of the solitary tract (NST)43, that, in turn, projects to 
hypothalamic nuclei43,44. The hypothalamus comunicates with vagal efferents, 
whose cell bodies are located in the dorsal motor nucleus of the vagus (DMV), 
through which it can slow gastric emptiyng32,45. Altogether, AP, NST and DMV 
form the dorsal vagal complex (DVC). 
In the hypothalamus, a variety of molecules and receptors involved in 
the control of appetite are produced, in particular endocannabinoids (ECs)46, 
neuropeptide Y (NPY), pro-opiomelanocortin (POMC), alpha melanocyte-
stimulating hormone (α-MSH), Agouti-related peptide (AgRP), cocaine- and 
amphetamine-regulated transcript (CART), CCK, and GLP-136,47. 
The endocannabinoid system (ECS) plays a crucial role in the regulation of 
energy homeostasis and feeding behavior. The receptors for ECs are in fact 
largely expressed in the CNS, in particular in the hypothalamus and 
brainstem, and in the periphery, in organs that are important for the 
metabolism, such as liver, pancreas, muscle and adipose tissue48,49. 
Moreover, ECS is involved in many physiological aspects, such as the 
modulation of appetite and reward, lipid storage, energy consumption and 
insulin homeostasis50–52. 
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1.2.1 The vagus nerve 
The vagus nerve is the tenth cranial nerve and innervates mainly the thoracic 
and abdominal cavities. Vagal fibers are not only composed of nerves but 
contains also glial and dendritic cells belonging to the immune system53. 
Moreover, paraganglia are often in close contact with its branches54,55 (Fig 
1.2). 
 
Fig. 1.2: Anatomy of the vagus nerve. Representation of the main branches of the vagus 
nerve. 
 
 Cervical and thoracic vagus 
The right and left branches of the cervical portion of the vagus nerve are both 
made of afferent and efferent fibers, that leave the skull from the jugular 
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foramen. Outside of the skull, the jugular (proximal) and nodose (distal) 
ganglions are located, where the cell bodies of sensitive neurons can be 
found. At this level, the vagus runs along the carotid artery and branches at 
the jugular ganglion into the auricular and meningeal branches, that provide 
sensorial innervation to the skin of the external acoustic meatus and to the 
dura of the posterior cranial fossa, respectively. Then, the pharyngeal branch 
departs at the nodose ganglion, and from its caudal part the superior 
laryngeal nerve branches, and runs under the carotid artery to the larynx, 
providing also smaller branches that innervate the caudal part of the pharynx 
and the esophagus. A cardiac cervical brach departs either from the cervical 
portion of the vagus or from the laryngeal nerve. This branch is called aortic56 
and contains a large number of afferent fibers receiveng stimuli from the 
baroceptors in the aortic arch. The laryngeal nerve departs at the level of the 
subclavian artery in the right part of the body, and at the level of the aortic 
arch in the left, then running along and innervating the trachea and the 
exophagus. Then, the fibres that innervate bronchi, lungs, and heart branch in 
the superior mediastinum. 
In particular, the afferent fibers that depart from the jugular ganglion 
produce neuroactvie peptides, such as substance P or Calcitonin Gene 
Related Peptide (CGRP), whereas those that depart from the nodose 
ganglion do not produce these molecules57,58. 
Moreover, abdominal and thoracic branches contain afferent or 
efferent fibers that decussate from one side to the other54,59,60. In the rat, there 
are few lines of retrotracing evidences about decussating efferent branches, 
however, possibly 20% of afferent branches may decussate in the thoracic 
cavity61. 
 Abdominal vagus 
The anterior (or ventral) portion, along with the left cervial vagus, branches in 
the common hepatic, gastric and coeliac portions. In the rat, there are about 
11000 nervous fibers in each subdiaphragmatic branch, of which about 8000 
are afferent and 3000 efferent. Moreover, less than 1% of all the fibers is 
myelinated. The common hepatic branch is important for the communication 
between the immune and nervous systems and for the thermoregulation, and 
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contains about 3000 fibres, of which 2200 are afferent, 200 efferent and 600 
non-vagal62. The terminations of vagal afferents end in the connective tissue 
around the intrahepatic triads, extrahepatic bile ducts, portal vein and 
paraganglions63. Other afferents run along the common hepatic branch and, 
to a lesser extent, along the periarterial plexus of the common hepatic artery, 
around the portal vein63. Bile ducts are more innervated compared to portal 
vein: here, vagal afferents are tightly connected to the main branches of bile 
ducts and are found also in the walls of intra- and extra- biliary ducts63. This 
branch is called hepatic, but it innervates also the pylorus, the pancreas and 
the proximal duodenum64,65. Once the hepatic branch reaches the hepatic 
proper artery, it moves towards the hepatic common and gastroduodenal 
arteries, and then it divides in two branches, one following the right gastric 
artery (to the stomach), an the other following the dorsal and ventral duodeno-
pancreatic arteries (to the proximal duodenum and pacreas). The anterior 
gastric branch innervates the ventral part of the stomach and, through small 
fibers inside the circular muscle of the pylorus, resches the duodenum. 
The dorsal (posterior) part of the gastric branch, on the other side, 
enters the dorsal part of the stomach, near the cardias, running along the left 
gastric artery, and innervates the proximal duodenum through trans-pyloric 
fibers. In the stomach, vagal nerves are in both layers of smooth muscle, in 
the myenteric plexus and in the lamina propria. The fibers located in the 
longitudinal and circular layers have been described as long axon bundles 
parallel to muscles and connected by short branches64,65. 
The most common vagal afferent ending is the intraganglionic laminar 
ending (IGLE), mainly linked to the neurons of the myenteric plexus66. This 
type of neuron is also observed in the whole intestine, both small and large, 
where vagal afferents penetrate through the myenteric plexus to the circular 
smooth muscle and the submucosa, to form a net of axon branches in the 
lamina propria. Thus, it has been hypothesized may function as distention 
receptor67,68. Then, the ventral celiac branch, after leaving the ventral portion 
of the esophagus, reaches the dorsla celiac branch near the left gastric artery. 
Both these branches go down the celiac artery to reach the celiac ganglion, 
9 
 
and then the small and large intestine running along the superior mesenteric 
artery. 
 Role of the vagus nerve in the homeostatic control of energy 
balance 
The intestine constantly sends signals about the quantity and quality of the 
nutrients to the CNS, that is able to process a variety of inputs and to 
transform them in information of various nature, that will determine a 
behavioral response. These processes can engage either the somatic or the 
autonomous nervous systems, the former being mainly controlled by the 
prefrontal cortex (PFC), hippocampus (Hippo) and nucleus accumbens 
(NAcc) and being influenced by the emotional cues linked to feeding; the 
latter, on the other hand, is more involved in the homeostatic control of energy 
balance. In particular, the parasympathetic nervous system, composed of 
afferent (sensitive) fibres that convey signals to the CNS, and efferent (motor) 
fibres, that convey signals from the CNS to the parasympathetic ganglions 
near target organs, receive stimuli from the brainstem, and in particular from 
the DVC and pars reticolata10,69. This bidirectional pathway, or vago-vagal 
reflex, is the major extrinsic neural way involved in the control of pancreatic 
and GI tract functions70. The main stimuli received by vagal afferents are: 
Mechanic stimuli. The GI tract is rich in mechanoreceptors, in 
particular located in the mucosa, sensitive to friction71, and on the outer 
muscle layer, sentitive to distention, such as IGLE fibres72. 
Chemicals and nutrients. In the rat, the majority of vagal fibers that 
innervate the duodenum respond, apart from mechanic stimuli, to chemical 
stimuli, such as pH and osmolality70. Moreover, these fibres respond to 
peptides acting in the intestine, such as CCK73,74, GLP-175, serotonin (5-HT)76, 
somatostatin75 and interleukin-β (IL-β)77. 
Other stimuli. Vagal afferents are also sensitive to temperature, 
osmotic pressure74 and pain. For example, a prolonged gastric distention 
activates vagal afferents and induces Fos in the NST78. 
Vagal afferent teminals are mainly found, in the CNS, in the NST, AP, 
and, to a lesser extent, in the DMV and in the trigeminus. The terminations of 
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the cardiac and pulmonar vagal afferents are located in the lateral subnuclei 
of the NST, whereas the terminations of the alimentary canal are found in the 
medial subnuclei of the NST79–81. Moreover, many of vagal afferents of the 
jugular ganglion produce peptides such as CGRP and substance P82,83, 
whereas glutammate has been found in cardiac afferents. In the same way, it 
has been demonstrated that pharmacological blockade of NMDA receptors is 
able to abrogate gustative inputs in the NST84. In fact, many studies suggest 
that ionotropic glutammate receptors, including NMDA, in the NST play a 
crucial role in the control of eating. For example, the blockade of NMDA 
receptors with a microinjection of dizocilpine, a non-competitive antagonist of 
this receptor, leads to a delay of the onset of satiety and to an increase of 
food consumption85. Moreover, the electric stimulation of the NST results in a 
current (either eccitatory or inhibitory) in the DMV, suggesting a connection 
between these two areas86. Moreover, pharmacological and histological 
evidences showed the presence of glutammate receptors in the DMV87, where 
the cell bodies of the neurons that innervate the GI tract are located88,89. In 
this area, two distinct populations of preganglionic neurons modulate the GI 
functions: on one hand cholinergic neurons, located in the rostral DMV and 
increase gastric motility90; on the other, non-adrenergic non-cholinergic 
(NANC) fibres, located in the caudal DMV and that decrease GI motility90,91. 
Therefore, the DMV is characterized by two parallel neuronal pathways that 
modulate gastric motility: an exitatory cholinergic pathway that increases 
gastric motility, and an inhibitory NANC pathway that slows gastric functions. 
Intraganglionic vagal afferent terminals are located in the capsule of 
connective tissue of the ganglions of the myenteric plexus, between the 
longitudinal and circular layers of smooth muscle32, and, therefore, respond to 
passive distention and active contractions of the muscles72. This type of vagal 
afferent has been found in the esophagus and along the GI tract92,93. 
Intramuscolar bundles are almost exclusively located in the 
longitudinal and circular layers of the stomach smooth muscle64, where the 
presence of food is detected also by vagal afferents found in the gastric 
mucosa, sensitive to mechanical stimuli94, whereas the quantity of ingested 
food is detected by vagal afferents located in the outer muscle layer, sensitive 
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to distention95. Moreover, vagal afferents of the gastric mucosa can respond 
to hormones released locally, such as leptin and ghrelin96. In fact, vagal 
afferents express leptin receptors97,98. In addition, the appetite-stimulating 
effects of ghrelin are abolished by total subdiaphragmatic vagotomy (TVX) or 
the treatment with capsaicin in rats99. Hence, since vagal neurons located in 
the nodose ganglia express ghrelin receptor99,100, it maybe hypothesized that 
ghrelin, like leptin, acts through the activation of vagal afferents.  
Several studies suggest that the inhibitory effects on feeding mediated 
by CCK101 involve vagal afferents, that express the CCK receptor A 
(CCKA)102,103. In the periphery, these neuronal terminals are located in the 
walls of the GI tract, both in the mucosa and in the muscolar layer104. 
Moreover, it has been demonstrated that the inhibition of gastric emptying is 
mediated by CCKA-expressing vagal afferents105. In addition, it has been 
observed that a total or selective vagotomy abolished or decreased, 
respectively, the satiety effect of CCK106. Furthermore, another important 
study demonstrated that the treatment with capsaicin, that destroys 
unmyelinated fibres (including unmyelinated vagal fibres), dampened the 
satiety effect of CCK107. 
Food intake, and, in particular, the intake of carbohydrates, fats and 
proteins, induces the release of GLP-1, that seems to be induced indirectly by 
the stimulation of the nerves of the apical portion of the intestine, or directly by 
the contact with the lower portion of the intestine108,109. Since GLP-1 
modulates pancreatic secrestions, it plays a crucial role in glucidic 
homeostasis110,111. The peripheral administration of GLP-1 induces satiety in 
rats and humans112,113. This effect may be due to the paracrine stimulation of 
the gastric mucosa by vagal afferents: in fact, GLP-1 receptor is expressed in 
the nodose ganglion, and, moreover, in the CNS, in the AP114,115, NST and 
lateral parabrachial nucleus (LPB)116. 
 
1.2.2 Mediators of energy balance 
 Peripheral signals 
The GI tract releases more that 20 different regulators and hormones, that are 
involved in the regulation of many physiological processes37. The release of 
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hormones such as PYY, GLP-1 and OXM is triggered by gastric distention 
and by the interaction between nutrients and the intestinal walls117,118, and, 
once released, intestinal hormones act on target organs, such as endocrine 
glands, smooth muscle and peripheral nervous system (PNS)39,119. It is well 
known that hormones and intestinal peptides play a crucial role in the 
modulation of hunger and satiety120: many studies support that signals like 
CCK, PYY, GLP-1 and OXM, on one side, reduce food intake by reducing the 
levels of orexigenic signals while increasing anorexigenic signals in the 
hypothalamus121,122, and, on the other, by triggering negative feedback 
mechanisms on the intestinal transit, that contribute to enhance the feeling of 
satiety during the intermeal interval123, hence aiding the regulation of the after 
meal GI motility110,118. 
Ghrelin is a peptide hormone produced by the stomach and released 
into the bloodstream, initially discovered for the affinity for the growth 
hormone secretagogue receptor (GHS-R). It is a peptidide chain of 28 
aminoacids and undergoes one post-translational modification that involves 
the addition of one molecule of ottanoic acid on the serine 3119,124, necessary 
for the binding to the GHS-R and to cross the BBB125. Ghrelin is defined as 
the “hunger hormone”125, and its circulating levels increase during fasting and 
decrease after a meal. Moreover, the administration of ghrelin in the CNS 
produces an increase of food intake and the release of the growth hormone 
(GH) in rats, whereas its peripheral administration reduces the use of fat from 
adipose storage126. Several studies show that the disruption of the ghrelin-
mediated signaling induce several alterations in the control of energy 
homeostasis127,128. The pharmacological inhibition of the GHS-R was thought 
to be a valid strategy for the treatment of obesity. In fact, GHS-R antagonists 
are able to decrease food intake in fasted animals127, and that the vaccination 
against ghrelin induces weight loss129. However, even though promising 
results have been obtained from animal models, an irreversible approach, 
such as vaccination, is not considered safe for human treatment124. Ghrelin 
agonists, on the other hand, may be used for the treatment of anorexia in 
oncologic patients, that experience appetite loss130, in patiens with dialysis-
induced malnutrition130, or to improve gastric emptying in diabetic patients with 
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gastroparesis131. Moreover, it has been shown that the gene encoding for 
ghrelin encodes for another peptide, called obestatin. preliminary studies 
demonstrate that central administration of obestatin reduce food intake, while 
the periheral administration reduce body weight132. These effects seem to be 
exerted by the activation of the GPR39, an orphan receptor. However, further 
studies did not confirm the previous results, suggesting that obestatin does 
not bind GPR39 and does not control feeding behavior133,134. 
PYY is a peptidic hormone related to the neuropeptide Y (NPY). Both 
these peptides have a structural feature characteristic of the PP proteins and 
exert their action by binding to Y receptors. There are two endogenous 
isoforms of PYY, based on the presence of the N-terminal, PYY1-36 e PYY3-36, 
the latter having hagher affinity to Y2 receptor (Y2R). In fact, the effects of the 
PYY3-36 are dampened by the administration of a Y2R antagonist135 and 
abolished in Y2R-KO mice121. Preliminary studies demonstrated that the 
peripheral administration of PYY3-36 reduces foof intake in rodents and 
humans121. However, these preliminary findings were controversial, since 
many laboratories could not reproduce them136. Then, further studies 
demonstrated that the effects of the peripheral administration of PYY3-36 on 
feeding were dampened by stressful conditions, such as the lack of handling 
or the introduction to a new environment137,138. Many subsequent studies then 
confirmed that the acute administration of PYY3-36 reduces food intake113,139. 
The fact that the biological effects of PYY3-36 are dampened by the 
pretreatment with a Y2R antagonist135 and abolished in Y2R-KO mice136 
further confirm that this peptide acts through the Y2R. Furthermore, an altered 
control of energy homeostasis is observed in PYY-KP mice, thus validating 
the role played by this peptide in its regulation140,141. 
The role of the CCK on the esocrine pancreas and gallbladder became 
clear when, in 1973, it was the first intestinal hormone proven to be involved 
in the control of feeding behavior142. CCK is released during the aftermeal 
period and exerts its effect through the activation of the CCK receptor 1 
(CCK1), expressed on vagal fibres. The pretreatment with antagonists of this 
receptor increase food consumption in rodent and humans124,143, and Otsuka 
Long-Evans Tokushima rats, KO for this receptor, are obese and 
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hyperphagic143. However, continuous infusions of CCK failed to reduce food 
intake, and, although the intermittent administrations reduce short-term food 
consumption, this effect is dampened by the compensatory increase of food 
intake during the intra-administration period144. Moreover, some studies 
suggest that physiological concentration of CCK do not activate vagal circuits, 
suggesting that the action of this peptide on FI is mainly due to its paracrin 
action more than to an endocrine one145.  
The pancreatic polypetide (PP) is synthesized and released by the 
endocrine pancreatic parenchyma and has a high affinity for Y4 and Y5 
receptors. As for PYY3-36, PP levels increase after a meal, and decrease 
during fasting. Acute PP administration reduce food intake in mice and 
humans146,147, while chronic administrations reduce body weight in ob/ob 
mice148. It has been hypothesized that the anorexiant effect of PP is due to the 
delay of gastric emptying147,149. 
Amylin is a 37 aminoacids-long peptide, belonging to the calcitonin 
peptides family, that is released, as insulin, by pancreatic β-cells after the 
ingestion of food. Although its main function seems to be linked to glucose 
homeostasis, it reduces food intake after peripheral administration150. In fact, 
the administration of Pramlintide, a synthetic analogous of amylin, reduces 
body weight in patients with type 1 and 2 diabetes151,152. The anorexiant 
effects of amylin may be due to the modulation of the serotonergic, 
histaminergic and dopaminergic systems, as long as the inhibition of NPY 
release153. Moreover, many studies reported that increased circulating levels 
of amylin are observed in obese patients154. 
GIP is a polypeptidic chain composed of 42 aminoacids, synthesized 
and released by the K cells of the duodenum after food consumption. There 
are no clear studies linking this peptide to the regulation of food intake, 
although mice with the genetic deletion of the gene encoding for its receptor 
are resistant to the diet-induced obesity (DIO)155. Therefore, further studies 
are required to investigate the physiological mechanism involved in the 
mechanism of action of GIP, that may involve adipocytes and neural circuits in 
the CNS156. 
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GLP-1 is co-secreted with PYY by the L cells of the intestinal mucosa 
upon the ingestion of food. It is produced by the cleavage of a precursor, the 
preproglucagone, that, after enzymatic cleavage, produces several 
biologically active peptides, such as glucagone, GLP-1 and -2 and OXM. 
GLP-1 has two different active forms, GLP-17-37, found in the periphery, and 
GLP-17-36 amide, found in the CNS38. GLP-17-36 amide- positive neurons have 
been found throughout the CNS, in particular in the paraventricular nucleus 
(PVN), in the dorsomedial nucleus (DMN), in the DVC, in the hypophysis and 
in the thalamus157. Moreover, GLP-1 is a potent incretine: in fact, its release 
after food consumption stimulates the release of insulin38,124. Furthermore, 
central administration of GLP-1 drastically reduces food intake in rodents, 
whereas peripheral administration reduces appetite in both rodents and 
humans158. Exendin-4 is an agonist of the GLP-1R, while its cleaved form, 
exendin9-39, is an antagonist of the same receptor. It has been demonstrated 
that the acute central administration of exendin9-39 increase food intake, and 
its chronic administration increases body weight124,158. Although it seems that 
endogenous GLP-1 is involved in physiological processes, such as the 
regulation of feeding, in a mouse model knock-out for the GLP-1R feeding 
and body weight are not altered158. Moreover, a phase III clinical trial 
demonstrated that exendin-4 ameliorates glucose homeostasis in patients 
with type 2 diabetes, and that it induces a reduction of food intake159. Along 
with exendin-4, the GLP-1R agonist exenatide has already been approved for 
the treatment of type 2 diabetes in co-treatment with metformin. 
GLP-2 shares the same synthesis pathway as GLP-1, glucagone and 
OXM. High concentrations of this peptide have been found in the brain, and 
its central administration reduces food intake160. However, in the periphery, 
GLP-2 is involved in the regulation of gastric motility, digestion and absorption 
of nutrients, and does not seem to influence appetite161. 
OXM is a 37 aminoacids-long plypeptidic chain produced by the 
cleavage of preproglucagone. Like GLP-1, is released upon the ingestion of 
food, and, when administered centrally, reduces food intake162. Although 
many studies suggest tha OXM exerts its biological action through the 
activation of the GLP-1R, supported by the fact that its anorectic effect is 
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abolished in GLP-1R KO mice, it seems that these effects do not perfectly 
match those exerted by GLP-1R38,124. In fact, it has been demonstrated that 
the administration of exendin9-39 in the arcuate nucleus (Arc) abrogates the 
OXM-induced anorectc effects, but not thos of GLP-1162. Moreover, chronic 
administration of OXM, either peripheral or central, induce a body weght 
reduction greater than that of pair-feeding animals, suggesting that OXM may 
act by increasing energy expenditure162. 
The role played by glucagone in the control of glucose homeostasis is 
well defined. It is produced by α-cells of Langerhans islets in the pancreas 
and increases glucose levels in response to a hypoglycemic state. Moreover, 
glucagone improves the stress response by increasing energy expenditure163. 
The administration of glucagone reduces food intake, probably through the 
modulation of the vagal tone and of the gastric emptying164. Furthermore, 
recent findings demonstrated that the co-administration of antagonists for 
glucagone receptore and GLP-1R ameliorates insulin sensitivity and DIO165.  
Insulin, produced by the β-cells of the pancreas, is released after the 
ingestion of food and induces its very well-known hypoglycemic effects166. 
Moreover, it acts on the CNS as a satiety factor: in fact, the central 
administration of insulin dose-dependently reduces food intake and body 
weight gain in rodents and baboons167,168. Insulin is carried in the CNS by a 
receptor-mediated transport169. Furthermore, insulin receptors are expressed 
throughout the brain, in particular in the Arc, the DMN and PVN170. 
 Neuroactive mediators 
Neuropeptides are small proteic molecules, released from the cells of the 
nervous system in response to a stimulus, able to control the comunication 
between neurons by binding secific receptors. Hypothalamic peptides may be 
classified based on the effect they exert on feeding behavior. On the 
orexigenic side, NPY is produced by neurons in the Arc that project to other 
hypothalamic nuclei171. Although NPY can exert several different effects on 
feeding behavior172, the most known is in the increase of appetite upon central 
administration173. The synthesis of NPY occurs in Arc and its release in the 
PVN, and both the processes are negatively regulated by leptin and insulin, 
and positively regulated by ghrelin173. Five receptors for NPY have been 
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described: Y1, Y2, Y3, Y4, Y5 and Y6; among them, Y5 receptor is the most 
involved in the modulation of NPY effects on feeding174,175. 
Another orexigenic peptide is the AgRP, a 132 aminoacid chain 
exclusively expressed in the Arc. It has been demonstrated that, upon central 
administration, either in the PVN or DMN, AgRP increases food 
consumption176. 
Hypocretins 1 and 2, also known as orexins A and B, are 
neuropeptides produced in the lateral hypothalamus (LH) and linked to the 
stimulation of appetite by binding their receptors, OX1R and OX2R. OX1R is 
mainly expressed in the ventromedial hypothalamus (VMH), whereas OX2R in 
the PVN177. Moreover, orexin-secreting neurons are located in the LH and 
DMH, and project to other hypothlamic nuclei, in particular to the Arc178,179, 
and input on NPY secreting neurons expressing OX1R178. 
Apart from orexigenic signals, there are a lot of anorexigenic peptides 
acting in the hypothalamus: CART is a neuropeptide synthesized in the DMH, 
PVN, LH and Arc180; melanocortins, in addition, are bioactive peptides that 
derive from the pro-opiomelanocortins (POMC) after a tissue-specific post-
translational cleavage181. The gene encoding for POMC is expressed in 
several tissues, such as hypothalamic neurons, the adenohypophysis and the 
pars intermedia182. Moreover, the intermedial lobe of the hypophysis produces 
α-MSH, an anorexiant peptide that binds to melanocortin receptors 3 and 4 
(MC3R and MC4R), expressed by brain areas known to be involved in the 
control of feeding behavior and in telencephalic structures, such as the 
cortex182. 
The corticotropin-releasing hormone (CRH) is a 41 aminoacids-long 
hormone and regulates the secretion of the adrenocorticotropic hormone 
(ACTH) from the hypophysis. CRH is highly expressed in the PVN and, when 
centrally administered, inhibits food intake and reduces body weight in rats171. 
On the other hand, the periheral administration of CRH in humans increases 
energy expenditure and fatty acid oxidation (FAO)171. Moreover, the infusion 
of leptin increases the expression of CRH, whereas the pretreatment with a 
CRH receptor antagonist attenuates the leptin-induced reduction of food 
intake and body weight171. 
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Among neurotransmitters, histamine is a hypophagic agent synthesized from 
the decarboxylation of histidine, exerted by the histidine-decarboxylase 
(HDC)183. In fact, the central infusion of α-fluoromethylhistidine, an inhibitor of 
HDC that, therefore, leads to a decrese of central histamine, is able to disrupt 
feeding and hydration patterns, along with deambulation184. Moreover, it has 
been demonstrated that histaminergic system is involved in the anticipatory 
phase of eating: in fact, the specific activation of the E3 subdivision of the 
ventral tuberomammillary nucleus (vTMN)185 is rats with restricted access to 
food. However, several lines of evidence suggest that histamine is also 
involved in the consummatory phase of feeding behavior, during which a rapid 
transitory increase of hypothalamic histamine levels is observed186. 
Histamine binds to 4 GPCR receptors: H1R, H2R, H3R, H4R187,188. 
H1R, coupled with Gq, is expressed in the brain, bronchial epithelium, 
cardiovascular system, liver and cells of the immune system189. In the CNS is 
expressed in the VMH, that is likely the site where histamine exterts its 
appetite-suppressing effects189. 
H2R, coupled with Gs, is expressed in the gastric mucosa, in the 
muscular layer of arteries, in the cells of the immune system and in the 
brain189. 
H3R, coupled with Gi/o, is highly expressed in the CNS, where it acts 
as presynaptic autoreceptor, thus inhibiting the release of histamine190. 
Moreover, it acts as heteroreceptor, modulating the release of other 
neuronsmitters, such as acetycholine, dopamine, noradrenaline, and 
serotonin.  
Lastly, H4R has a primary role in the inflammatory response189. 
Several studies have demontrated that the intra-hypothalamic 
administration of histamine, where the activation of H1R induces satiety, 
increases mRNA expression levels of the uncoupling protein 1 (Ucp1), marker 
of energy expenditure, in the brown adipose tissue (BAT), and, moreover, 
increases the electrophysiological activity of the sympathetic nerves around 
that area191,192. Furthermore, it is likely that histamine released in the 
periphery is involved in metabolic and homeostatic processes linked to food 
consumption193. 
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1.2.3 Central circuits involved in the homeostatic control of feeding 
behavior 
Feeding and metabolism are regulated by complex systems in the CNS194. 
The main area of the CNS involved in the control of food intake is the 
hypothalamus, that is costantly informed by signals secreted in the periphery 
about the nutritional and energetic statuses of the body43. These signals are 
then integrated and conveyed to other brain areas. Satiety signals are 
generated in the GI tract during meal consumption and modulate feeding 
through the release of peptides that reach the NST via the vagal afferent 
system195 (Fig. 1.3). 
Among all the systems of the gut-brain axis that interplay in the 
regulation of feeding behavior, an important role is played by the ECS. In the 
CNS, this system plays a role in the motivation for the research and 
consumption of food, through the activation of mesolimbic pathways that 
regulate reward196. N-arachidonoylethanolamide (or anadamide, AEA) and 2-
arachidonoylglycerol (2-AG) are the most studied ECs197 and have a 
hyperphagic effect by acting on CB1 receptors in the PVN198 and in the lateral 
hypothalamic area (LHA), or by influencing the action of hormones like 
ghrelin197. The role of this system has gained a great deal of attention, starting 
from the development of synthetic compounds acting on CB1 receptor, the 
rimonabant, as a potential target for the treatment of obesity50 
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Fig. 1.3: Crosstalk between circuits modulating feeding behavior. Lori M. Zeltser, Feeding 
circuit development and early-life influences on future feeding behavior, Nature Reviews 
Neuroscience volume 19, pages 302–316. 
 
 
 Brainstem 
The brainstem is one of the most important areas for the homeostatic control 
of feeding behavior, since it acts as an integration center between sensitive 
inputs and motor outputs. the NST is located in the most caudal portion of the 
brainstem, and represents the first relay station of vagal afferents, that convey 
the informations about the quantity of food consumed from the periphery199. In 
particular, it is in contact with the preganglionic vagal neurons, in order to 
regulate nutrient adsorption in the alimentary canal79, and sympathetic 
preganglionic nerves, in order to modulate energy expenditure10. The NST is 
then connected with other brain areas involved in the homeostatic control of 
feeding behavior: in particular, it has direct inputs towards the hypothalamus, 
and contacts indrectly telencephalon and the cerebral cortex10. Moreover, it is 
known that part of the NST projections that contact the hypothalamic neurons 
are the A2 noradrenergic fibres200, and many studies have demonstrated that 
the ablation of these fibres dampens the effects of some satiety factors, such 
as CCK199. 
The NST is composed by different subnuclei that specifically respond 
to stimuli received10. For instance, the gustative fibres of the tongue and the 
posterior oropharynx input in the rostral part of the NST79, whereas the 
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afferents from below the diaphragm project to the caudal part of this 
nucleus69. Neurons of the DMV respond mainly to gastric distention201, while 
the neurons below the AP respond mainly to duodenal signals, whereas the 
neurons located in the medial part of the NST respond both to gastric and 
duodenal signals201. Notably, in this nucleus, there are neurons that express 
POMC97, melanocortin202 and leptin97 receptors. 
The AP, in close contact with the NST, is another important nucleus 
involved in the homeostatic control of feeding behavior, and expresses 
receptors for amylin, GLP-1 and ghrelin. Moreover, it is able to convey 
informations about gastric emptying42,203. Studies conducted in rats that 
underwent the surgical lesion of the AP highlighted the involvement of this 
area in the regulation of the signals sent from the periphery204,205. The AP is a 
circumventricular organ outside the BBB, that lacks tight junctions and is rich 
in fenestrated capillaries206. Thanks to these features, some peptides and 
other signaling molecules may have direct access to the AP wich is one of the 
main integration stations in the CNS that conveys numerous physiological 
signals from the bloodstream206. Moreover, many studies demonstrated that 
AP projects extensively to other nuclei of the brainstem and to the 
hypothalamus207. 
In particular, it projects to the NST and LPB, known integrative stations 
of the brainstem207,208. Moreover, neurons of the AP project direclty to the 
dorsal and medial subnuclei of the NST207. Furthermore, the AP projects to a 
lesser extent to the nucleus ambiguous, to the DMV, the dorsal parts of the 
tegmental nucleus and to the spinal tract of the trigeminus207. 
The afferent neurons pojecting to the AP come from functionally 
distinct parts of the brainstem and of the hypothalamus. Apart from the 
bidirectional connections to and from the NST and LPB, the majority of the 
hypothalamic connections comes from the PVN and the DMH207,209. Moreover, 
it has been demonstrated that the AP receives direct inputs from vagal 
afferents207. 
It has been observed that the AP contains the receptors for a variety of 
hormones that regulate feeding behavior, such as CCK, intestinal vasoactive 
peptide, NPY, vasopressin (AVP), substance P and insulin210,211.  
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Another important brain structure involved in the homeostatic control of 
feeding behavior is the LPB, located in the pons. Its anatomical position, 
between the medulla and the prosencephalon, allows it to integrate the 
signals coming from both ways, hence helping to organize behavioral 
responses212. Moreover, the LPB integrates a variety of sensitive inputs, 
associated to food consumption or to stress212,213. In particular, the LPB 
receives sensitive informations mainly from the NST214, and projects to the 
PVN and Arc10. 
 Hypothalamus 
The mammalian hypothalamus consists in over 40 nuclei in histologically 
distinct areas215. The medial part of the hypothalamus is mainly composed of 
large nuclei that receive bloodborne stimuli and pass them down onto other 
hypothalamic nuclei, controllig endocrine responses. Then, the lateral portion 
is a large area that bridges the hypothalamic nuclei with extrahypothalamic 
brain areas, such as the cortex and the limbic system215. 
Since its lesion induces hyperphagia and body weight gain, the VMH 
has been identified as the satiety center in the hypothalamus23. On the other 
hand, the LH has been identified as the “hunger center” of the hypothalamus, 
since its lesions induce weight loss216. 
Among hypothalamic nuclei, the PVN interplays with the endocrine 
and autonomic nervous systems and is involved in many behavioral 
responses. Moreover, the PVN is able to comunicate with the preganglionic 
neurons that innervate the pancreas, and with the parasympathetic and 
sympathetic nervous systems217. PVN neurons project towards di- and 
telencephalic structures218 and to other hypothalamic areas, such as DMH, 
VMH and Arc218,219. In general, the PVN can be divided in magnocellular and 
parvocellular. Magnocellular neurons contain oxytocin (OXY) and AVP, that 
are released in the posterior lobe of the pituitary gland220. Many medial 
parvocellular neurons contain CRH and tireotropin-releasing hormone, that 
are released in the ME. The dorsal, ventral and lateral parvocellular neurons, 
on the other hand, project to the periacqueduttal grey, the LPB and the NST, 
and to both sympathetic and parasymathetic preganglionic neuronal 
populations220,221. The better-known endocrine signals produced by the PVN 
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are those of the magnocellular projections, that reach the posterior part of the 
pituitary gland releasing OXY and AVP, and those of the parvocellular 
projections, that release CRH and TRH. The non-endocrine signals are those 
coming from the dorsal raphe, LPB, DMV and NST222. Therefore, the PVN 
seems to be in the best position to integrate internal stimuli, such as the 
availability of nutrients in the GI tract and adipostatic signals, to thus organize 
endocrine and autonomic responses10. 
The supraoptic nucleus (SON) lies behind the optic chiasma, and is 
composed, as the PVN, of magnocellular neurons10. These neurons contact 
the posterior part of the hypophysis, through which the SON contributes to the 
endocrine control of the organism. The major inputs to the SON come from 
the branstem, in particular from the NST223. 
The Arc is a hypothalamic region in close contact with the ME, a 
circumventricolar organ rich in fenestrated capillaries that lacks a functional 
BBB224. It contains two major neuronal populations that control appetite and 
satiety. The former is composed of orexigenic neurons, and express NPY and 
AgRP225, while the latter contains anorexigenic neurons, that contain α-MSH 
(derived from POMC), and CART10,225.  
The TMN is a group of large cells located in the tuberal caudal and 
mammillary rostral areas and form the median hypothalamic area. In the 
medial part of the vTMN226 a complex network of histaminergic neurons is 
found, that project to several brain areas193,227. These neurons are involved in 
many physiological responses, such as circadian rythm, emotions, learning 
and memory228,229. 
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1.3 Gut microbiota 
Microbes are everywhere, and it is known that microbial populations are 
resident, in humans, on the skin, in the oral cavity, in the urogenital tract and 
in the gastro-intestinal (GI) tract. In all these areas, the microbial populations 
partake in the physiological control of the homeostasis by establishing a 
symbiotic relationship with the host230. Human microbiome is involved in many 
mechanisms that allow the maintenance of the well-being of the host, like 
metabolic and immunological processes231. These lines of evidence, 
therefore, led to hypothesize the existence of the “olobiome”, represented by 
the symbiotic interaction between the microbiome and the host232. On the 
other hand, this interaction may play a role in the onset of pathological 
conditions, and, therefore, in the past 20 years many studies were conducted 
to demonstrate how feeding behavior can alter the gut microbiome233. In fact, 
it has been shown that different host’s characteristics, like genetic 
background, gender, age, and immunological profile, play a pivotal role in 
shaping the gut microbiome234, as long as environmental and behavioral 
factors, such as pharmacological therapies, surgeries, physical activity or 
stressful conditions235. In newborns, the microbiota is spread during delivery 
and is, then, influenced by a variety of factors, such as the type of delivery 
(natural or c-section) or breastfeeding236. For example, the microbial flora of 
naturally delivered babies is characterized by the presence of Lactobacillus, 
Prevotella, and Atopobium, whereas in babies delivered by c-section the flora 
is rich in Staphylococci, as for the mother’s skin236. Moreover, in the recent 
years, new lines of evidence show that the intrauterine environment is not 
sterile, but colonized by Enterococcus fecalis, Staphylococcus epidermis, e 
Escherichia coli237. The newborn’s flora, rich in aerobic bacteria, undergoes 
changes during the post-natal period towards a flora composed mainly by 
anaerobic bacteria238. This first colonization happens together with the 
activation of the hypothalamus-pituitary-adrenal axis (HPA axis), that has a 
strong impact on the ENS231. Moreover, it has been shown that the 
metabolites produced by the enteric flora may induce the release, by the 
enteroendocrine cells of the GI tract, of mediators involved in the control of 
feeding, lipid storage, and energy homeostasis7,239. Among these mediators, 
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short-chain fatty acids (SCFAs) activate the GPR41 receptor expressed by 
the enteroendocrine cells240, involved in the gut microbiota-mediated control of 
adiposity and inflammatory processes241. 
Then, the population of the gut microbiome becomes more stable 
during adult life242, with a last change during the elderly life: in fact, aging is 
associated to physiological changes tha influese the composition of the gut 
microbiome231. The microbiome is composed by over a 100 billion of 
microorganisms, the majority belonging to the reign of Bacteria243. Moreover, 
the entire genome of the commensal flora contains over 3 million genes, 100 
time more than the human genome243. Therefore, the variety of protein 
products yields a pool of metabolic and biochemical functions that have a high 
impact on the host’s physiological processes244. Both the host and the gut 
microbiota produce a variety of small molecules during the catabolism of food 
and xenobiotics, that play a crucial role in the communication between the 
cells of the host and of the microbiome. Moreover, the microbiota composition 
changes in different portions of the GI tract236,245, and an interplay between all 
the different populations along the GI tract has been observed246. The 
exchange of low molecular weight metabolites, like peptides and small 
proteins, underlies this type of chemical communication, together with 
pathway mediated by the immune system230. 
The human body eliminates up to 100 mg of volatile phenols per day, 
in particolar 4-cresol and phenol, either as glucuronate conjugate or 
solfates247. In mammals, the production of these chemical species is due to 
the activity of different microbial populations: for example, cresol is produced 
by the species Clostridium, Bifidobacterium, and Bacteroides fragilis230, 
whereas E. coli has been associated with the production of phenol230. 
Moreover, an alteration of 4-cresol metabolites in urine has been associated 
with several pathophysiological conditions, that span from weight loss to 
inflammatory bowel diseases230. Moreover, these conditions have been 
associated to a variation of gut microbiota composition, in particular to a 
decrease of the populations of Lactobacillus and Bacteroidetes in 
inflammatory bowel diseases248, and to an unbalance between the 
populations of Firmicutes and Bacteroidetes in weight loss249. The enzymatic 
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activities of gut microbiota products can directly act on the fermentation of 
carbohydrates and on the metabolism of bile acids. Indigestible 
carbohydrates, the so-called functional fibers, are an important energy source 
for many members of the gut microbiota populations, such as Bacteroides 
thetaiotaomicron and Bacteroides ovatus250. In fact, the fermentation of these 
fibers leads to the production of SCFAs, such as acetate, propionate, butyrate 
and lactate249. In particular, butyrate is a crucial substrate for cell metabolism 
of colon epithelium. In fact, it has been observed that germ-free mice show a 
severe energetic deficiency251, characterized by an increased activity of the 
AMP kinase, that is involved in the monitoring of the energetic state of the 
cell252. Moreover, the hepatic metabolism of germ-free animals is different 
than that of colonized ones, and this difference is probably due to a higher 
presence of SCFAs in the liver: it has been shown that the liver uptakes 
acetate and propionate and uses them as substrates for lipo- and 
gluconeogenesis. Furthermore, SCFAs promote the differentiation and the 
proliferation of colon epithelial cells, probably through the modulation of 
genetic expression due to the butyrate-induced inhibition of the histone 
deacetylase (HDAC)253. Moreover, SCFAs are able to modulate gene 
expression by activating two different GPCR, GPR41 and GPR43, that 
partake in different pathways based on the cell type they are expressed in254. 
For example, the activation of GPR43, in neutrophiles, has an anti-
inflammatory effect255, whereas, in intestinal L cells, it induces the release of 
GLP-1256. By activating GPR41, the gut microbiome induces the release of 
PYY257, and the genetic deletion of this receptor prevents the accumulation of 
fat. Although many studies demonstrate the interplay between GPR41/43, 
enteroendocrine cells activity, and metabolites produced by the gut 
microbiota, many lines of evidence suggest that other biologically active 
compounds, hence acting on different receptors, can induce the release of 
GLP-1/2 and PYY258, for example bioactive lipids such as oleoylethanolamide 
(OEA) or 2-oleoyl-glycerol (2-OG), that bind the GPR119 receptor259. In fact, a 
very recent finding demonstrates the beneficial effects of OEA on the gut 
microbiota260. 
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However, to date, little is known about the role that each bacterial species has 
in the production of bioactive metabolites. It has been observed that 
Akkermansia muciniphila, that breaks down mucine, produces propionate and 
butyrate, that bind the GPR43 receptor261. Moreover, a recent study reported 
that obese or insulin-resistant mice show a decrease of the abundance of this 
species, and that the daily administration of A. muciniphila for four weeks 
reverts this phenotype262. Moreover, a direct correlation between the 
abundance of this bacterial species and the secretory activity of L cells has 
been found263. 
The gut microbiome regulates lipid and glucidic metabolisms, acting 
both on the liver and on the production of bile acids. Colonized mice display 
higher levels of triglycerides stored in the liver, and an increase in the 
synthesis of very low-density lipoproteins (VLDL)264, that are involved in the 
transport of triglycerides from the liver to other tissues. Furthermore, an 
increased production of triglycerides in colonized mice is associated to a 
reduction of the expression of the angiopoietin-like protein 4 (ANGPTL4) in 
the small intestine251,265, that is a potent inhibitor of the lipoproteic lipase 
(LPL), a mediator of the cellular uptake of triglycerides. It has been 
demonstrated that germ-free mice knockout for the gene encoding for 
ANGPTL4 show an increase of fat mass and of the body weight, suggesting a 
role of both gut microbiota and ANGPTL4 in regulating adiposity251,265. 
Choline is an important constituent of plasma membranes, that can be 
either introduced with the diet (mainly through the consumption of eggs and 
meat) or endogenously synthesized266. It has a major role in lipid metabolism 
and in the synthesis of VLDL in the liver, and its inadequate supply is 
associated with an alteration of the gut microbiota and with hepatic steatosis, 
both in mice267 and in humans268. In particular, low levels of Gamma-
proteobacteria combined with high levels of Erysipelotrichi in human fecal 
microbiota are linked to hepatic steatosis268. The enzymatic activities of the 
gut microbiota and of the host interplay in the transformation of the choline 
into toxic metabolites, such as trimethylamine, that is further converted into 
trimethylamine-N-oxide in the liver269,270, thus reducing choline availability, that 
may be the cause of the onset of the non-alcoholic fatty liver disease (NAFLD) 
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in mice270. Moreover, an increase in trimethylamine-N-oxide is linked to a 
higher cardiovascular disease risk271. 
Primary bile acids, such as cholic and chenodeoxycholic acids, are 
synthesized in liver from cholesterol, and partake in the solubilization of lipids, 
dietary fats and liposoluble vitamins, to aid their intestinal adsorption, and the 
gut microbiota is able to metabolize these compounds into secondary bile 
acids. In fact, higher levels of primary bile acids, and a lower variability in 
secondary bile acids, has been observed in germ-free rodents272. Moreover, 
bile acids bind nuclear receptors273, as the farnesoid X receptor (FXR)274, 
involved in the regulation and the synthesis of bile acids, and the G protein-
coupled bile acid receptor 1 (or TGR5). Both these receptor are involved in 
the regulation of glucose metabolism in mice, negatively in the case of FXR, 
and positively in that of TGR5275. FXR is activated by primary bile acids, 
whereas TGR5 binds secondary bile acids, like deoxycholic (derived from 
cholic acid) and lithocholic (derived from chenodeoxycholic acid) acids. The 
signal induced by the activation of TGR5 in L enteroendocrine cells leads to 
an increase of GLP-1 secretion, improving glucose tolerance in obese mice275. 
Moreover, in the BAT and in the muscle, the activation of this receptor 
increases energy expenditure and protects from the onset of a DIO 
phenotype276. Commensal flora may contribute to the pathophysiological 
mechanisms underlying the onset of type 2 diabetes and obesity, by 
controlling lipid and glucidic metabolism through the regulation of the 
production of bile acids. Therefore, alterations in the capability of the 
commensal microflora of processing cholesterol, choline, and dietary lipids 
may contribute to the development of cardiovascular diseases230,261. 
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1.4 Changes induced by the prolongated exposure to a high fat 
diet 
 1.4.1 Dysbiosis 
The metabolites produced by the gut microbiota, apart from the intestinal 
function, directly influence the activity of the liver, of the CNS, of the adipose 
tissue and of the skeletal muscle, thus playing a crucial role in the regulation 
of energy homeostasis and in other physiological processes230,249. In fact, 
there is evidence supporting a strong link between a dysregulation of the gut 
microbiota and the onset of pathological conditions, such as obesity, type 2 
diabetes, and cardiovascular diseases254 (Fig. 1.4). A healthy microflora is 
characterized by a high diversity in bacterial species and by a high resistance 
to physiological stress277, whereas, in pathological conditions, the gut 
microbiota loses these main features278. In fact, the dysbiosis, the imbalance 
of the gut microflora, has been associated with the development of several 
pathologies, such as colon cancer, irritable bowel syndrome, gastric ulcer, 
NAFLD, obesity, metabolic syndrome, asthma, allergies, hypertension, and 
behavioral alterations230. Although the gut microbiota profile is unique for each 
individual, and hence characterized by a high variability, it is known that the 
diet can alter its composition. For example, the gut microbiota of an African 
population, whose diet is mainly composed of polysaccharides obtained from 
plants, shows lower levels of Firmicutes and higher levels of Bacteroidetes, 
mainly Prevotella and Xylanibacter, compared to the Mediterranean 
population, whose gut microbiota is rich in Shigella and Escherichia279. 
Prevotella and Xylanibacter are known for their ability to degrade cellulose 
and xylans, and hence associated with a higher production of SCFA, 
maximizing the extraction of energy from foods rich in fibers. Changes in the 
daily consumption of carbohydrates, even for a short period of time, can 
influence specific bacteria. The consumption prebiotics, like inulin, has been 
linked to an increase of the levels of F. prausnitzii and Bifidobacterium sp. in 
humans280. Moreover, a reduction of adiposity and concentration of pro-
inflammatory molecules produced by the gut microbiota (such as the 
lipopolysaccharide (LPS)) was observed in a mouse DIO model after prebiotic 
consumption281. Moreover, the diet supplementation with resistant starch 
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leads to an increase of Ruminococcus bromii and Eubacterium rectale, that 
are involved in the fermentation of dietary fibres282. Furthermore, the gut 
microbiota is influenced by the ingestion of fats. In fact, the exposure to HFD 
determines a decrease of Bacteroidetes abundance, and an increase of 
Firmicutes and Proteobacteria283. In particular, in obese mice, the most 
abundant class belonging to the phylum Firmicutes is the class Mollicutes283, 
and the same profile has been observed in obese patients278. Similar 
alterations in the phyla have been observed after the exposure to both HFD 
and sucrose rich diet (SRD)284. In particular, it has been observed that the 
increase of fat is inversely correlated with the abundance of the genus 
Akkermansia (phylum Verrucomicrobia), while its directly correlated with the 
genus Lactoococcus (phylum Firmicutes) and Allobaculum (phylum 
Bacteroidetes)284, and these changes can occur within 24 hours285. 
However, whether the changes of the gut microbiota are more due to 
the genetic background of the host or to the diet needed to be fully elucidated. 
To address this point, Carmody and colleagues conducted a study involving 
more than 200 species of mice, and exposing them to different diets, 
demonstrating that both the HFD and SRD lead to reproducible alterations of 
the gut microbiota, regardless of the genetic background of the host286. 
Moreover, another study demonstrated that obese prone (OP) rats have a 
different composition of the gut microflora compared to obese resistant (OR) 
rats, and that the fecal transplant from OP rats is able to induce the obese 
phenotype in germ-free animals287. Interestingly, the HFD-induced changes of 
the gut microbiome are associated to the type of dietary fats consumed288. 
Recently, many studies investigated the correlation between obesity 
and the alterations of specific bacterial taxa. For example, the levels of 
Bilophila wadsworthia289, Clostridiales190, Streptococcaceae290, and 
Oscillibacter291 are increased in obese (or exposed to HFD) rodents, whereas 
the phyla Actinobacteria, Bifidobacteriaceae (in particular the genus 
Bifidobacterium), Verrucomicrobia (in particular the species Akkermansia 
muciniphila), and Prevotellaceae (mainly the genus Prevotella) are 
decreased292. B. wadsworthia is known for its ability to produce hydrogen 
sulfide, a molecule with cytotoxic activity towards epithelial cells, that could be 
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linked to the disruption of intestinal permeability and inflammation observed in 
dysbiotic conditions293. Moreover, due to their LPS production, Bilophila sp. 
and Oscillibacter sp. may also partake in the development of these 
conditions294. On the other hand, in patients that underwent a Roux-en-Y 
gastric bypass (RYGB), a surgical procedure that induces weight loss and 
improves diabetes295, an increase of Faecalibacterium prausnitzii, generally 
decreased by obesity and diabetes, was observed296. 
Overall, the HFD-induced dysbiosis is crucial for the onset of obesity 
and its metabolic disruptions. Moreover, it has been reported that the 
decrease of the richness of the gut microbiota exacerbates the dysmetabolic 
conditions297. The exact mechanisms underlying the contribution of the gut 
microbiota to the onset of obesity is still debated. However, it has been 
demonstrated that the microbiome of obese mice is able to extract more 
energy from food298 by fermenting more indigestible fibers, that leads to the 
production of SCFA, that are an important source of energy239. In fact, it has 
been observed that lean and obese individuals show different concentrations 
of SCFA299. Moreover, the gut microbiome seems to be involved in the 
modulation of the expression of genes linked to fat storage290. It is believed 
that a reduction of fasting-induced adipose factor (FIAF) could take part in this 
process, since it has been shown that its expression is selectively silenced in 
germ-free mice after being colonized with the microbiota of obese animals265. 
Obesity, insulin-resistance and diabetes are all associated with systemic 
inflammation300 and with altered intestinal permeability, probably caused by 
the reduction of the proteins of the tight junctions301. Moreover, the gut 
microflora of OP rats is characterized by increased levels of 
Enterobacteriales, an order particularly involved in inflammatory responses302. 
the gut microbiota in a source of molecules, such as LPS and peptidoglycan, 
that may contribute to the development of inflammation in peripheral 
tissues303. In fact, the administration of LPS in mice leads to inflammation of 
the adipose tissue and insulin-resistance235. Moreover, the increase of 
circulating LPS levels is associated with metabolic endotoxemia304. However, 
even though many studies reported an increased number of T lymphocytes305 
and mastocytes306, and a decreased number of regulatory T lymphocytes307 in 
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models of obesity, the interaction between the immune system and the gut 
microbiota is yet to be fully explained. Moreover, many studies showed a 
direct correlation between LPS circulating levels and consumption of dietary 
fats, both in mice235 and humans307, that may be due to either the inclusion of 
LPS in chylomicrons along with fats308, or to the increased permeability of the 
intestinal epithelium of obese mice, through which LPS reaches directly the 
bloodstream235. The increase of the permeability is, moreover, associated with 
the increase of visceral fat deposition and hepatic steatosis309, and patients 
with high abdominal adiposity and type 2 diabetes show elevated circulating 
levels of DNA from bacteria310. LPS binds the toll-like receptor 4 (TLR4), 
whereas peptidoglycans bind NOD-like receptors, and both activate a pro-
inflammatory response235,311. It has been shown that the TLR4 is necessary 
for the development of insulin-resistance: in fact, in mice lacking the gene 
encoding for this receptor, the exposure to HFD failed to induce 
hyperinsulinemia and insulin-resistence, but did not fail to induce obesity312. 
LPS, peptidoglycan, and other pathogen-associated molecular patterns 
(PAMP) may bind to the family of NOD receptors containing the pyrin domain 
(NLRPs) and the apoptosis-associated speck-like protein containing a 
caspase activation and recruitment domain (ASC), thus forming a complex 
called inflammosome313. Obesity is associated with an increase of the NLRP3 
in the adipose tissue, and the deletion of this receptor improves insulin 
sensitivity314. NLRP3, NLRP6 and ASC are also important regulators of the 
gut microflora, and the deletion of the genes encoding for these proteins leads 
to an increase of Bacteroidetes (Prevotellaceae) and Candidatus 
Saccharibacteria267,315. 
Moreover, recent studies suggest that gut microbiota may be 
responsible of the onset of inflammation in the CNS316 through the leakage of 
inflammatory cytokines through the BBB317, the stimulation of the microglia318, 
and the activation of vagal afferents319. Apart from passing through the BBB, 
cytokines may induce inflammation in the CNS by engaging other pro-
inflammatory mediators in the periphery and promoting their migration in the 
CNS318,320, or by activating directly the vagus nerve321. 
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In the past few years, many studies supported the role of the gut microbiota 
on the host’s metabolism, that may contribute to the development of 
pathological conditions such as obesity, diabetes, and other associated 
pathologies257,316. Moreover, an increasing number of evidences point out the 
gut microbiota as a possible target for the treatment of metabolic disorders322. 
Therefore, the next step may be the development of novel experimental 
approaches in order to decipher the complex molecular mechanisms involved 
in the microbiota-induced signaling, to find novel markers and 
pharmacological targets for the treatment of metabolic disorders. 
 
Fig. 1.4: Effects of the exposure to high-fat diet on the gut microbiota (dysbiosis). 
 
 
1.4.2 Alterations of gene expression 
Over the years, the effects of the prolonged exposure on both the 
transcriptomic and proteomic levels of regulation of gene expression have 
emerged323,324, in particular in key homeostatic tissues, such as the 
hypothalamus, adipose tissue, liver and muscle324,325.  In these tissues, the 
exposure to HFD induces the same gene expression profile, even when it is 
not paralleled by overweight325. 
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In the hypothalamus, the NPY/AgRP and POMC/CART are under the control 
of circulating hormones, mainly leptin and insulin326, and it has been 
demonstrated that the exposure to HFD leads to a reduction of the expression 
of leptin receptor, and to an increase of the expression of NPY and of the 
NPY/POMC ratio327. Moreover, these latter effects have been observed also 
in animals exposed to a cafeteria diet328. 
Regarding the adipose tissue, fat-rich diets increase the expression of genes 
related to FA uptake327,329, that, in turn, alter the expression of genes 
regulating lipid metabolism, reducing the lipogenic capacity and activating 
lipolytic capacity325,327. In particular, the exposure to HFD regulates the 
expression of PPAR-γ, and this regulation depends on the period of exposure: 
short periods of exposure decrease PPAR-γ expression, and this effect is 
reverted upon long periods of HFD exposure330. In general, HFD exposure 
increases the expression of genes involved in FA catabolism, such as CPT 
1324,325. However, the modulation of adipogenesis-related genes is unclear, 
since it seems to be influenced by the period of exposure and fat 
proportion331. Moreover, gender-specific considerations should be made in 
terms of modulation of gene expression in the adipose tissue. For example, in 
female rats, the cluster of differentiation (CD36) gene is more increased that 
in males upon HFD exposure, suggesting a higher accumulation of fats327, 
and females show higher FAO in muscle while in males the expression of 
genes involved in thermogenesis increases327,332. 
During exposure to HFD, FA that are not uptaken or stored are 
metabolized by the liver into triglycerides, leading to NAFLD, that affects 
several cellular processes and leads to the alteration of the expression of 
genes involved in lipid metabolism333. In particular, the compensatory 
response to the higher fat consumption leads to an increase of expression of 
genes involved in FA catabolism in the liver, while decreases the expression 
of those related to lipogenesis324,327,334. Moreover, it has been showed that the 
increase of HFD consumption is paralleled by the increase of CPT-1 mRNA 
levels, that may be the cause of the insulin-mediated anti-lipolytic 
signaling325,333,334. Moreover, HFD consumption leads to an increase of mRNA 
expression of genes involved in the catabolism of FA, in particular PPAR-α327, 
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while decreasing the gene expression of enzymes linked to FA 
anabolism324,327,334. However, these effects may vary depending on the fat 
content of the diet and on the duration of the exposure period: for instance, it 
has been demonstrated that the exposure to a diet containing more than 45% 
of calories from fat induces the upregulation of lipogenesis-related genes335, 
whereas the exposure to diets containing less than 45% of calories from fat 
for a long period leads to uncertain results333,336. 
Skeletal muscle is the major site for FA and carbohydrate oxidation, 
and it is known to be able to adapt to physiological and pathophysiological 
changes in energy expenditure337. In fact, the exposure to HFD increases the 
number of muscle mitochondria, decreases the mRNA levels of genes 
involved in in FA synthesis and increases those of FA uptake, lipolysis and 
FAO324,325,327, probably in reaction to the enhanced utilization of lipids327,338. 
The changes in gene expression observed upon the exposure to HFD 
alter also the response of the body during fasting, thus impairing restoration of 
a healthy genetic profile. As discussed before, the changes induced by HFD-
exposure depend on the duration of the exposure and on the fat content of the 
diet324. In fact, it has been demonstrated that the exposure to a cafeteria diet 
in early life induces long-term changes in gene expression patterns339,340, and 
the reversion to a control condition after a long-term exposure is still 
debated341,342. 
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1.5 Oleoylethanolamide 
The increasing incidence of obesity and other eating-related disorders 
highlighted the necessity of a discovery of a novel target for the 
pharmacological treatment of these diseases and their related comorbidities. 
Therefore, after the discovery of AEA as an EC neurotransmitter343, the 
members of the FAE family gained a great deal of interest, that led to the 
discovery of these molules as modulators of feeding behavior25. This class of 
lipid mediators is found in animal and plant tissues344, and is involved in a 
wide range of physio-pathological processes including feeding behavior, 
pain345, innate immunity346 and reward circuitry347. The relevance of these 
compounds in physiological functions emerged with the discovery of anti-
allergic and anti-inflammatory properties of palmitoylethanolamide (PEA), the 
ethanolamide of palmitic acid348 and, in particular, the ability of AEA to bind 
and activate the cannabinoid receptors319. Indeed, several studies 
demonstrated that AEA interacts with the same receptors activated by 
tetrahydrocannabinol (Δ9-THC)349. Moreover, FAEs are synthesized on 
demand in response to many different stimuli, for example neural activation 
(in the rat brain)350,351 or the exposure to metabolic stressors (in mouse 
epidermal cells)352. The FAEs that have been better characterized are 
palmitoylethanolamide (PEA) and OEA. 
 
1.5.1 Synthesis, degradation, and distribution 
OEA is synthesized in the enterocytes of the small intestine from the oleic 
acid released upon the ingestion of dietary fat26, that is uptaken from the 
lumen by CD36, expressed on the apical surface of enterocytes in rodent 
duodenum and jejunum353. It has been demonstrated that the mobilization of 
OEA in the small intestine is induced by fat intake, not food intake alone. In 
fact, OEA levels in the small intestine increased after the intraduodenal 
infusion of a lipid emulsion, but not after di administration of carbohydrate, 
protein, or saline solutions354,355. 
OEA synthesis pathway is an enzymatic reaction in two steps: in the 
first step, oleic acid is transferred from the sn-1 position of a 
glycerophospholipid to the amine group of phosphatidylethanolamines, and 
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yields N-oleoylphosphatidylethanolamine (NOPE), that belongs to the NAPE 
family, and this reaction is catalyzed by a Ca2+-dependent N-acyltransferase 
(NAT). Then, NOPE is cleaved to form OEA and phophatidic acid by a NAPE-
specific phospholipase D (NAPE-PLD), that has been found to be expressed 
in the epithelium and in the lamina propria of the mouse duodenum26. 
However, it has been demonstrated that the genetic deletion of the NAPE-
PLD does not impair OEA synthesis, suggesting that there are NAPE-PLD-
indepented mechanisms for OEA synthesis356. However, the genetic deletion 
of NAPE-PLD induces the obese phenotype, with insuline resistance, adipose 
tissue inflammation and altered microbiota, suggesting that the synthesis of 
NAEs is crucial for the homeostatic regulation of energy balance357. 
It is known that feeding induces OEA formation in the proximal 
intestine25,358, due to the increased levels of oleic acid-containing NAPEs, and 
to the activation of the NAPE-PLD26. Interestingly, food intake increases 
specifically the synthesis of OEA (and the analogue linoeoylethanolamide, 
LEA) without affecting the levels of other FAEs, such as PEA and 
stearoylethanolamide (SEA)26. Moreover, food intake does not change OEA 
level in the stomach, colon and submucosa of small intestine, but exclusively 
in the lumen26. Moreover, OEA synthesis is regulated by the feeding state: 
many lines of evidence demonstrate that OEA levels in the upper intestine are 
decreased by food deprivation and increased upon refeeding25,26,355,358. 
Interestingly, a novel study demonstrated that the feeding state does not 
affect OEA levels in the liver359. In genetically obese rats, duodenal levels of 
OEA are 12-fold higher than wildtype controls, prompting the idea that it might 
be an adaptive response to hyperphagia360. Conversely, in DIO animals 
jejunal OEA levels are blunted, suggesting that the prolonged exposure to 
HFD reduces the responsiveness fed or fasted states355. 
OEA is catabolized into oleic acid and ethanolamine by enzymatic 
hydrolysis, that can be catalyzed by three different enzymes: fatty acid amide 
hydrolase (FAAH or FAAH-1), FAAH-2 and N-acylethanilamine-hydrolyzing 
acid amidase (NAAA). FAAH is the main anzyme for NAE degradation361, 
although it has higher affinity for AEA362, and is expressed in the liver and in 
the small intestine363, in particular in the epithelium and in the lamina propria 
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of the mouse duodenum26. However, the genetic deletion of the gene 
encoding for FAAH decreases NAEs in a tissue-specific manner, suggesting 
the presence of additional catabolic enzymes with different tissue 
distributions364. In fact, in FAAH knock out mice, OEA levels decrease more in 
the brain364–366 than in the circulation and the heart364,367.  
FAAH-2, expressed in humans and primates, but not in rodents, has 
20% sequence identity with FAAH-1, and has a higher affinity to OEA more 
than AEA368. NAAA is the third NAE-hydrolizing enzyme, and belongs to the 
lysosomal choloylglycine hydrolase family369, and has a higher affinity for PEA 
than for OEA370,371. 
OEA is widely distributed throughout the body, even though plasma 
levels are lower than organ levels372, suggesting that its signaling may be 
paracrine more than endocrine26. Moreover, in plasma, OEA is found in the 
lipoprotein-free fraction, likely carried by albumin373. In the brain, OEA has 
been detected in many brain structrures, such as cortex, hippocampus, 
thalamus, striatum, hypothalamus, cerebellum and brainstem26. In the liver, 
OEA levels increase after dietary oleic acid-intake, likely by providing the 
substrate for OEA synthesis163,374, and, in the white adipose tissue, is 
triggered in rats after cold exposure375 or after oxytocin administration376. 
 
1.5.2 Receptors 
It is well known that OEA activates PPAR-α340,377,378. In fact, it has been 
demonstrated that OEA binds the ligand-binding domain of this receptor with 
a KD ⁓ 40nM and increases the transcription activity of this factor with a 
median effective concentration of ⁓120 nM340. When activated, PPAR-α 
dimerized with the retinoid receptor and, together, bind to specific sequences 
in the DNA called PPAR response elements (PPRE) to regulate gene 
transciption379 of target genes, mainly involved in lipid transport and 
metabolism380. The OEA-induced activation of PPAR-α, and the resulting 
transcription of the PPAR-α-controlled genes, initiates the cascade of events 
leading to the induction of satiety and to the modulation of lipid metabolism 
exerted by this bioactive lipid. The PPAR-α-mediated OEA effects have been 
extensively studied in PPAR-α-KO mice, in which OEA fails to induce its 
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effects of feeding and on lipolysis340,377. Moreover, even though OEA activates 
PPAR-β/δ340, it has been demonstrated that the effects of feeding are 
exclusively PPAR-α-dependent: in fact, PPAR-α agonists, like Wy-14643 and 
GW7647, are able to modulate feeding, whereas PPAR-β/δ and PPARγ failed 
to exert these effects340. Apart from the well-known transcriptional effects of 
OEA, PPAR-α exerts non trascriptional effects as well: it has been 
demonstrated that two PPAR-α agonists, GW-7647 and PEA, are able to 
induce a rapid decrease in the amplitude of evoked Ca2+ transient currents381, 
and that PPAR-α can modulate the firing-rate of neurons by acting on nicotinic 
receptors382. 
OEA also binds the transient receptor potential vanilloid type-1 
(TRPV1), highly expressed on sensitive vagal afferent neurons, after it has 
been phosphorylated by the protein-kinase C, leading to an increase of Ca2+ 
levels and thus to the depolarization of the membrane383,384. However, it has 
been demonstrated that the hypophagic effect of OEA is not TRPV1-
dependent, since the peripheral administration of OEA still reduces short-term 
food intake in TRPV1-KO mice384. 
Finally, OEA is a medium potency agonist for GPR119, a G-protein 
coupled receptor expressed in rodent and human pancreatic and intestinal 
cells385 that recognizes a broad panel of lipid molecules in addition to OEA386. 
However, also in the case of this receptor, it has been demonstrated that the 
genetic ablation of the gene encoding for GRP119 does not abolish the 
hypophagic effects of the periheral administration of OEA387, thus further 
confirming the crucial role played by PPAR-α receptors in mediating the 
effects of OEA. 
 
1.5.3 OEA’s effects on feeding, gene expression, and lipid 
metabolism 
The most known effect of OEA after peripheral administration is a long-lasting 
and dose-dependent reduction of food intake378,388, that is not linked to fear or 
anxiety, does not change plasma corticosterone levels, and does not induce 
conditioned taste aversion in rats25. Moreover, the behavioral effects of OEA 
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are selective to feeding, since its peripheral administration does not alter 
water intake or sodium appetite25. 
The hypophagic action of OEA depends on the feeding state of the 
animal. In free-feeding rats, in fact, OEA increases the latency to eating onset, 
decreases the meal frequency, but does not affect meal size; conversely, in 
food-deprived rats, OEA is also able to decrease the size of the first meal, in 
addition to the effects on the other parameters389. Furthermore, OEA 
decreases gastric emptying in a dose-dependent manner, an effect that could 
contribute to the reduction of food intake390. 
Among NAEs, PEA and LEA also induce satiety391. However, LEA fails 
to induce satiety effects when administered at the same dose as OEA, even 
though it is found in higher concentrations in the upper small intestine358. On 
the other hand, PEA induces satiety to a lesser extent compared to OEA25. 
Peripheral OEA administration is known to increase the expression of 
both PPAR-α and PPAR-α-controlled genes, that encode for proteins involved 
in the control of lipid metabolism. In particular, it has been demonstrated that 
i.p. OEA administration increases mRNA levels of PPAR-α in the liver, 
duodenum and jejunum340, as well as in adipose tissue and soleus muscle377, 
and OEA-induced acrivation of PPAR-α induces the levels of expression of 
CD36340,377,378 in all these tissues. Moreover, it has been shown that OEA is 
able to increase mRNA levels of the fatty acid binding protein (FABP), an 
intracellular protein with high affinity for fatty substrate380, in the adipose tissue 
and soleus muscle377, and, in particular, of the liver-specific isoform (L-
FABP)340. Interestingly, CD36 is located, in enterocytes, on the apical 
membrane of brush border, suggesting its involvement in dietary fat uptake392, 
further confirming its pivotal role in OEA’s mechanism of action. Furthermore, 
in the liver, adipose tissue, and soleus muscle377,378, OEA increases the 
expression of the uncoupling proteins (UCPs), whose expression levels are 
used to assess mitochondrial fatty acid β-oxidation. Moreover, OEA shows 
lypolitic effects and increases lipid mobilization from storage sites. In fact, it 
has been shown that OEA induces the release of non-esterified fatty acids 
(NEFA) and glycerol in rat dissociated adipocytes, without affecting glucose 
uptake and oxidation, in a concentration-dependent manner377. In the same 
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way, OEA concentration-dependently induced the release of NEFA and 
glycerol in a rat adipose cells colture, even though, interestingly, the 
incubation with the highest concentration inhibited these same effect393. 
Furthermore, OEA-induced NEFA and glycerol release has been 
demonstrated also in vivo, paralleled by an increase of 3-hydroxybutyrate377, 
and another study demonstrated the decrease of lipid content in the liver of 
Zucker rats378. Overall, these findings show the lypolitic effects of OEA, that 
may contribute to the effects on body weight induced by this lipid mediator. 
Many studies support the role of OEA in fatty acid β-oxidation, 
observed in cell coltures from rat skeletal muscle, heart, and liver cells 
incubated with OEA, with no effects on glucose metabolism377. Lastly, OEA 
lowers the levels of circulating lipids independently from its effects on body 
weight loss. In fact, rats that underwent a 1-week OEA treatment showed 
lower circulating levels of triglycerides compared to the pair-feeding group25. 
Moreover, peripheral OEA administration decreases circulating levels of 
cholesterol and triglycerides after one393, two378, and four394 weeks, without 
affecting HDL cholesterol393 or glucose378 circulating levels. 
 
1.5.4 OEA and the CNS 
As described in the previous paragraphs, the CNS plays a pivotal role in the 
control of feeding and energy homeostasis thanks to the signals produced in 
the gut. Multiple lines of evidence demonstrate that OEA not only impacts lipid 
metabolism and oxidation378,393, but also regulates neural circuits involved in 
the control of ingestive behavior. As already discussed, two of the main areas 
involved in the integration of the signals coming from the periphery are the 
NST and the AP, located in the brainstem. The NTS is the first relay station of 
vagal afferents and contains different populations of neurons that send 
projections to many different areas of the CNS, such as the hypothalamus10. 
In particular, the medial part of the caudal NST (SolM) is the site where the 
cell bodies of the noradrenergic A2 fibers are located200. It has been 
demonstrated by many studies that OEA increases Fos, both mRNA25,395 and 
protein205,396 levels, in these brain areas, where this activation is also 
paralleled by an increase of the noradrenergic tone205,397. In fact, it has been 
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demonstrated that peripheral OEA administration increases the levels of 
dopamine-β-hydroxylase (DBH, step-counter enzyme for noradrenergic 
synthesis) in both NST and AP, markedly in the SolM205, that led to the 
investigation of the role played by the noradrenergic fibres in mediating the 
satiety effects of OEA. The lesion of A2 fibres with the injection of the 
retrograde toxin saporin (DSAP) conjugated to a monoclonal antibody against 
DBH into the PVN revealed that these neurons are crucial for the satiety 
effects397. Moreover, the ablation of the noradrenergic fibres led to the loss of 
the OEA-induced effects on the hypothalamus: in fact, it has been 
demonstrated that the peripheral administration of OEA induces the release of 
oxytocin from the PVN, the SON and the neurohypophysis, and the treatment 
with the antagonist of the oxytocin receptor in the 3rd ventricle abolishes OEA-
induced satiety, demonstrating the pivotal role played by this neuropeptide in 
mediating OEA’s effects397,398. Moreover, many studies showed that OEA 
activates oxytocin-expressing neurons in the PVN397–399. 
The histaminergic system controls many physiological processes, 
including feeding186, and novel findings demonstrate that OEA requires an 
intact histaminergic system to exert its effcts on feeding and on the oxytocin 
secretion in the PVN399. All these findings demonstrate that OEA exerts 
multiple effects on the CNS by engaging several neural circuits, such as the 
noradrenergic397, oxytocinergic398 and histaminergic399. 
It is clear that OEA, to induce its effects on feeding and body weight, 
exerts many effects on both periphery and CNS. However, how the OEA-
mediated signal could, from the periphery (where OEA is produced)26, reach 
the CNS has been long debated. Many lines of evidence indicated that gut 
vagal afferents were responsible for NST activation and, in turn, for OEA’s 
effects on the CNS. In fact, it had been observed that a total 
subdiaphragmatic vagotomy (TVX)340 or the pretreatment with a neurotoxic 
dose of capsaicin25 abrogated the hypophagic effects of OEA. However, a 
recent study conducted in rats that underwent a subdiaphragmatic vagal 
deafferentation (SDA), the most selective surgery targeting vagal afferents 
known to date, demonstrated that vagal afferent neurons are ot necessary for 
the hypophagic effect of OEA388, thus weakening all previous hypotheses. 
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Therefore, attention was directed to the AP, a circumventrivular organ lacking 
a fully functional BBB, that not only receives direct inputs from vagal 
afferents207 but is also able to detect bloodborne signals203, and it has been 
demonstrated that the surgical lesion of this area abrogated the hypophagic 
and neurochemical effects of OEA205. Hence, as demonstrated in this work, 
OEA, after being produced in the small intestine, reaches the CNS through 
the bloodstream, and activates the SolM-projecting noradrenergic neurons in 
the AP. This leads to the activation of the A2 noradrenergic fibers project to 
the PVN (and possibly to the vTMN), increasing oxytocin neurosecretion, 
regulated also by the histaminergic activity of the vTMN (Fig. 1.5). 
Moreover, OEA not only partakes in the homeostatic control of feeding 
behavior, but also on the non-homeostatic, by acting on the reward 
circuitry400,401. 
Overall, these findings demonstrate that, to induce satiety, OEA 
requires the involvement of multiple neural circuits, highlighting the multi-
faceted effects this compound has on feeding behavior. However, OEA’s 
central effects are not only restricted to feeding. In fact, it has been 
demonstrated that peripheral OEA administration improves memory 
consolidation402. attenuates depressive-like behavior403 involving 
noradrenergic, serotonergic404 and histaminergic405 systems and ameliorates 
cognitive performances in a mouse model of ischemia406. 
 
 
Fig 1.5: Mechanism of action of OEA. OEA is produced in the upper intestine upon the 
ingestion of dietary fat [1], enters the bloodstream and is conveyed to the AP, where it activates 
the SolM-projecting noradrenergic neurons [2]. From the SolM, OEA activates A2 PVN-
projecting (and possibly vTMN-projecting) noradrenergic fibers, increasing oxytocin 
neurosecretion, also with the aid of the histaminergic system [3].
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1.5 Aim of the study 
According to the WHO, obesity is one of the most widespread chronic 
pathological conditions worldwide1. However, to date, there are no 
pharmacological treatments proven safe and effective. The obese phenotype 
is induced by the prolonged exposure to HFD, that has been linked to 
alterations in the mechanisms underlying the homeostatic control of energy 
balance. Moreover, it is known that the gut and the brain are constantly in 
communication through the so- called gut-brain axis, that plays a pivotal role 
in the regulation of feeding behavior and energy homeostasis37. In particular, 
the GI tract, after the ingestion of food, releases a variety of signals, like 
peptide hormons, such as CCK and PYY, and lipid mediators, that act both on 
the periphery and on the CNS to regulate feeding118. Among lipid mediators, 
OEA has gained a great deal of interest for its anti-obesity effects. OEA is a 
FAE synthesized in the small intestine upon the ingestion of dietary fat26, and, 
in laboratory animals, the i.p. administration of OEA is able to induce a dose-
dependent and long-lasting reduction of food intake and body weight25,205,378, 
suggesting that it may be a potential pharmacological target for the treatment 
of obesity. The anorexiant effects of OEA require the PPAR-α, through which 
OEA is able to modulate lipid metabolism and FAO377,393, and to induce gene 
expression, in particular in the liver and in the upper intestine340. PPAR-α is 
also required for the effects of OEA on the CNS: in fact, it is known to induce 
c-fos expression in areas involved in the control of feeding behavior, such as 
the NST and AP in the brainstem, and the PVN and SON in the 
hypothalamus25,395. Moreover, the central effects of OEA engage the 
oxytocinergic398, noradrenergic205,397 and histaminergic205,399 neural circuits. 
However, how the OEA-mediated signal may be conveyed from the periphery 
to the CNS has long been debated. Since its hypophagic effects are abolished 
by total subdiaphragratic vagotomy340 or the pretreatment with a neurotoxic 
dose of capsaicin25, it has been suggested that this lipid compound may 
activate PPAR-α-expressing vagal afferents. However, novel findings 
demonstrate that OEA does not require intact vagal afferent system388, but it 
rather requires an intact AP to exert its behavioral effects205. Moreover, the 
surgical lesion of the AP also prevents the neurochemical effects of OEA205, 
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while the selective role of the vagal afferent system in mediating the OEA-
induced activation of neural circuits involved in the control of feeding behavior 
still needs to be further elucidated.  
Therefore, the aim of the 2nd chapter of this thesis is to address this 
point. In order to do so, we subjected male rats to the SDA surgery, the most 
selective surgery targeting vagal afferents. Sham animals were used as 
controls. Two hours after OEA administration, brains were removed from the 
skulls and cut at the cryostat in 20 µm-thick slices. Then, we performed Fos 
immunohystochemistry to assess whether vagal afferents are necessary for 
OEA to activate the AP, NST, PVN, Arc and vTMN; moreover, in the AP and 
NST, we investigated the expression of dopamine-β-hydroxilase (DBH) to 
evaluate the involvement of vagal afferents in the OEA-induced increase of 
the noradrenergic tone. Since it is known that oxytocin secretion is crucial for 
the satiety effect of OEA, we then performed a double staining, for Fos and 
oxytocin, in the PVN of both sham and SDA animals. 
As aforementioned, OEA is able to modulate gene expression through 
PPAR-α activation: in particular, it has been demonstrated that i.p. OEA 
administration increases the expression of PPAR-α and CD36 in the liver and 
upper intestine340, where it increases FAO and modulates lipid 
metabolism377,393. However, little is known about OEA effects on gene 
expression in the main areas involved in the homeostatic control of feeding 
behavior after peripheral administration. Therefore, the aim of the 3rd chapter 
of this thesis is to investigate the possible OEA-induced changes in gene 
epression, 2 and 4 hours after i.p. administration, in specific brain areas (AP, 
NST, Arc/ME and dHippo) and in peripheral organs (Liver, duodenum (Duo), 
and jejunum (JJ)). In order to do so, upon sacrifice, we microdissected, with 
the aid of brain matrix and surgical forceps, the brain areas, and collected 
samples of the peripheral organs, and analyzed gene expression by RT-
qPCR. 
The long-term exposure to HFD is responsible of the induction of the 
obese phenotype407, and is known to disrupt the mechanisms underlying the 
homeostatic control of energy balance by acting on many different 
physiological processes408. In particular, the obese phenotype is characterized 
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by a significant reduction of OEA levels in the gut355, and by changes in the 
gut microbiota, both in its composition and number of total bacteria409. 
Therefore, the aim of the last chapter of this thesis is to investigate the effects 
of the chronic peripheral administration of OEA in a rat model of DIO not only 
on its known effects on feeding and body weight, but also on the composition 
and number of bacteria of the gut microbiota, and on gene expression in the 
brain. In order to do so, we exposed male rats to HFD or LFD for 11 weeks to 
induce obesity, and then we subjected them to a chronic treatment with OEA 
(10 mg kg-1, i.p.). During the chronic treatment, part of the rats that were gived 
HFD were shifted to LFD in order to mimic dieting. Upon sacrifice, we 
collected the brains and the fecal contents, and analyzed gene expression by 
RT-qPCR, measured the number of total bacteria and the relative abundance 
of the major phyla, classes and orders through PCR, targeting the gene 
encoding for the rRNA 16s. 
Therefore, the main aim of this thesis is to investigate in depth the 
mechanism of action of this bioactive lipid compound, highlighting its complex 
role in modulating different aspects of the control of energy homeostasis. 
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Chapter 2: 
Role of vagal afferents on the neurochemical 
effects of oleoylethanolamide 
 
 
 
 
Abstract 
Oleoylethanolamide (OEA), a PPAR-α agonist, is a mediator of satiety. After 
peripheral administration, OEA induces Fos expression and activation in areas of the 
CNS involved in the control of feeding behavior and energy homeostasis, such as the 
nucleus of the solitary tract (NST) and in the area postrema (AP) in the brainstem, the 
hypothalamic paraventricular (PVN), supraoptic (SON) and ventral tuberomammillary 
(vTMN) nuclei. Moreover, it is known to increase the noradrenergic trasmission in the 
NST and AP, by increasing the expression of the dopamine-β-hydroxylase (DBH). 
Visceral ascending fibers were hypothesized to mediate such effects, but recent 
findings demonstrate that abdominal vagal afferents are not necessary for the 
anorectic effect of OEA. In fact, OEA is able to decrease food intake both in rats that 
underwent a subdiaphragmatic vagal deafferentation (SDA), a surgical procedure that 
eliminates all abdominal vagal afferents but spares about 50% of the vagal efferents, 
and in SHAM controls. Thus, the aim of the present work was to better elucidate the 
role of abdominal vagal afferents in mediating OEA's effects on the CNS. To meet this 
aim, we subjected rats to SDA surgery, using SHAM rats as control. By using 
immunohistochemistry, Fos and DBH expression patterns were investigated in the 
NST, in the AP, and in the hypothalamus after OEA administration (10 mg kg -1). 
Consistently with the behavioral results, OEA increases Fos expression in the NST 
and in the AP.  Moreover, in these nuclei, SDA did not cause any alteration of DBH 
expression. In the hypothalamus, in line with the behavioral results, OEA is able to 
increase Fos expression in the PVN and the vTMN, even though in the latter does not 
reach statistical significance.  
Overall, our findings indicate that vagal afferents are not strictly necessary for 
the satiety effect of OEA at both behavioral and neurochemical levels. 
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2.1 Introduction 
To date, obesity represents one of the main health problems worldwide. This 
pathology is multifactorial in nature, and an increasing number of studies 
highlight how the exposure to an unhealthy diet can alter the mechanisms 
through which the central nervous system (CNS) regulates energy 
homeostasis and feeding behavior1. In fact, the CNS and the GI tract are 
constantly in reciprocal communication through the gut-brain axis, a complex 
network of neural and hormonal signals that links the periphery and the brain 
to control feeding behavior2. 
The vagus nerve is the tenth cranial nerve, and, since it reaches both 
the thoracic and the abdominal cavities, is one of the main connections of the 
gut-brain axis3. In fact, the signals produced by the variety of endogenous 
molecules acting in the periphery are conveyed, through the many receptors 
located on the vagal afferent system in the gut, to the brain areas involved in 
the regulation of feeding behavior3. The stimuli detected by the vagal afferents 
are mechanical, such as distention and contraction4; chemical, such as 
nutrients in the gut lumen5 or hormonal, like CCK6,7and GLP-18. Moreover, 
vagal afferents can detect neurotrasmitters and neuro-modulating agents (like 
serotonin9 and somatostatin8), and cyotkines, as well as other inflammation 
mediators produced by the gut microbiome10. Therefore, vagal afferents play 
a pivotal role in conveying a large number of signals from the periphery to the 
nucleus of the solitary tract (NST)11, a brain area located in the brainstem that 
is the main relay station of the vagal afferents in the CNS. In turn, the parts of 
the NST involved in the regulation of feeding behavior send projections to the 
hypothalamus11, in particular towards the paraventricular and suraoptic nuclei 
(PVN and SON, respectively)12, that are also linked to the endocrine system 
to regulate energy homeostasis11. 
In this scenario, in the last decade, the satiety factor 
oleoylethanolamide (OEA) has gained a great deal of interest as a possible 
novel therapeutic target to treat obesity and other aberrant eating-related 
disorders. In fact, OEA is known to reduce food intake in laboratory 
animals13,14 without inducing stress or malaise15. OEA is a fatty acid 
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ethanolamide (FAE), synthesized in the small intestine upon the ingestion of 
dietary fat13, that requires the intestinal peroxisome proliferator activated 
receptor-α (PPAR-α) to exert its prosatiety effects16. Moreover, the 
hypophagic effect of OEA (injected i.p. at the dose of 10 mg kg-1) triggers 
many different effects in the CNS. In first place, peripheral OEA administration 
is paralleled by the activation of areas in the CNS involved in the control of 
feeding behavior, such as the NST and area postrema (AP) in the brainstem, 
and the PVN, the SON and the ventral tuberomammillary nucleus (vTMN) in 
the hypothalamus17. Furthermore, it has been demonstrated that the 
noradrenergic neurons that rise in the NST and project to the PVN are 
crucially involved in the activation of the hypothalamic areas induced by 
exogenous OEA, and that the ablation of these projections dampens OEA's 
satiety action18. 
In addition, in both PVN and SON, OEA increases c-fos mRNA in 
neurons expressing oxytocin (OXY), that leads to an increase of OXY mRNA 
levels and elevated circulating OXY levels19. All these effects on the 
oxytocinergic system are crucial in OEA's mechanism of action, as it has been 
demonstrated that the blockade of OXY receptors in the brain by 
intracerebroventricular infusion of the selective OXY antagonist, L-368,899, 
prevented the anorexic effects of OEA19. Furthermore, apart from the 
oxytocinergic system, OEA requires an intact histaminergic system to exert its 
pro-satiety effects20. Lastly, it has been long investigated whether OEA may 
exert its effects on feeding through the arcuate nucleus (Arc): in fact, previous 
experiments conducted in rats demonstrated that peripheral OEA 
administration failed to induce the expression of c-fos mRNA15, whereas 
recent experiments conducted in mice show that OEA is able to increase Fos 
expression in this hypothalamic nucleus21. Moreover, the particular interest 
regarding this area rises from the fact that, like the AP, the Arc is a 
circumventricular organ, that receives bloodborne signals, such as leptin22, to 
the CNS. 
However, the mechanism through which the OEA-mediated signal is 
conveyed to the CNS is still uncertain. Many studies suggest the involvement 
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of visceral vagal afferents13: as a matter of fact, the OEA-induced satiety 
effect is abolished in animals that were treated with capsaicin15 or that 
underwent a truncal subdiaphragmatic vagotomy (TVX)16. 
On one hand, both vagal afferents and efferents are lesioned in the 
TVX, that impairs the normal crosstalk from and to the CNS, leading to 
disruptions in sensory mechanisms, gastrointestinal secretions and motor 
functions of the GI tract23. 
On the other hand, the lesion induced by systemic capsaicin treatment 
is not specific for vagal afferents24, as it removes unmyelinated visceral 
sensory neurons of both vagal and spinal afferents. Moreover, up to 20% of 
vagal afferents are left intact because are myelinated25,26. Furthermore, 
capsaicin treatment exerts neurotoxic effects also on neurons of the NST and 
AP, which receive projections from unmyelinated primary sensory neurons 
destroyed by the capsaicin treatment27,28. 
Therefore, a novel approach to selectively investigate the role of vagal 
afferents in the behavioral effects of OEA was used, the subdiaphragmatic 
vagal deafferentation (SDA)29. This surgery completely and selectively 
eliminates all abdominal vagal afferents, while sparing approximately half of 
the efferents. It is the most selective surgery targeting only vagal afferents, 
unlike TVX, and, unlike capsaicin treatment, it eliminates both myelinated and 
unmyelinated vagal fibers. In striking contrast with the previous findings15,16, 
this study demonstrated that vagal afferents are not necessary for the 
hypophagic effects of OEA. Moreover, a recent study demontrated that, 
conversely, the AP is crucial for both the hypophagic and neurochemical 
effects of OEA17. The AP is a circumventricular organ, devoid of a functional 
bloo-brain barrier (BBB), where the receptors for many mediators of feeding 
behavior (such as amylin, GLP-1 and ghrelin) may be found30,31. 
Therefore, the aim of this work is to selectively investigate the role of 
abdominal vagal afferents in mediating the OEA-induced activation of the 
areas in the CNS involved in the control of feeding behavior. Moreover, we 
aim to investigate whether SDA surgery may impact the effects of OEA on the 
noradrenergic and oxytocinergic system. 
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2.2 Materials and methods 
2.2.1 Animals 
Male Sprague Dawley rats, weighing 180-200 gr upon arrival (Charles Rivers, 
Sulzeld, Germany) were used in this experiment. After arrival, the animals 
were individually housed in acrylic infusion cages in a temperature- and 
humidity-controlled room (22 ± 2 °C and 60% relative humidity), with a 12:12 h 
light/dark cycle with light on at 6.30 p.m. All the animals had free access to 
water and standard chow pellets (N 3433 diet, caloric density: 3.11 kcal g-1, 
Provimi Kliba SA, Switzeland). All rats were implanted with an intraperitoneal 
catheter to minimize animal handling during treatments. All procedures were 
approved by the Veterinary Office of The Canton of Zurich. 
2.2.2 Drugs and treatments 
Prior to surgery, rats received a s.c. injection of antibiotics (4 mg kg-1 of 
trimethoprim and 20 mg kg-1 of sulfadoxine, Borgal 24%; Intervet/Shering-
Plough Animal Health, Kenilworth, NJ) for infection prophylaxis. Fifteen 
minutes before surgery, animals received an i.p. injection of atropine (0.05 mg 
kg-1; Sintetica, Mendrisio, Switzerland), followed by an injection of a mixture of 
80 mg kg-1 ketamine (Ketasol-100; Dr. E. Gräub AG, Bern, Switzerland) and 5 
mg kg-1 xylazine (Rompun; Bayer, Leverkusen, Germany), the final volume 
being 1.2 mg kg-1. 
After surgery, 5 mg kg-1 of carprofen (Rimadyl; E. Gräub, Bern, 
Switzerland) and 4 mg kg-1 Borgal 24% were injected for 2 days for analgesia 
and infection prophylaxis, respectively. All rats were allowed to recover from 
surgery for at least 2 wk before the experiments started. OEA (Sigma-Aldrich) 
was dissolved in sterile saline/PEG/Tween 80 (90/5/5, v/v/v; 2 ml kg-1) and 
administered by i.p. injection 10 min before dark onset at the dose of 10 mg 
kg-1. Control animals received an i.p. injection of vehicle, saline/PEG/Tween 
80 (90/5/5, v/v/v; 2 ml/Kg). Each solution was freshly prepared on the 
experimental day. 
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2.2.3 Intraperitoneal catheter implantation 
Catheter implantation was performed under aseptic conditions. Instruments 
were autoclaved, and the catheters were sterilized (Kodan Forte Farblos, 
Schulke & Mayr, Switzerland) prior to use. The proximal end of the catheter 
was led subcutaneously from the neck to a 4 cm midline incision in the 
abdomen and inserted in the abdominal cavity through a puncture hole. 
Intraperitoneal catheters ended in the peritoneal cavity and were anchored on 
the left side of the abdominal wall with Histoacryl glue. The abdominal muscle 
wall and skin were closed with absorbable sutures (3–0 and 5–0 Vicryl, 
respectively; Ethicon, Norderstedt, Germany). All rats were allowed to recover 
from surgery for at least 2 weeks before starting the experiments. 
2.2.4 Subdiaphragmatic vagal deafferentation (SDA) 
Twenty-seven rats were subjected to either SDA (n=15) or sham (n=12) 
surgery. In the SDA, the left dorsal (afferent) vagal rootlet at the level of the 
brainstem and the dorsal (left) esophageal trunk of the vagus in the abdomen 
were visualized and sectioned as previously described32,33. This procedure 
results in a complete elimination of all vagal afferents from below the 
diaphragm, while leaving approximately half of the abdominal vagal efferents 
intact (Fig 2.1). The sham procedure consisted of similarly exposing the vagal 
rootlets and abdominal vagus without manipulating them. Five milliliters of 
warm of Ringer lactate solution (Ri-Lac; B. Braun Medical AG, Sempach, 
Switzerland) were injected intraperitoneally after closing the abdomen. 
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Fig 2.1: Schematic illustration of vagal fibers 
targeted by SDA. Afferent and efferent fibers are 
represented in red and blue, respectively. In the 
SDA procedure, the left (dorsal) subdiaphragmatic 
trunk of the vagus nerve is fully transected 
(indicated by the first scissor symbol), leading to a 
disconnection of both afferent and efferent fibers 
in the left (dorsal) trunk of the vagus nerve. The 
right (ventral) subdiaphragmatic trunk of the vagus 
nerve is left intact. In addition, a left-sided 
intracranial vagal rhizotomy is performed 
(indicated by the second scissor symbol) to 
selectively disconnect the remaining vagal 
afferents. This SDA procedure induces a complete 
(100%) disconnection of vagal afferents while 
leaving 50% of the vagal efferents functionally 
intact. 
 
 
2.2.5 Immunohistochemistry 
On the day of the terminal experiment, food was removed from the cages 1 h 
prior to dark onset, and rats were administered or OEA (10 mg kg-1, i.p.) or 
vehicle (saline/PEG/Tween80, 90/5/5, v/v/v, i.p.) 30 minutes prior to dark 
onset. Two hours after drug administration, animals were deeply anesthetized 
with pentobarbital sodium (80 mg kg-1; Kantonsapotheke, Zurich, 
Switzerland) and transcardially perfused with ice-cold sodium phosphate 
buffer (0.1 M PBS, pH 7.4), followed by fixative solution containing 4% 
paraformaldehyde. Fixed brains were removed from the skull, collected, 
postfixed overnight, cryoprotected in 20% sucrose-phosphate buffer (for 48 h 
at 4°C), and then snap frozen in dry-ice-cold 2-methylbutane (-60°C), to be 
stored at -80°C until processing. 
Brains were cut on a cryostat (model HM550; Thermo Fisher Scientific, 
Kalamazoo, MI, USA) into five series of 20-μm coronal sections containing 
hypothalamic and brainstem structures, and mounted on positively charged 
microscope slides (SuperFrost Plus, Menzel, Germany) and stored at −20°C. 
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Fos and DBH chromogenic immunostaining 
OEA is known to reduce food intake15–19,34, and this effect is paralleled by the 
activation of brain areas linked to the control of feeding behavior17,18,34. Since 
it has been previously described that SDA does not abrogate the satiety effect 
of OEA29 (Fig 2.2), we aimed to investigate whether SDA is able to impair 
OEA’s central effects. 
One series containing the NST (n= 4-5 per group), the AP (n= 3-4 per 
group), and the dorsal motor nucleus of the vagus (DMV) (n= 4-5 per group) 
(from -13.68 to -14.30 mm from Bregma35), the PVN (n= 5-7 per group) (from -
1.5 to -2.12 mm from Bregma35), the Arc (n= 5-7 per group) (from -2.12 to -
4.52 mm from Bregma35) and the vTMN (n= 5-7 per group) (from -3.80 to -
4.52 mm from Bregma35) was used for Fos immunostaining, and one more 
series containing the NST and AP (n= 5-7 per group for both areas) was used 
for dopamine-β-hydroxylase (DBH) immunostaining. Both analyses were 
conducted using the 3,3'-diaminobenzidine (DAB)-H2O2-horseradish 
peroxidase detection method. Briefly, sections were rehydrated in PBS (pH 
7.4) and then incubated for 1.5 h in a solution containing 2% normal donkey 
serum (Jackson Immunoresearch) in 0.1% Triton X-100, followed by 
incubation with the primary antibody (rabbit polyclonal anti-c-fos primary 
antibody 1:5000, Santa Cruz Biotechnologies, Santa Cruz, California or 
mouse monoclonal anti-DBH antibody, MAB308, Millipore) at 4°C. Sections 
were then incubated with the secondary antibody (donkey anti-rabbit 
biotinylated secondary antibody, Jackson Immunoresearch, 1:500 or donkey 
anti-mouse biotinylated secondary antibody, Jackson Immunoresearch, 
1:400) in 0.1% PBST for 2h at room temperature. After incubation for 1h with 
the ABC Kit (Vectastain ABC kit; Vector Laboratories), sections were stained 
by incubation in DAB (Vector Laboratories) chromogen solution. The slides 
were then rinsed with PBS, dehydrated in graded alcohol, immersed in xylene 
and cover-slipped with Eukitt (Sigma-Aldrich). 
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Fig 2.2: Effects of peripheral OEA administration on feeding of sham and SDA rats. 
Intraperitoneal OEA injection reduced food intake in sham (n=12; left) and SDA (n=15; right) 
rats during the first hour following injection. The reduction in cumulative food intake was still 
present to some degree between 3 and 6 h. Data were analyzed for individual time points by 
the Wilcoxon signed rank test. No significant differences in the food intake reduction by OEA 
were observed between SDA and sham rats (Mann-Whitney U-test). *P < 0.05, **P < 0.005 vs. 
vehicle in the same surgery group. Data are presented as means ± SE. 
 
 
Fos and DBH double fluorescent immunostaining 
A second series of sections containing AP and NST (n=1 per group for both 
areas) (from -13.68 to -14.30 mm from Bregma35) was double-stained for Fos 
and DBH to qualitatively assess their colocalization within these brainstem 
structures. Sections were rinsed with PBS and incubated for 1 h in a solution 
containing 0.3% Triton X-100 (Sigma-Aldrich) and 2% of normal goat serum 
(Jackson Immunoresearch) in PBS. Sections were then incubated with the 
primary antibodies (rabbit polyclonal anti-c-fos primary antibody 1:500 dilution, 
Santa Cruz Biotechnologies, Santa Cruz, California; mouse anti-DBH 
monoclonal primary antibody, 1:1000 dilution, MAB308, Millipore) for 2 
overnights at 4 °C. Sections were then incubated with the secondary 
antibodies (anti-rabbit Alexa Fluor 594 secondary antibody 1:300 dilution; 
Invitrogen; anti-mouse Alexa Fluor 488 secondary antibody 1:250 dilution, 
Invitrogen) for 90 min at room temperature in the presence of Hoechst 33258 
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(1:5000 dilution; Sigma–Aldrich), used to detect cell nuclei. After final washes, 
slides were cover-slipped with fluoromount (Sigma-Aldrich). 
Fos and OXY double fluorescent immunostaining 
A second series of sections containing the PVN (n=5-7 per group) (from -1.5 
to -2.12 mm from Bregma35) was double-stained for Fos and OXY to assess 
their colocalization within this hypothalamic structure. After rehydration in 
PBS, sections were incubated in 2% normal goat serum (Jackson 
ImmunoResearch) in 0.3% PBST for 1 h. Sections were then incubated for 
one overnight at room temperature with rabbit polyclonal anti-c-fos antibody 
(1:5000 dilution, Ab-5, Calbiochem) and a mouse monoclonal anti-OXY 
antibody (1:1000 dilution; MAB 5296, Millipore). Sections were then rinsed in 
PBST and incubated with a goat anti-mouse Alexa Fluor 488 (1:400 dilution; 
Invitrogen) and a goat anti-rabbit Alexa Fluor 594 (1:300 dilution; Invitrogen) 
for 2 h. After additional washes, the sections were cover-slipped with 
Fluoromount (Sigma-Aldrich). 
 
2.2.6 Image analyses 
All the brain sections obtained from sham and SDA animals included in the 
analyses were observed under a Nikon Eclipse 80i microscope equipped with 
a color charge-coupled device camera and controlled by the software NIS-
Elements-BR (Nikon). Slices were photographed in bright field or 
epifluorescent conditions. The rat brain atlas by Paxinos and Watson35 was 
used as reference for the localization of the brain areas of interest. 
The DAB- immunostaining was measured semi-quantitatively as 
optical density (OD) by using the Scion Image software and considering, for 
background normalization, the averaged OD either of non-immunoreactive 
regions or of white matter structures within the same brain slice. For the 
double immunofluorescence analyses, Fos- or OXY-positive cells were 
manually counted and the colocalization was assessed as the percentage of 
OXY-positive cells within Fos-positive neurons. The investigator was blinded 
to animal treatment, and measurements were obtained in at least three 
consecutive tissue sections per animal containing the desired structure. 
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2.2.7 Statistical analyses 
Immunohistochemical and immunofluorescence data were statistically 
analyzed by two-way ANOVA, with “surgery” and “treatment” as the two 
factors. Tukey’s test was used as a post hoc test to perform multiple 
comparisons. Moreover, because of the difference in the number of slides 
examined and the high degree of freedom, the error degrees of freedom were 
kept constant at a value based on the actual number of animals per group 
used in each experiment. In all instances, the threshold for statistical 
significance was set at P<0.05. 
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2.3 Results 
2.3.1 OEA induces the expression of Fos and DBH in the AP and in the 
NST of both sham and SDA rats 
Neurons of the AP and NST receive direct inputs from vagal afferents, and, in 
turn, project to brain areas that partake in the central control of food intake36–
40. Moreover, previous studies demonstrated that the behavioral effects of 
OEA are paralleled by a selective induction of c-fos in these brain areas34,41. 
Since we already demonstrated that the behavioral effects of OEA are not 
abolished after SDA29, we wanted to further demonstrate whether the SDA 
surgery may prevent the effects of OEA on Fos and DBH expression in the 
AP and in the different subnuclei of the NST (Fig 2.3A). 
We found that SDA did not prevent the OEA-induced Fos expression 
of the AP (Fig 2.3B). Moreover, Fos optical density was increased in most of 
the NST subnuclei of both SHAM and SDA rats treated with OEA, as 
compared to respective controls treated with VEH (Fig 2.3 panels C-F). The 
Fos immunostaining of the SolVL of both SHAM and SDA rats was unaffected 
by OEA treatment (Fig 2.3F). Surprisingly, in the SolC of SDA rats the OEA-
induced increase in Fos expression is attenuated compared to SHAM rats 
treated with OEA (Fig 2.3C), suggesting an involvement of vagal afferents in 
the activation of this subnucleus after OEA administration. 
In addition, we aimed to investigate the effects of peripheral OEA 
administration on vagal efferents. To do so, we measured Fos optical density 
in the DMV, and we found that OEA increases Fos expression in both sham 
and SDA rats (Fig 2.3G). As for the SolC, the increase of Fos expression in 
the SDA animals treated with OEA is attenuated compared to sham OEA-
treated controls, suggesting that a vago-vagal reflex may play a role in OEA’s 
mechanism of action. 
We demonstrated that the noradrenergic fibers that from the NST 
project to the PVN are responsible of the activation of this hypothalamic 
nucleus18, and that the peripheral administration of OEA is able to induce 
DBH expression in the AP and NST17. Hence, the second aim of this study 
was to evaluate the role of abdominal vagal afferents in mediating the OEA-
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induced increase in DBH expression in the brainstem. The results were 
similar to those obtained from measuring Fos optical density (Fig 2.4 panels 
A-E). In fact, OEA treatment led to an increase of DBH expression in the AP 
and in most of the NST subnuclei analyzed of both SHAM and SDA rats, 
compared to respective controls treated with VEH. Again, the DBH 
immunostaining of the SolVL of both SHAM and SDA rats was unaffected by 
OEA treatment (Fig 2.4E). The results from the two-way ANOVA analyses 
conducted for each of the brain areas and for both DBH and Fos expression 
levels are reported in Table 2.1; the results from the post-hoc analyses are 
reported in Fig 2.3 and 2.4, respectively. 
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Fig 2.3: Effects of peripheral OEA administration on the activation within the DVC. Rat 
brain diagram taken from Paxinos brain atlas showing NST subnuclei, AP and DMV, in which 
Fos signal was quantified (A). Semiquantitative analysis of Fos immunostaining within the AP 
(B), commissural (SolC) (C), medial (SolM) (D), dorsomedial (SolDM) (E), ventrolateral (SolVL) 
(F) parts of the NST, and DMV (G) of both sham and SDA rats, treated with either vehicle 
(saline solution, PEG, Tween 80, 90/5/5 v/v/v; 2ml kg-1) or OEA (10 mg kg-1, i.p.). Data are 
expressed as mean ±SEM. *p<0.05; **p<0.01; ***p<0.001 vs vehicle in the same surgery 
group; °p<0.05; °°°p<0,001 vs sham in the same treatment group. AP: n= 3-4 per group; NST 
and DMV: n=4-5 per group. 
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Fig 2.4: Effects of peripheral OEA administration on the noradrenergic transmission 
within the DVC. Semiquantitative analysis of DBH immunostaining within the AP (A), 
commissural (SolC) (B), medial (SolM) (C), dorsomedial (SolDM) (D) and ventrolateral (SolVL) 
(E) parts of the NST of both sham and SDA rats, treated with either vehicle (saline solution, 
PEG, Tween 80, 90/5/5 v/v/v; 2ml kg-1) or OEA (10 mg kg-1, i.p.) (n=5-7 per group). Data are 
expressed as mean ±SEM. *p<0.05; **p<0.01; ***p<0.001 vs vehicle in the same surgery 
group. AP and NST: n=5-7 per group.
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    Ftreatment Fsurgery Finteraction df 
Fos AP 10.148 (P<0.01) 0.636 (P=0.438) 0.012 (P=0.914) 1/15 
 SolC 28.594 (P<0.001) 8.929 (P<0.01) 4.884 (P<0.05) 1/18 
 SolM 22.995 (P<0.001) 0.643 (P=0.433) 0.852 (P=0.368) 1/18 
 SolDM 16.687 (P<0.001) 0.069 (P=0.795) 0.04 (P=0.843) 1/18 
 SolVL 5.692 (P<0.05) 0.232 (P=0.636) 0.121 (P=0.732) 1/18 
  DMV 50.974 (P<0.001) 1,28 (P=0.273) 0,439 (P=0.516) 1/18 
DBH AP 10.19 (P<0.01) 2.132 (P=0.158) 0.151 (P=0.701) 1/23 
 SolC 27.025 (P<0.001) 3.541 (P=0.073) 0.011 (P=0.917) 1/23 
 SolM 16.911 (P<0.001) 0.339 (P=0.566) 1.071 (P=0.311) 1/23 
 SolDM 15.492 (P<0.001) 0.056 (P=0.815) 0.744 (P=0.397) 1/23 
 SolVL 2.671 (P=0.116) 0.255 (P=0.618) 0.117 (P=0.735) 1/23 
 
Table 2.1: Results of the two-way ANOVA analyses of Fos and DBH expression observed 
in the NST subnuclei of both SHAM and SDA rats after intraperitoneal injection of OEA 
or vehicle. Area postrema (AP), commissural (SolC), medial (SolM), dorsomedial (SolDM) and 
ventrolateral (SolVL) parts of the NST, dorsal motor nucleus of the vagus (DMV). 
 
 
2.3.2 SDA may not prevent OEA-induced increase of Fos expression in 
DBH+ neurons in the NST and AP 
We qualitatively investigated, performing double immunofluorescence 
analyses, the colocalization of Fos and DBH in the AP (Fig 2.5A) and in the 
SolM (Fig 2.5B) of SHAM and SDA rats. The images analyzed seemed to 
follow, for both Fos and DBH, the densities observed in the 
immunohistochemistries carried out singularly (see previous chapter) in all 
groups. Moreover, the images likely supported that OEA induces Fos in DBH-
expressing cells in both SHAM and SDA animals. These analyses, therefore, 
would be in line with the behavioral results29, and previous findings17, 
highlighting the role of the noradrenergic projections that rise from the NST in 
mediating OEA’s central effects. 
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Fig 2.5: Effects of peripheral OEA administration on the activation of noradrenergic 
neurons within the DVC. Representative photomicrographs (x20 magnification, scale bar = 
100 µm) of double fluorescent Fos/DBH immunostaining (red/green) within the AP (A) and the 
SolM (B) of both sham and SDA rats, treated with either OEA (10 mg kg-1, i.p.) or vehicle 
(saline, PEG, Tween 80: 90/5/5 v/v/v; 2 ml kg-1).  
 
 
2.3.3 SDA does not prevent OEA-induced increase of Fos expression 
in OXY+ neurons in the PVN 
Our previous work demonstrated that the PVN is activated after OEA 
administration17. Therefore, in the present work we evaluated whether this 
effect could be prevented by SDA surgery. We measured the optical density 
of Fos in the PVN (Fig 2.6B), and the results by two-way ANOVA showed a 
significant effect of treatment (Ftreatment= 16.883, df= 1/21, P<0.001), but not of 
surgery (Fsurgery= 3.139, df= 1/21, P= 0.090) nor of the interaction between the 
two factors (Finteraction= 0.865, df= 1/21, P= 0.362). The results from the test for 
multiple comparisons showed that, in keeping with our previous 
observations17, OEA treatment significantly induced Fos expression in the 
PVN of SHAM-operated rats (P<0.01 vs VEH-treated controls), and, in line 
with the behavioral results29, in SDA rats (P<0.05 vs VEH-treated controls). In 
our previous work we demonstrated that OEA induces Fos in OXY-expressing 
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cells of the PVN17–19. Hence, we wanted to assess whether vagal afferents are 
necessary for this effect. Our results show that the percentage of Fos+/OXY+ 
cells is increased in the PVN after OEA treatment in both SHAM and SDA 
rats. In particular, the results from the two-way ANOVA revealed significant 
effects of the treatment (Ftreatment= 8.896; df= 1/23, P<0.01), but no significant 
effect of the surgery (Fsurgery= 2.198, df= 1/23, P= 0.152) nor of the interaction 
between the treatment and the surgery (Finteraction= 0.000, df= 1/23, P= 0.992). 
Moreover, the results from the test for multiple comparisons showed that OEA 
treatment significantly induced Fos expression in OXY-positive cells the PVN 
of SHAM-operated rats (P<0.05 vs VEH-treated controls), and, in line with the 
behavioral results29, of SDA-operated rats (P<0.05 vs VEH-treated controls) 
(Fig 2.6C). 
Also, we analyzed separately the activation of the parvocellular (PaP) 
and magnocellular (PaM) portions of the PVN. Again, following the results 
obtained from the analysis of the PVN in toto, we found that OEA increases 
Fos expression in both sham and SDA rats. In particular, in both portions, 
data obtained from the two-way ANOVA analysis revealed significant effects 
of the treatment (PaM: Ftreatment= 11.313, df= 1/18, P<0.01; PaP: Ftreatment= 
13.690; df= 1/18, P<0.01), but no significant effect of the surgery (PaM: 
Fsurgery= 0.648, df= 1/18, P= 0.431; PaP: Fsurgery= 0.011, df= 1/18, P= 0.918) 
nor of the interaction between the treatment and the surgery (PaM: Finteraction= 
0.040; df= 1/18; P= 0.844; PaP: Finteraction= 0.138, df= 1/18, P= 0.715). 
Moreover, the results from the test for multiple comparisons showed that OEA 
treatment significantly induced Fos expression in the PaM and PaP of both 
sham- (P<0.01 vs veh-treated controls) and SDA-operated rats (P<0.05 vs 
veh-treated controls) (Fig 2.6D-E). 
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Fig 2.6: Effects of peripheral OEA administration on the activation of the PVN. Rat brain 
diagram showing the PVN (A). Semiquantitative analysis of Fos immunostaining (B) and 
percentage of cells coexpressing Fos/OXY (C) within the PVN; semiquantitative analysis of Fos 
immunostaining within the parvocellular (PaP) (D) and magnocellular (PaM) (E) portions of the 
PVN, of both sham and SDA rats, treated with either vehicle (saline solution, PEG, Tween 80, 
90/5/5 v/v/v; 2ml kg-1) or OEA (10 mg kg-1, i.p.) (n=5-7 per group). Data are expressed as mean 
±SEM. *p<0.05; **p<0.01 vs vehicle in the same surgery group. 
 
2.3.4 Effects of SDA on OEA-induced Fos expression in the 
hypothalamus  
Our previous work demonstrated that the vTMN participates in OEA’s effect 
on eating17,20. Therefore, we aimed to investigate whether the lesion of vagal 
afferents may prevent OEA’s effects on this hypothalamic nucleus. We 
measured the optical density (Fig. 5B), and data obtained from the two-way 
ANOVA analysis showed a statistical significance of the treatment (Ftreatment= 
9.438, df= 1/15, P<0.01), but not of the surgery (Fsurgery= 0.194, df= 1/15, P= 
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0.665) or the interaction between the two factors (Finteraction= 0.508, df= 1/15, 
P= 0.486). The results from the test for multiple comparisons showed that 
OEA increases Fos expression in SHAM animals (P<0.01 vs VEH-treated 
controls) but not in SDA animals, were the same trend is observed, although it 
does not reach the statistical significance (Fig 2.7B). 
Previous studies showed that the peripheral administration of OEA (10 
mg kg-1) does not induce changes in the expression of c-fos in the Arc15. 
Conversely, recent experiments conducted in mice demonstrated that OEA 
increases Fos expression in the Arc21. Our results show that OEA has no 
effect on the activation of this hypothalamic nucleus (Fig 2.7C). In fact, the 
results from the two-way ANOVA did not show a statistical significance of the 
treatment (Ftreatment= 0.013, df= 1/19, P= 0.910), nor of the surgery (Fsurgery= 
0.574, df= 1/19, P= 0.458) or the interaction between the two factors 
(Finteraction= 1.535, df= 1/19, P= 0.230). 
Fig 2.7: Effects of peripheral OEA administration on other areas of the hypothalamus. 
Rat brain diagram taken from Paxinos brain atlas showing the PVN (A). Semiquantitative 
analysis of Fos immunostaining within the ventral part of the tuberomammilary (vTMN) (B) and 
arcuate (Arc) (C) nuclei, of both sham and SDA rats, treated with either vehicle (saline solution, 
PEG, Tween 80, 90/5/5 v/v/v; 2ml kg-1) or OEA (10 mg kg-1, i.p.) (n=5-7 per group). Data are 
expressed as mean ±SEM. **p<0.01 vs vehicle in the same surgery group. 
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2.4 Discussion 
The study of the gut-brain axis, and, in particular, of all the molecules that 
partake in the control of energy balance, is of crucial importance in order to 
find novel therapeutic targets to treat obesity. Among the molecules that play 
a role in the control of feeding, OEA has gained a great deal of attention due 
to its anorexiant effects15–19,34, however, to date, the machanism through 
which it reaches the CNS still needs to be fully elucidated. 
It has been reported that both the TVX16 and the systemic treatment 
with a neurotoxic dose of capsaicin15 are able to abolish the anorexiant effect 
of OEA, strongly suggesting an involvement of the vagal afferent system in its 
mechanism of action. However, there are limits to both these approaches: 
with the TVX surgery, both afferent and efferent fibers are lesioned, leading to 
changes in the sensory mechnisms and motor functions of the GI tract23; on 
the other hand, is toxic to unmyelinated fibres, so both vagal and spinal 
neurons are lesioned25,26. Moreover, capsaicin is not able to lesion since the 
myelinated vagal afferent fibres, are up to 20% of the total25. Therefore, 
because of the limits presented by these techniques, the SDA surgery was 
used in this study. SDA is the most selective surgery targeting vagal afferents, 
and eliminates all of the afferent fibers while sparing around 50% of the 
efferent ones32,33. Using this approach, it is possible to avoid the side effects 
induced by the TVX23, and to lesion selectively the afferent fibers of the vagus 
nerve, both myelinated and unmyelinated24. 
A recent study tested the hypophagic effect of OEA in rats subjected to 
SDA surgery and, surprisingly, demonstrated that vagal afferents are not 
necessary for the hypophagic effects of peripherally administered OEA29. 
Moreover, a novel study conducted by our research team demonstrated that 
the lesion of the AP, a cirumventricular organ that lacks a functional BBB, 
abolishes both the behavioral and the neurochemical effects of OEA17. 
Hence, to broaden our knowledge about the mechanism of action of this 
molecule, this study we investigated the role of vagal afferents in the 
neurochemical effects of OEA. 
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First, we focused our attention on the activation of the DVC. In 
particular, we carried out the densitometric analysis of the immunostaining 
directed towards Fos in the AP, the DMV, the NST and its subnuclei, namely 
the commissural (SolC), medial (SolM), dorsomedial (SolDM) and 
ventrolateral (SolVL) subnuclei. 
It is known that the AP, together with the NST, receives direct inputs 
from the vagus nerve27,28. Moreover, as already demonstrated by our 
laboratory, the peripheral administration of OEA is able to induce the 
expression of Fos in the AP17. 
In the present study, we demonstrate for the first time that the OEA-
induced activation of the AP does not require intact vagal afferents: in fact, in 
line with the behavioral results29, OEA induces the expression of Fos in both 
sham and SDA rats. This supports the hypothesis that OEA does not act 
mainly through the vagus nerve, as supported by prevoius evidence15,16, but 
through this circumventrivular organ17, even though these results may seem in 
contrast. Regarding the lesion of vagal afferents with capsaicin, a possible 
explanation may be found in the fact that the peripheral administration of this 
neurotoxic compound may damage neurons of the AP that receive direct 
inputs from the vagal umyelinated fibres27,28. Thus, one interpretation 
accommodating the data we obtained with the previous capsaicin data is that 
unmyelinated spinal visceral afferents mediate the eating-inhibitory effect of 
OEA. On the other hand, the reason behind the loss of OEA’s pro-satiety 
effect after TVX surgery, that leaves the spinal visceral afferents intact, is less 
clear. One possible explanation, other than the side effects that this surgery 
can induce42,43, lies in a potential role of vagal efferents in mediating OEA’s 
effects: in fact, in this study we report for the first time that OEA induces the 
expression of Fos in the DMV, and this effect does not require an intact vagal 
afferent system. Moreover, preliminary data obtained in our laboratory show 
that the OEA-induced increase of Fos expression in the DMV is blunted in 
animals that underwent a surgical lesion of the AP, further supporting the 
hypothesis that this circumventricolar organ plays a pivotal role in mediating 
OEA’s effects. 
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Previous studies conducted by our laboratory demonstrated that the 
hypophagic effect of OEA is paralleled by the increase of Fos expression in 
the subnuclei of the NST17,34. 
In the present study, the results obtained by the densitometric 
analyses of the subnuclei of the NST show that, as already demonstrated17,34, 
OEA induces the expression of Fos in all subnuclei of the NST, except for the 
SolVL, in SHAM rats. Moreover, in line with the behavioral results29, the 
peripheral administration of OEA is able to induce Fos expression in all 
subnuclei of the NST, except for the SolVL, in SDA animals. Surprisingly, the 
increase of Fos expression in the SolC of OEA-treated SDA animals is 
attenuated compared with sham OEA-treated animals, suggesting a role 
played by vagal afferents in activating this portion of the NST after OEA 
administration. 
Moreover, OEA induces the major increase in Fos expression at the 
level of SolM, a subnucleus particularly involved in the regulation of food 
intake, since it responds to the peripheral signals involved in the control of 
feeding behavior, such as leptin44. As already showed by our previous work17, 
this portion of the NST plays a pivotal role in OEA’s mechanism of action, 
since it receives projections from the AP 12, and is where the cell bodies of A2 
noradrenergic neurons that send projections to the PVN12 are located. 
The same results obtained in the subnuclei of the NST for Fos 
expression were obtained after the densitometric analysis of the expression of 
DBH. In particular, along with Fos expression, peripheral OEA administration 
increases the DBH expression in both sham and SDA rats. Again, as 
expected17,and in keeping with our previous observation this increase is 
mainly observed at the level of the SolM. 
Based on our previous observations, that show that OEA activates the 
noradrenergic neurons of both the AP and SolM17, we further qualitatively 
investigated whether this effect is still observed in SDA animals. In line with 
the behavioral results29, peripheral administration of OEA is able to increase 
Fos expression in DBH-positive cells in both sham and SDA rats, further 
98 
 
confirming that vagal afferents are not necessary for the activation of this 
pathway, and, hence, for OEA’s satiety effect. 
We have already demonstrated that the NST-PVN noradrenergic 
pathway is crucial for OEA’s mechanism of action18. Moreover, the 
noradrenergic fibers projecting to the PVN have their cell bodies in the SolM12. 
In particular, evidence demonstrate that the saporin-induced lesion of these 
fibres injected in the PVN18 induces the loss of the cell bodies in the SolM, 
specially where the A2 cells are located, that directly project to the 
oxytocinergic neurons of the PVN45. Hence, we evaluated the activation of this 
hypothalamic area and the effects on the oxytocinergic system induced by the 
peripheral administration of OEA. As it has been already demonstrated, OEA 
is able to induce Fos expression in the PVN of sham rats17. In this study, for 
the first time, we demonstrate that the activation of this hypothalamic nucleus 
does not require intact vagal afferent system. We then analyzed the two major 
oxytocinergic sub-population of neurons of the PVN separately, the PaP (that 
project to several other brain areas) and the PaM (that send projections to the 
neurohypophysis)46. As for the PVN, SDA surgery does not impair the OEA-
mediated activation of these two distinct portions of oxytocinergic neurons. 
Moreover, since it is known that OEA induces Fos in OXY+ cells17–19, we finally 
investigated if this effect is mediated by vagal afferents. The results we 
obtained by counting Fos+/OXY+ double-labeled cells show that the activation 
of the oxytocinergic cells exerted by OEA does not require an intact vagal 
afferent system. 
Recents studies involving mice with a genetic deletion of the gene 
coding for histidine dexarboxylase (HDC-KO mice) showed that OEA’s 
hypophagic action requires an intact histaminergic system20. Based on these 
findings, we analyzed the activation of the vTMN, the only source of 
histminergic neurons in the CNS47. The data obtained show that the 
peripheral administration of OEA induces Fos expression in the vTMN of 
sham rats, and the same trend is observed in SDA animals, even though it 
does not reach statistical significance. However, since the activation of the 
vTMN is necessary for the satiety effect of OEA17,20, and SDA does not 
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prevent OEA’s effects on feeding, we can presume that the increase in Fos 
expression in the vTMN of SDA rats, although not significant, is still sufficient 
for OEA to exert its anorexic effects. 
Finally, since the results regarding the activation of the Arc after OEA 
administration are unclear, we analyzed the activation of this nucleus and the 
hypothetical role of vagal afferents in this effect. Recent experiments 
conducted in mice demonstrated that OEA increases Fos expression in the 
Arc21, whereas, in the present work, OEA does not activate this hypothalamic 
nucleus. The difference between the two results could be due to the feeding 
state of the animals: in fact, the animals in the former work were starved for 
12 h before OEA administration, and food deprivation has been demonstrated 
to influence the activation of the Arc nucleus48. Therefore, our results are in 
line with previous results15, where peripheral administration of OEA has no 
effect on the activation of this circumventricular organ. 
In conclusion, the data obtained with the present study show that the OEA-
induced effects on the CNS do not require an intact vagal afferent system. 
Conversely, the present work further supports the pivotal role played by the 
AP, but not other circumventricular organs such as Arc, in mediating such 
effects. 
Due to the lack of efficient pharmacological therapies for treating 
obesity, discovering new aspects about the role of the mediators of the gut-
brain axis in the regulation of feeding behavior is of crucial importance. Almost 
20 years of preclinical and clinical research clearly support the hypothesis that 
OEA may represent a successful canditate to treat obesity and aberrant 
eating-related disorders. 
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Chapter 3: 
Role of oleoylethanolamide in regulating gene 
expression in both brain and peripheral organs 
 
 
 
Abstract 
Oleoylethanolamide (OEA), is a fatty acid ethanolamide (FAE), known to induce 
satiety by modulating the meal pattern in laboratory animals. It has been observed 
that these behavioral effects require the activation of the peroxisome proliferator-
activated receptor-α (PPAR-α), of which OEA is a high affinity ligand. PPAR-α is a 
transcription factor and, among the genes under its control, an important role is 
played by the cluster of differentiation 36 (CD36) and interleukin 6 (IL-6), for their 
effects on the modulation of uptake of FA and inflammatory responses, respectively. 
After its peripheral administration (10 mg kg-1, i.p.), OEA is able to modulate lipid 
metabolism and increase FA oxidation in the liver in a PPAR-α dependent fashion; at 
the level of the central nervous system (CNS), OEA engages neural circuits involved 
in the control of feeding behavior. In particular, in our previous work, we demonstrated 
that the area postrema (AP) is crucial not only for the behavioral effects of OEA, but 
also is responsible of the activation of the pathways that underlie OEA central effects. 
Therefore, the aim of the present work is to evaluate if the effects induced by OEA 
peripheral administration (10 mg kg-1, i.p.) are paralleled by changes in gene 
expression. In particular, we collected brain areas (AP, nucleus of the solitary tract 
(NST), arcuate nucleus, median eminence (Arc/ME), dorsal hippocampus (dHippo) 
and peripheral organs, in particular Liver, duodenum (Duo) and jejunum (JJ), from 
rats that were treated with vehicle or OEA (10 mg kg-1, i.p.) and sacrificed at different 
time points, and analyzed the expression of PPAR-α, CD36 and IL-6 through RT-
qPCR. 
Overall, our findings confirm the pivotal role played by AP in the hypophagic 
effect of OEA and deepen our knowledge about its mechanism of action in peripheral 
organs, especially in the liver. 
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3.1 Introduction 
Oleoylethanolamide (OEA), is a gut-derived fatty acid ethanolamide (FAE), 
produced in the small intestine upon the ingestion of dietary fat1. OEA is 
known to reduce food intake through the modulation of the meal pattern2, by 
activating the peroxisome proliferator-activated receptor-alpha (PPAR-α)3. In 
fact, it has been demonstrated that OEA is able to activate this receptor at 
nanomolar concentrations, and that its genetic deletion abrogates the 
hypophagic effects of OEA3. PPAR-α, moreover, is a transcriptional regulator 
of genes involved in peroxisomal and mitochondrial β-oxidation, FA transport4 
and hepatic glucose production5, and is particularly abundant in peripheral 
districts with high FA oxidation (FAO) rates, such as liver and brown adipose 
tissue, although it is also expressed in the intestine and the vascular 
endothelium6. Hence, by activating this receptor, OEA acts in the periphery by 
increasing FAO7. These effects are due to OEA’s ability to regulate gene 
expression in the liver, jejunum and duodenum of wild-type mice, and these 
effects are absent in PPAR-α KO mice3. 
On the other hand, OEA acts in the central nervous system (CNS) by 
activating key brain areas involved in the control of feeding8–11: in fact, it has 
been shown that OEA’s behavioral effects rely on the activation of the 
noradrenergic10,11, oxytocinergic11,12, and the histaminergic11,13 neural circuits. 
In our previous work, we demonstrated the crucial role played by the area 
postrema (AP), a circumventricular organ that lacks a functional blood-brain 
barrier (BBB) located in the brainstem, in mediating OEA’s both behavioral 
and neurochemical effects11. In the same work, we further demonstrated that 
PPAR-α is expressed in this brain region, and thus we hypothesized that OEA 
may enter the CNS through the fenestrated capillaries of the AP, activate 
PPAR-α receptors and then, in turn, exert all the downstream events involving 
the brain structures that partake in OEA’s mechanism of action11. AP is in 
close contact with the nucleus of the solitary tract (NST), the primary relay 
station of vagal afferents14, that is also strongly activated by OEA 
administration8,9,11. The NST is known to send projections towards many brain 
areas, in particular the hypothalamic areas that partake in OEA’s mechanism 
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of action10. Moreover, in our previous work11, we hypothesized that OEA may 
reach the AP through the bloodstream, and, to date, it seems to be the only 
circumventricular organ that partakes in OEA’s mechanism of action. 
Obesity alters fat uptake15 and induces inflammation, that may lead to 
cognitive impairment16. In fact, recent findings demonstrate that a prolonged 
exposure to a high fat diet increases the risk of hippocampal alterations, 
leading to deficits in learning and memory17, suggesting that a disruption of 
FA homeostasis in the dorsal hippocampus (dHippo) plays a role in cognition. 
Moreover, it has been observed that both the administration of PPAR-α 
agonists18 and OEA19 improve memory by activating this brain area.  
It is known that OEA, by activating PPAR-α, triggers gene expression 
in peripheral organs, such as liver, duodenum, and jejunum3. However, little is 
known about the effects that OEA may exert at the gene expression level in 
the CNS. Therefore, the aim of the present work is to assess the effects of 
acute peripheral administration of OEA on gene expression in the CNS, in 
particular in the AP; the NST; the caudal part of the hypothalamus containing 
the arcuate nucleus (Arc) and the median eminence (ME) (Arc/ME), to 
investigate whether these circumventricular organs partake in OEA’s 
mechanism of action; and in the dorsal part of the hippocampus (dHippo). 
Moreover, we carried out these analyses in peripheral organs such as liver, 
where OEA increases PPAR-α mRNA levels, and modulates lipid metabolism 
and FAO7,20, duodenum (Duo) and jejunum (JJ), where OEA is known to be 
produced1. In order to do so, we treated rats with an acute i.p. administration 
of vehicle (veh) or OEA (10 mg kg-1) and sacrificed them at different time 
points. We then collected samples of the peripheral organs and brain areas 
and analyzed gene expression levels through RT-qPCR. In order to assess 
the effects of OEA on fat uptake and inflammation, the genes we targeted are 
PPAR-α and two genes under its control, the cluster of differentiation 36 
(CD36), also known as FA translocase (FAT), and interleukin 6 (IL-6). CD36, 
whose gene expression is positively regulated by PPAR-α agonists21 
coordinates the uptake and processing of free FA22 and plays a role in the 
regulation of energy balance. Therefore, it is involved in the onset of 
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metabolic disorders such as insulin resistance, type 2 diabetes mellitus, 
obesity, and non-alcoholic hepatic steatosis23. On the other hand, IL-6, whose 
gene expression is repressed by PPAR-α24, is a known pro-inflammatory 
cytokine and myokine. 
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3.2 Materials and methods 
3.2.1 Animals 
A total of 112 male Wistar-Han rats (Janvier Labs, Le Genest-Saint-Isle, 
France) were used in this study. All animals, weighing 275–325 g upon arrival, 
were individually housed in wire mesh cages under a 12:12 h dark-light cycle 
in a climate-controlled room (22 ± 2◦C and 60% relative humidity). All rats 
were fed with standard chow pellets (N 3430, Provimi KIiba, Gossau, 
Switzerland) ad libitum. All experiments were performed upon the approval of 
the Veterinary Office of the Canton of Zurich and according to the European 
Community directives 2010/63/EU. 
 
3.2.2 Drugs and treatments 
OEA was synthesized as previously described25, dissolved in the vehicle (veh; 
saline/PEG/Tween80, 90/5/5 v/v/v, 2 ml kg-1), and administered 10 mg kg-1 via 
i.p. injections. Both veh and OEA solutions were freshly prepared on each test 
day and administered about 30 min before dark onset. 
 
3.2.3 Behavioral experiment and organ harvesting 
On test day, food was weighed and temporarily removed from the cages 1 h 
prior to dark onset. Starting from 30 minutes before the dark phase, all the 
animals received an i.p. injection of either veh or OEA and were again given 
free access to food. After 2.5, 5, 15, 30, 60, 120 or 240 minutes, animals were 
deeply anesthesized with isoflurane, and blood, peripheral organs (Liver, Duo 
and JJ), and brain areas (AP, NST, Arc/ME and dHippo) were harvested. 
Briefly, samples of the peripheral organs taken in consideration were 
dissected, collected in an eppendorf tube and immediately snap frozen in 
liquid nitrogen. Regarding the brain areas, Arc/ME and dHippo were dissected 
with the aid of a rat brain matrix, whereas AP and NTS were extracted with 
the aid of curved forceps and a scalpel, and immediately snap frozen in liquid 
nitrogen. Food was measured again after sacrifice to assess the amount of 
food consumed by the animals after OEA or veh administration (n= 8 per 
group). 
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3.2.4 RT-qPCR analyses 
All samples from 120 and 240 minutes were analyzed by RT-qPCR to assess 
the changes in gene expression after OEA administration (n= 4-8 per group). 
Total RNA was extracted using, according to the manufacturer’s instructions, 
the ReliaPrep™ RNA Tissue Miniprep System (Promega, Fitchburg, WI, USA) 
from all the tissues. cDNA was then synthesized using the SensiFAST™ 
cDNA Synthesis Kit (BIOLINE, London, UK) from 1 μg of total RNA. qPCR 
was performed with an ABI 7500 instrument and software (Applied 
Biosystems, Foster City, CA, USA). The following conditions were used for 
amplification: an initial holding stage of 10 min at 95 °C, then 40 cycles 
consisting of denaturation at 95 °C for 15 s, annealing and extension at 60 °C 
for 60. Each sample was measured in duplicate during the same run. Data are 
normalized to the GAPDH mRNA expression. The sequences of the primers 
used are listed in Table 3.1. 
 
GAPDH 
Fwd AAGAAGGTGGTGAAGCAGGC 
Rev TCCACCACCCAGTTGCTGTA 
CD36 
Fwd TGAGCCTACATTATGCACTAGC 
Rev CACACCACCGTTTCTTCAAC 
IL-6 
Fwd CACTTCACAAGTCGGAGGCT 
Rev TCTGACAGTGCATCATCGCT 
PPAR-α 
Fwd CGGGATGTCACACAATGCAATC 
Rev CAGATCGTGTTCACAGGTAAGG 
 
Table 3.1: List of the primers used in the study.  
3.2.5 Statistical analyses 
Feeding data were statistically analyzed by Student’s t-test for mean 
comparison between veh- and OEA-treated animals at the same time-point 
(IBM SPSS, version 22, IBM Analytics). PCR data were statistically analyzed, 
using the 2-∆Ct method, by two-way ANOVA, with “time” and “treatment” as the 
two factors. Tukey’s test was used as a post hoc test to perform multiple 
comparisons. 
In all instances, the threshold for statistical significance was set at P<0.05. 
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3.3 Results 
3.3.1 Behavioral results 
OEA is known to reduce food intake when administered i.p. to free feeding 
rats few minutes before dark onset, at a dosage (10 mg kg−1) that does not 
readily allow penetration into the brain9,10,12. In this experiment, cumulative 
food intake was monitored after the sacrifice at each time point considered 
(2.5, 5, 15, 30, 60, 120 and 240 min). In particular, the results of the t-test 
analyses performed for each time point showed that OEA is able to 
significantly decrease food intake at 5 (P<0.05), 15 (P<0.001), 30 (P<0.001), 
60 (P<0.01) and 120 (P<0.05) min, whereas no significant reduction was 
observed at 2.5 and 240 min time point (Fig 3.1). 
 
Fig 3.1: Effects of peripheral OEA administration on food intake at different time points. 
Time course of the cumulative food intake of animals sacrificed at different time points, treated 
with either vehicle (saline solution, PEG, Tween 80, 90/5/5 v/v/v; 2ml kg-1) or OEA (10 mg kg-1, 
i.p.) (n=8 per group). Data are expressed as mean ±SEM. *p<0.05; **p<0.01; ***p<0.001 vs 
vehicle at the same time point. 
 
 
3.3.2 Effects on gene expression in different brain areas 
Regarding the gene expression analyses, we started analyzing OEA’s effects 
on gene expression in the AP, a circumventricular organ located in the 
brainstem. The AP in known to be the site of action of OEA11, where it could 
possibly activate the PPAR-α receptor, its main pharmacological target3. In 
fact, our results show that the treatment with OEA (10 mg kg-1, i.p.) is able to 
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induce PPAR-α expression 120 min after administration. The results of the 
Two-way ANOVA did not show a significant effect of the time (Ftime= 3.441; 
df= 1/31; P= 0.074), nor of the treatment (Ftreatment= 2.936; df= 1/31; P= 0.098) 
or of the interaction between these two factors (Finteraction= 3.441; df= 1/31; P= 
0.074). Moreover, the results of Tukey’s test for multiple comparisons showed 
that OEA is able to significantly increase the levels of expression of PPAR-α 
120 min after administration in the AP (*P<0.05 vs 120 min veh). Interestingly, 
PPAR-α mRNA levels significantly decrease 4h after administration (°P<0.05 
vs 120 min in the same treatment group) (Fig. 3.2). No differences were 
observed in the levels of expression of the other genes analyzed (Table 3.2). 
Since it is well known that peripheral administration of OEA (10 mg kg-
1, i.p.) induces the activation of the NST8,9,11, we aimed to investigate if this 
activation is paralleled by changes in gene expression at this level. 
Surprisingly, no changes in the expression of PPAR-α or its downstream 
target genes were observed in the NST (Table 3.2), suggesting that other 
mechanisms underlie the activation of the NST (Fig. 3.2). 
 
 
Fig. 3.2: Effects of peripheral OEA administration on gene expression in different brain 
areas 2 and 4 hours after administration. mRNA expression levels of PPAR-α, CD36 and IL-
6 in the AP (A-C) and in the NST (D-F) of animals treated with veh or OEA (10 mg kg-1, i.p.) 
and sacrificed 120 or 240 min after treatment (AP: n= 8 per group; NST: n= 5-6 per group). 
Data are expressed as mean ±SEM. *p<0.05 vs vehicle at the same time point; °p<0.05 vs 120 
min in the same treatment group. 
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Moreover, we aimed to investigate if OEA, through the bloodstream, could 
reach other circumventricular organs. Therefore, we evaluated the effects of 
OEA on gene expression in the caudal part of the hypothalamus, containing 
the ME and the Arc nuclei, already known to receive blood-borne signals such 
as leptin26. We found that the peripheral administration of OEA has no effects 
on the expression on PPAR-α or on the IL-6 mRNA levels in these 
hypothalamic nuclei (Table 3.2). Surprisingly, i.p. OEA administration (10 mg 
kg-1) increased mRNA levels of CD36: the results of the Two-Way ANOVA 
showed a significant effect of the time and of the interaction between time and 
treatment (Ftime= 5.451; df= 1/30; P= 0.027; Finteraction= 5.451; df= 1/30; P= 
0.027), but not of the treatment alone (Ftreatment= 2.548; df= 1/30; P= 0.122). 
Moreover, the results of the Tukey’s post hoc test for multiple comparisons 
showed that CD36 mRNA levels are significantly increased 120 min after 
administration (*P<0.05 vs veh-treated controls at the same time point), and 
they decrease over time (°°P<0.01 vs 120 min in the same treatment group) 
(Fig.3.3). 
No changes were observed in the mRNA levels of PPAR-α and IL-6 
(Table 3.2) within the hippocampus, whereas the peripheral administration of 
OEA (10 mg kg -1, i.p.) is able to increase CD36 mRNA levels in this brain 
area, although, as we observed in the Arc/ME, this effect is not paralleled by 
an increase of PPAR-α mRNA levels as we might have expected. In 
particular, the results of the Two-way ANOVA did not show a significant effect 
of time, nor of treatment or of interaction between these two factors (Ftime= 
1.130; df= 1/19; P= 0.304; Ftreatment= 2.760; df= 1/19; P= 0.116; Finteraction= 
1.130; df= 1/19; P= 0.304). Moreover, the Tukey’s post-hoc test for multiple 
comparisons showed that OEA is able to significantly increase CD36 mRNA 
levels 120 min after administration (*P<0.05 vs veh treated controls at the 
same time point) (Fig. 3.3). 
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Fig. 3.3: Effects of peripheral OEA administration on gene expression in different brain 
areas 2 and 4 hours after administration. mRNA expression levels of PPAR-αlpha, CD36 
and IL-6 in the Arc/ME (A-C) and in the dHippo (D-F) of animals treated with veh or OEA (10 
mg kg-1, i.p.) and sacrificed 120 or 240 min after treatment (Arc/ME: n= 7-8 per group; dHippo: 
n= 5-6 per group). Data are expressed as mean ±SEM. *p<0.05 vs vehicle at the same time 
point. 
 
 
3.3.2 Effects on gene expression in different peripheral organs 
It is known that OEA acts in the periphery, where it regulates lipid metabolism 
and FAO7,20. In particular, it has already been shown that it increases mRNA 
levels of PPAR-α and its target genes (such as CD36 and FABP-1) in the 
liver3. In the present work we found that, as expected, peripheral OEA 
administration (10 mg kg-1, i.p.) increases the expression of PPAR-α: the 
results of the Two-way ANOVA showed a significant effect of time (Ftime= 
26.147; df= 1/28; P<0.001) and of interaction between time and treatment 
(Finteraction= 26.147; df= 1/28; P<0.001), but no significant effect of treatment 
(Ftreatment= 3.682; df= 1/28; P= 0.066). Moreover, the Tukey’s post hoc test for 
multiple comparisons revealed that PPAR-α mRNA levels significantly 
increased 120 min after OEA administration (***P<0.001 vs veh-treated 
controls at the same time point) and decreased 240 min after treatment 
(°°°P<0.001 vs 120 min in the same treatment group). Interestingly, at this 
time point, PPAR-α mRNA levels are lower compared to veh-treated controls 
(*P<0.05 vs veh at the same time point) (Fig. 3.4). Moreover, OEA treatment 
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(10 mg kg-1, i.p.) seems to reduce CD36 mRNA levels, even though it does 
not reach statistical significance (P=0.050). No differences were observed in 
the expression of IL-6 (Table 3.2).  
As next step of our experiments, we analyzed gene expression in the 
upper intestine, were OEA is produced1. In both the Duo and JJ, as 
expected3, peripheral OEA administration (10 mg kg-1, i.p.) increases PPAR-α 
mRNA levels. In particular, the results of the Two-way ANOVA did not show, 
in the Duo, a significant effect of time, nor of treatment or of interaction 
between these two factors (Ftime= 2.851; df= 1/28; P= 0.104; Ftreatment= 4.224; 
df= 1/28; P= 0.050; Finteraction= 2.851; df= 1/28; P= 0.104). Moreover, the 
results of the Tukey’s post hoc test for multiple comparisons show that PPAR-
α mRNA levels increase 120 min after OEA administration (*P<0.05 vs veh at 
the same time point) and decrease 240 min after treatment (°P<0.05 vs 120 
min in the same treatment group). Regarding the JJ, peripheral OEA 
administration (10 mg kg-1, i.p.) increases PPAR-αlpha mRNA levels 120 min 
after its administration. In particular, the results of the Two-way ANOVA 
showed a significant effect of the treatment (Ftreatment= 4.940; df= 1/26; 
P<0.05), whereas no significant effect was observed for either the time or for 
the interaction between the two factors (Ftime, Finteraction= 3.242; df= 1/26; P= 
0.085). Moreover, the results of the Tukey’s post hoc test for multiple 
comparisons showed that PPAR-α mRNA levels significantly increase 120 
min after administration (*P<0.05 vs veh-treated controls at the same time 
point) and decrease 240 min after administration (°P<0.05 vs 120 min in the 
same treatment group). 
We further analyzed the levels of expression of CD36: surprisingly, in 
the Duo, i.p. administration of OEA (10 mg kg-1) did not induce changes in 
mRNA levels of this transporter (Table 3.2), whereas, in the JJ, the results of 
the Two-way ANOVA showed a significant effect of the treatment (Ftreatment= 
5.510; df= 1/29; P<0.05), while no significant effect of the time or of the 
interaction between the two factors was observed (Ftime, Finteraction= 0.666; df= 
1/29; P= 0.422). Moreover, in line with previous findings3 the results of the 
Tukey’s test for multiple comparisons show that the peripheral administration 
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of OEA is able to significantly increase CD36 mRNA levels 240 min after 
administration (*P<0.05 vs veh at the same time point). Lastly, in both the Duo 
and the JJ, peripheral OEA administration increases IL-6 mRNA levels 120 
min after administration. In particular, in the Duo, the results of the Two-way 
ANOVA showed a significant effect of the time, the treatment and of the 
interaction between the two factors (Ftime= 8.611; df= 1/21; P<0.01; Ftreatment= 
15.127; df= 1/21; P<0.01; Finteraction= 8.611; df= 1/21; P<0.01). Moreover, the 
Tukey’s post hoc test for multiple comparisons showed that IL-6 mRNA levels 
significantly increase 120 min after OEA i.p. administration (***P<0.001 vs 
veh-treated controls in the same time point) and decrease 240 min after 
treatment (°°P<0.01 vs 120 min in the same treatment group). In the JJ, the 
results of the Two-way ANOVA showed a significant effect of the time, the 
treatment and of the interaction between the two factors (Ftime= 12.899; df= 
1/26; P<0.01; Ftreatment= 5.455; df= 1/26; P<0.01; Finteraction= 12.899; df= 1/26; 
P<0.01). Moreover, the Tukey’s post hoc test for multiple comparisons 
showed that IL-6 mRNA levels significantly increase 120 min after OEA i.p. 
administration (***P<0.001 vs veh-treated controls in the same time point) and 
decrease 240 min after treatment (°°°P<0.001 vs 120 min in the same  
treatment group). 
 
 
Table 3.2: Results of the two-way ANOVA analyses of mRNA expression levels observed 
in brain areas and peripheral organs after intraperitoneal injection of OEA or vehicle. 
Area postrema (AP), nucleus of the solitary tract (NST), arcuate nucleus/median eminence 
(Arc/ME), dorsal hippocampus (dHippo), liver and duodenum (Duo). 
 
    Ftime Ftreatment Finteraction df 
AP CD36 0.232 (P=0.634) 1.207 (P=0.281) 0.232 (P=0.634) 1/29 
  IL-6 0.002 (P=0.969) 1.304 (P=0.264) 0.002 (P=0.969) 1/29 
NST PPAR-α 1.019 (P=0.326) 0.004 (P=0.952) 1.019 (P=0.326) 1/22 
 CD36 2.036 (P=0.170) 0.127 (P=0.726) 2.036 (P=0.170) 1/22 
  IL-6 0.136 (P=0.716) 0.220 (P=0.884) 0.136 (P=0.716) 1/22 
Arc/ME PPAR-α 2.456 (P=0.128) 0.001 (P=0.972) 2.456 (P=0.128) 1/30 
  IL-6 1.188 (P=0.285) 0.627 (P=0.435) 1.188 (P=0.285) 1/30 
dHippo PPAR-α 0.340 (P=0.856) 0.015 (P=0.904) 0.340 (P=0.856) 1/21 
  IL-6 0.010 (P=0.920) 0.078 (P=0.783) 0.010 (P=0.920) 1/21 
Liver CD36 0.725 (P=0.402) 4.205 (P=0.051) 0.725 (P=0.402) 1/29 
  IL-6 0.188 (P=0.669) 2.869 (P=0.103) 0.188 (P=0.669) 1/29 
Duo CD36 0.576 (P=0.454) 0.001 (P=0.978) 0.576 (P=0.454) 1/30 
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Fig. 3.4: Effects of peripheral OEA administration on gene expression in different 
peripheral organs 2 and 4 hours after administration. mRNA expression levels of PPAR-α, 
CD36 and IL-6 in the Liver (A-C), in the Duo (D-F) and the JJ (G-I) of animals treated with veh 
or OEA (10 mg kg-1, i.p.) and sacrificed 120 or 240 min after treatment (Liver and Duo: n= 7-8 
per group; JJ: n= 6-7 per group). Data are expressed as mean ±SEM. *p<0.05; ***p<0.001 vs 
vehicle at the same time point; °p<0.05; °°°p<0.001 vs 120 min in the same treatment group. 
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3.4 Discussion 
OEA induces a long-lasting and dose-dependent reduction of food intake in 
laboratory animals in a PPAR-α-dependent fashion3. The behavioral results of 
the present work, are in line with numerous previous findings3,8–12,27, and 
highlight the ability of OEA to reduce food intake over time. Moreover, by 
activating PPAR-α, OEA is able, in the CNS, to trigger a complex neuronal 
cascade underlying its behavioral effects8–11. In our previous work, we 
demonstrated that the AP, a circumventricular organ located in the brainstem, 
is crucial for OEA’s behavioral and neurochemical effects11. In the present 
work, we demonstrate, for the first time, that the acute peripheral 
administration of OEA (10 mg kg-1, i.p.) induces the transcription of PPAR-α in 
the AP selectively, although this effect is not followed by the modulation of the 
expression of the genes known to be under its control. This may seem in 
contrast with the role of PPAR-α as a transcription factor, however, many lines 
of evidence suggest that PPAR-α participates also to non-transcriptional 
activities. In particular, it has been demonstrated that PPAR-α agonists (GW-
7647 and palmitoylethanolamide), in mouse sensory neurons co-cultured with 
tumor cells, decrease the amplitude of Ca2+-evoked transient currents28. 
Similarly, it has been reported that PPAR-α activity modulates, on one hand, 
the firing rate of neurons acting through nicotinic receptors29, and, on the 
other, the calcium-activated K+ channels, crucial for peripheral nociception30. It 
has been hypothesized that the short-term hypophagic effect of OEA, is due 
to PPAR-α’s effect on ion channels31, that could explain the reduction of food 
intake observed even 5 min after administration. Moreover, it may be 
hypothesized that the OEA-induced increase in PPAR-α expression observed 
at 120 min time point could enhance this effect, that could be the mechanism 
underlying the long-lasting effect of peripheral administered OEA observed up 
to 24 h after its administration11. In the present work, we further demonstrate 
that the increase of PPAR-α mRNA expression selectively occurs in the AP: in 
fact, no changes in mRNA expression of PPAR-α or its target genes is 
observed in the NST, even though this area is in proximity with the AP. We 
previously suggested that the activation of neurons in the AP might be 
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synaptically transmitted to noradrenergic neurons of the NST, particularly to 
the noradrenergic neurons present in the medial part of the NST. The data we 
obtained in the present work suggest that 1) peripherally administered OEA 
activates PPAR-α in the AP; 2) this event leads to a depolarization of AP 
noradrenergic neurons, that, in turn, 3) increase Fos and DBH levels in the 
NST11, hence supporting our hypothesis. 
The caudal hypothalamus plays a major role in regulating feeding 
behavior32, and contains neurons that are sensitive to the presence of free FA 
thanks to the expression of several transporters, including CD3633,34. Since 
our findings support that peripherally administered OEA reaches the AP, we 
then investigated if it can reach and induce changes in gene expression in the 
Arc/ME through the same route. Our results demonstrate for the first time that 
peripheral OEA administration induced the transcription of CD36 in this brain 
area, whereas, to date, this effect of OEA has only been investigated in the 
upper intestine3,20. Unexpectedly, OEA fails to increase PPAR-α mRNA levels, 
even though this effect is observed in peripheral organs, thus leading us to 
hypothesize either that 1) the increase of PPAR-α mRNA levels occurs before 
the time points considered, or 2) the mechanism underlying this increase is 
OEA-related but might not be PPAR-α-dependent, as has been suggested3. In 
fact, it has been observed that PPAR-α mRNA levels significantly increase, in 
hepatoma cell cultures, not only in presence of the PPAR-α agonist Wy 
14,643, but also of the fatty acid analog perfluorodecanoic acid, and, with the 
highest efficacy, dexamethasone35,36. Hence, it could be hypothesized that the 
OEA-induced activation of PPAR-α (with the consequent transcription of its 
target genes) and its increase in mRNA levels might follow two distinct, 
although parallel, pathways, that surely need further investigation. 
As mentioned before, OEA improves memory and cognition by acting 
on the hippocampus19; interestingly, both cognition and memory might be 
impaired by the exposure to a high fat diet-inducing FA imbalance17. 
Therefore, it may be hypothesized that the beneficial effects of OEA on 
memory and cognition may be due to the upregulation of CD36, that, in turn, 
may ameliorate the FA sensing and uptake. Similar results were obtained in 
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microglial cells from a mouse model of Alzheimer Disease, were an increased 
expression of CD36 improved the clearance of Aβ plaques37. 
Regarding peripheral organs, we confirmed that OEA is able to 
increase PPAR-α mRNA levels in the Liver, Duo and JJ, as previously 
described3. However, in contrast with previous observations, we found that 
OEA decreased CD36 mRNA levels in the liver. Novel findings demonstrate 
that the pharmacological inhibition of CD36 improves obesity by reducing 
visceral fat accumulation and insulin resistance in obese mice38. Moreover, a 
recent clinical study showed that an increased expression of PPAR-α and a 
decreased expression of CD36 in the liver is observed in patients that 
underwent a Roux-en-Y gastric bypass (RYGB) surgery39, and increased OEA 
signaling has been observed in a rat model of RYGB40. Hence, peripheral 
OEA administration may mimic the beneficial adjustments that occur after 
RYGB, that is one of the most effective and used surgical approaches to treat 
obesity41,42. 
Surprisingly, OEA treatment (10 mg kg-1, i.p.) increased IL-6 mRNA 
levels 120 min after administration in the Duo and the JJ, and this effect is no 
longer observed after 240 min. In the small intestine, we demonstrated that 
OEA induces an increase of PPAR-α mRNA levels, that represses the 
transcription of the IL6 gene via protein-protein interaction24. Hence, the 
PPAR-α products deriving from the OEA-induced increase in PPAR-α mRNA 
levels 120 min after administration could possibly be responsible of the 
decrease in IL-6 mRNA levels observed 240 min after administration. 
Moreover, this is in line with the well-known anti-inflammatory and anti-obesity 
effects of OEA, since a reduction of inflammatory cytokines43 and of food 
intake11,27 are observed long  after administration. 
Overall, the present work better elucidates the mechanism of action of 
OEA: in first place, it confirms the primary role that AP has in the OEA-
induced neurochemical cascade, it elucidates the role played by OEA in 
modulating lipid sensing in the caudal hypothalamus and in the hippocampus; 
lastly, it gives new insights on the effects of OEA in peripheral organs, in 
particular in the liver associated with its anorexigenic effect. 
121 
 
3.5 References 
1. Fu, J. et al. Food intake regulates oleoylethanolamide formation and degradation in the 
proximal small intestine. J. Biol. Chem. (2007). doi:10.1074/jbc.M607809200 
2. Gaetani, S., Oveisi, F. & Piomelli, D. Modulation of meal pattern in the rat by the 
anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology (2003). 
doi:10.1038/sj.npp.1300166 
3. Fu, J. et al. Oleylethanolamide regulates feeding and body weight through activation of 
the nuclear receptor PPAR-α. Nature (2003). doi:10.1038/nature01921 
4. Rakhshandehroo, M., Knoch, B., Muller, M. & Kersten, S. Peroxisome proliferator-
activated receptor alpha target genes. PPAR Res (2010). 
5. Xu, J. et al. Peroxisome proliferator-activated receptor α (PPARα) influences: Substrate 
utilization for hepatic glucose production. J. Biol. Chem. (2002). 
doi:10.1074/jbc.M201208200 
6. Lefebvre, P., Chinetti, G., Fruchart, J. C. & Staels, B. Sorting out the roles of PPARα in 
energy metabolism and vascular homeostasis. Journal of Clinical Investigation (2006). 
doi:10.1172/JCI27989 
7. Guzm??n, M. et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear 
receptor peroxisome proliferator-activated receptor ?? (PPAR-??). J. Biol. Chem. 
(2004). doi:10.1074/jbc.M404087200 
8. Rodríguez De Fonseca, F. et al. An anorexic lipid mediator regulated by feeding. 
Nature (2001). doi:10.1038/35102582 
9. Romano, A. et al. High dietary fat intake influences the activation of specific hindbrain 
and hypothalamic nuclei by the satiety factor oleoylethanolamide. Physiol. Behav. 
(2014). doi:10.1016/j.physbeh.2014.04.039 
10. Romano, A. et al. Hindbrain noradrenergic input to the hypothalamic PVN mediates the 
activation of oxytocinergic neurons induced by the satiety factor oleoylethanolamide. 
AJP Endocrinol. Metab. (2013). doi:10.1152/ajpendo.00411.2013 
11. Romano, A. et al. Role of the area postrema in the hypophagic effects of 
oleoylethanolamide. Pharmacol. Res. 122, (2017). 
12. Gaetani, S. et al. The Fat-Induced Satiety Factor Oleoylethanolamide Suppresses 
Feeding through Central Release of Oxytocin. J. Neurosci. (2010). 
doi:10.1523/JNEUROSCI.0036-10.2010 
13. Provensi, G. et al. Satiety factor oleoylethanolamide recruits the brain histaminergic 
system to inhibit food intake. Proc. Natl. Acad. Sci. (2014). 
doi:10.1073/pnas.1322016111 
14. Berthoud, H. R. The vagus nerve, food intake and obesity. Regul. Pept (2008). 
doi:S0167-0115(08)00062-1 [pii];10.1016/j.regpep.2007.08.024 [doi] 
15. Dadson, P. et al. Fatty acid uptake and blood flow in adipose tissue compartments of 
122 
 
morbidly obese subjects with or without type 2 diabetes: effects of bariatric surgery. 
Am. J. Physiol. - Endocrinol. Metab. (2017). doi:10.1152/ajpendo.00044.2017 
16. Theoharides, T. C., Stewart, J. M. & Hatziagelaki, E. Brain ‘fog,’ inflammation a nd 
obesity: Key aspects of neuropsychiatric disorders improved by luteolin. Front. 
Neurosci. (2015). doi:10.3389/fnins.2015.00225 
17. Stranahan, A. M. et al. Diet-induced insulin resistance impairs hippocampal synaptic 
plasticity and cognition in middle-aged rats. Hippocampus (2008). 
doi:10.1002/hipo.20470 
18. Xu, H. et al. WY14643 Attenuates the Scopolamine-Induced Memory Impairments in 
Mice. Neurochem. Res. (2016). doi:10.1007/s11064-016-2002-1 
19. Yang, L. C. et al. Chronic oleoylethanolamide treatment improves spatial cognitive 
deficits through enhancing hippocampal neurogenesis after transient focal cerebral 
ischemia. Biochem. Pharmacol. (2015). doi:10.1016/j.bcp.2015.02.012 
20. Yang, Y. K., Chen, M., Georgeson, K. E. & Harmon, C. M. Mechanism of 
oleoylethanolamide on fatty acid uptake in small intestine after food intake and body 
weight reduction. Am. J. Physiol. Integr. Comp. Physiol. (2007). 
doi:10.1152/ajpregu.00270.2006 
21. Motojima, K., Passilly, P., Peters, J. M., Gonzalez, F. J. & Latruffe, N. Expression of 
putative fatty acid transporter genes are regulated by peroxisome proliferator-activated 
receptor ?? and ?? activators in a tissue- and inducer-specific manner. J. Biol. Chem. 
(1998). doi:10.1074/jbc.273.27.16710 
22. Pepino, M. Y., Kuda, O., Samovski, D. & Abumrad, N. A. Structure-Function of CD36 
and Importance of Fatty Acid Signal Transduction in Fat Metabolism. Annu. Rev. Nutr. 
(2014). doi:10.1146/annurev-nutr-071812-161220 
23. Silverstein, R. L. & Febbraio, M. CD36, a scavenger receptor involved in immunity, 
metabolism, angiogenesis, and behavior. Science Signaling (2009). 
doi:10.1126/scisignal.272re3 
24. Delerive, P. et al. Peroxisome proliferator-activated receptor α negatively regulates the 
vascular inflammatory gene response by negative cross-talk with transcription factors 
NF-κB and AP-1. J. Biol. Chem. (1999). doi:10.1074/jbc.274.45.32048 
25. Giuffrida, A., Rodríguez De Fonseca, F. & Piomelli, D. Quantification of bioactive 
acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem. 
(2000). doi:10.1006/abio.2000.4509 
26. Wada, N. et al. Leptin and its receptors. J. Chem. Neuroanat. (2014). 
doi:10.1016/j.jchemneu.2014.09.002 
27. Karimian Azari, E. et al. Vagal afferents are not necessary for the satiety effect of the 
gut lipid messenger oleoylethanolamide. AJP Regul. Integr. Comp. Physiol. (2014). 
doi:10.1152/ajpregu.00067.2014 
28. Khasabova, I. A., Xiong, Y., Coicou, L. G., Piomelli, D. & Seybold, V. Peroxisome 
123 
 
Proliferator-Activated Receptor   Mediates Acute Effects of Palmitoylethanolamide on 
Sensory Neurons. J. Neurosci. (2012). doi:10.1523/JNEUROSCI.0130-12.2012 
29. Melis, M. et al. Peroxisome proliferator-activated receptors-alpha modulate dopamine 
cell activity through nicotinic receptors. Biol. Psychiatry (2010). 
doi:10.1016/j.biopsych.2010.04.016 
30. LoVerme, J. et al. Rapid Broad-Spectrum Analgesia through Activation of Peroxisome 
Proliferator-Activated Receptor- . J. Pharmacol. Exp. Ther. (2006). 
doi:10.1124/jpet.106.111385 
31. Piomelli, D. A fatty gut feeling. Trends in Endocrinology and Metabolism (2013). 
doi:10.1016/j.tem.2013.03.001 
32. Rinaman, L. Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, 
endocrine, cognitive, and behavioral functions. AJP Regul. Integr. Comp. Physiol. 
(2011). doi:10.1152/ajpregu.00556.2010 
33. Foll, C. Le, Dunn-Meynell, A., Musatov, S., Magnan, C. & Levin, B. E. FAT/CD36: A 
major regulator of neuronal fatty acid sensing and energy homeostasis in rats and 
mice. Diabetes (2013). doi:10.2337/db12-1689 
34. Le Foll, C., Irani, B. G., Magnan, C., Dunn-Meynell, A. A. & Levin, B. E. Characteristics 
and mechanisms of hypothalamic neuronal fatty acid sensing. AJP Regul. Integr. 
Comp. Physiol. (2009). doi:10.1152/ajpregu.00223.2009 
35. Sterchele, P. F., Sun, H., Peterson, R. E. & Vanden Heuvel, J. P. Regulation of 
peroxisome proliferator-activated receptor-α mRNA in rat liver. Arch. Biochem. Biophys. 
(1996). doi:10.1006/abbi.1996.0077 
36. Lemberger, T. et al. Regulation of the peroxisome proliferator-activated receptor α gene 
by glucocorticoids. J. Biol. Chem. (1994). 
37. Wang, C.-Y. et al. CD36 Upregulation Mediated by Intranasal LV-NRF2 Treatment 
Mitigates Hypoxia-Induced Progression of Alzheimer’s-Like Pathogenesis. Antioxid. 
Redox Signal. (2014). doi:10.1089/ars.2014.5845 
38. Yang, J., Park, K. W. & Cho, S. Inhibition of the CD36 receptor reduces visceral fat 
accumulation and improves insulin resistance in obese mice carrying the BDNF-
Val66Met variant. J. Biol. Chem. (2018). doi:10.1074/jbc.RA118.002405 
39. Pardina, E. et al. Hepatic CD36 downregulation parallels steatosis improvement in 
morbidly obese undergoing bariatric surgery. Int. J. Obes. (2017). 
doi:10.1038/ijo.2017.115 
40. Hankir, M. K. et al. Gastric Bypass Surgery Recruits a Gut PPAR-α-Striatal D1R 
Pathway to Reduce Fat Appetite in Obese Rats. Cell Metab. (2017). 
doi:10.1016/j.cmet.2016.12.006 
41. Puzziferri, N. et al. Long-term follow-up after bariatric surgery: A systematic review. 
JAMA - Journal of the American Medical Association (2014). 
doi:10.1001/jama.2014.10706 
124 
 
42. Stefater, M. A., Wilson-P??rez, H. E., Chambers, A. P., Sandoval, D. A. & Seeley, R. J. 
All bariatric surgeries are not created equal: Insights from mechanistic comparisons. 
Endocr. Rev. (2012). doi:10.1210/er.2011-1044 
43. Di Paola, M. et al. Oleoylethanolamide treatment affects gut microbiota composition 
and the expression of intestinal cytokines in Peyer’s patches of mice. Sci. Rep. (2018). 
 
125 
 
Chapter 4: 
Role of oleoylethanolamide in the metabolic 
changes induced by a prolonged exposure to a 
high fat diet 
 
 
 
OEA is an endogenous lipid signal produced in the small intestine upon the ingestion 
of dietary fat. Although it is a structural analog of anandamide, it does not activate 
endocannabinoid receptors, but it binds the peroxisome-proliferator activated 
receptor-α, through which it stimulates lipolysis and reduces feeding and body weight. 
As a drug, OEA is able to reduce food intake and body weight gain (BWG) in both 
lean and obese rodents and has recently emerged as a potential novel 
pharmacological target for the treatment of obesity. 
Based on these premises, in this study we investigated the anti-obesity 
effects of OEA in a rat model of diet-induced obesity (DIO), not only focusing on the 
regulation of feeding behavior and BWG, but also on the composition of the gut-
microbiota, and on the expression of genes involved in the control of feeding behavior 
in key regions of the central nervous system, such as the brainstem and the 
hypothalamus. 
The rat model of DIO was obtained by exposing male rats to high fat diet 
(HFD) for 11 weeks. Then, all the animals were chronically treated (14 days) with 
either vehicle or OEA (10 mg kg-1, i.p.) during which they were exposed to HFD, low 
fat diet (LFD) or underwent a shift of the diet (SHIFT animals, that were given HFD for 
the first part of the experiment (11 weeks), then shifted to LFD during the chronic 
treatment. Moreover, an additional experimental group of pair-feeding rats (that 
received vehicle injection and was given the average amount of food consumed by 
OEA-treated rats in the matching diet group) was monitored to investigate a possible 
indirect effect of OEA on body weight.  
We found that OEA reduces food intake and body weight gain independently 
from the diet regimen adopted and contributes to the reduction of body weight gain 
regardless of its anorexic action. In addition, two weeks of OEA treatment affected the 
general composition of the gut microbiota increasing the number of total bacteria and 
its diversity in all the groups (LFD, HFD, SLFD). 
Analysis of gene expression in the brainstem reveals that the exposure to 
HFD and OEA treatment together increase the expression of N-acyl 
phosphatidylethanolamine phospholipase D (NAPE-PLD), PPAR-α, and c-fos genes. 
In the hypothalamus, OEA is able to increase the expression of the melanocortin 4 
receptor (MC4R) in both HFD-fed and SFLD animals compared to the LFD-fed 
animals.  
Overall, our study provides important new information on the therapeutic 
potential of OEA for the treatment of obesity. 
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4.1 Introduction 
The communication between the gut and the brain, the so- called gut-brain 
axis, plays a pivotal role in the regulation of feeding behavior and energy 
homeostasis1. In particular, the gastrointestinal (GI) tract, after the ingestion of 
food, releases a variety of signals, like peptide hormones, such as CCK and 
PYY, and lipid mediators to regulate feeding2. Among the latter ones, N-
acylethanolamines (NAEs) and N-acylphosphatidilethanolamine (NAPEs) are 
known to mediate satiety3, and, due to its effects on food intake, the most 
studied NAE in this context is oleoylethanolamide (OEA), an unsatured analog 
of anandamide that does not bind CB receptors, but exerts its action through 
the peroxisome proliferator-activated receptor-alpha (PPAR-α)4. 
It has been demonstrated that OEA, mainly produced in the upper 
intestine upon the ingestion of dietary fats5, acts as a satiety factor in rodents, 
and, when peripherally administered, alters the meal pattern by prolonging the 
latency to eat and the meal frequency, without affecting the quantity of food 
consumed4,6,7. Moreover, peripheral OEA administration exerts several effects 
in the central nervous system (CNS): in fact, it activates key areas involved in 
the control of feeding behavior, both in the brainstem and in the 
hypothalamus8, and engages noradrenergic9, oxytocinergic8–10, and 
histaminergic11 systems to modulate feeding.  
It has been reported that the excessive ingestion of a high fat diet 
(HFD) is responsible of the induction of the obese phenotype (diet-induced 
obesity DIO)12, characterized by a significant reduction of OEA levels in the 
gut13, and by a change in the microbiome, both in its composition and number 
of total bacteria14. Moreover, it has been shown that a prolonged exposition 
(7-14 days) to HFD significantly reduces, in a DIO animal model, the 
concentration of anorexiant NAEs, including OEA, that could lead, in turn, to 
the hyperphagia observed in this experimental model15,16. This hypothesis 
was recently supported by a study that showed how the feeding-induced 
mobilization of OEA is disrupted in the same animal model13. 
The incidence of dysbiosis, an imbalance in the composition of the gut 
micorbiome correlated to other pathologies associated with incorrect eating 
habits, is increasing17. In fact, the prevalent consumption of fat-enriched 
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foods, along with the reduction of the consumption of fruits and vegetables, 
has noxious effects on the gut microbiome, that lead to alterations in its 
quality that contribute to the development of obesity and diabetes18,19. In fact, 
many studies have demonstrated that the exposure to HFD, obesity and 
metabolic syndrome induce changes in the composition and total number of 
gut bacteria20,21. 
On the other hand, whether long-term exposure to a HFD induces 
changes in gene expression in the CNS is still unclear. Exogenous OEA is 
reportedly a PPAR-α agonist that, in turn, induces the transcription of its target 
genes4. Hence, the aim of this work is to evaluate, in a rat model of DIO, the 
impact of peripheral OEA administration on i) food intake and body weight; ii) 
on the diet-induced changes of the gut microbiome; iii) on the changes of 
gene expression in key areas of the CNS involved in the control of feeding 
behavior, such as the brainstem and the hypothalamus. In particular, we 
focused our attention, in the brainstem, on ppara, napepld and cfos, to 
investigate the effects of prolonged exposure to HFD on OEA’s main 
pharmacological target (ppara), on its synthesis (napepld) and on one of its 
main effects in this area (cfos induction). On the other hand, in the 
hypothalamus, we focused our attention on the melanocortin system by 
analyzing the effects of HFD on mc4r, due to its involvement in the reduction 
of food intake22. 
To this aim we exposed male Wistar-Han rats to either HFD or low-fat 
diet (LFD). After 11 weeks of exposure to HFD in order to induce obesity, all 
rats underwent a chronic treatment (2 weeks) of either vehicle (veh, 
saline/PEG/Tween80, 90/5/5/, v/v/v) or OEA (10 mg kg-1). Moreover, during 
the chronic treatment, the animals were divided in different diet groups: i) 
animals that were fed with a LFD ad libitum throughout the whole experiment; 
ii) animals that were given a HFD ad libitum throughout the entire experiment; 
iii) animals that were exposed to HFD ad libitum during the first 11 weeks of 
induction of obesity and then were shifted to LFD ad libitum during the 2 
weeks of treatment; iv) pair-feeding animals, that were given the average 
amount of food consumed by the OEA-treated animals in the matching diet 
groups. 
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4.2 Materials and methods 
4.2.1 Animals and diets 
A total of 96 male Wistar-Han (Charles River, Calco, Italy) were used in this 
study, weighing 305-315 gr upon arrival. All the animals were single housed in 
plexiglass cages in a temperature- and humidity-controlled room (T=22±2 °C; 
60% of relative humidity), with a 12:12 h dark/light cycle. All the animals had 
free access to water and food, unless otherwise stated. After one week of 
housing, during which were exposed to standard chow diet, all the animals 
were exposed either to a purified LFD, with a total of 10% of the calories 
coming from fats (Open Source DIETS, D12450B), or to a purified HFD, with 
a total of 60% of the calories coming from fats (Open Source DIETS, 
D12492). The caloric density of the diets was 3.85 kcal/gr and 5.24 kcal/gr, 
respectively. 
Housing, animal maintenance, and all experiments were conducted in 
accordance with the Council Directive of the European Community 
(86/609/EEC) of the Italian Decreto Legislativo n.26 (2014) and National 
Institutes of Health guidelines on animal care and were approved and 
supervised by a veterinarian. 
 Induction of obesity 
In order to induce the obese phenotype, 60 out of the 96 animals were 
exposed ad libitum to the HFD for 11 weeks, while the remaining were fed 
with LFD ad libitum. The induction of the obese phenotype was assessed 
monitoring the weight of the animals daily and was considered established 
when the body weight (BW) of HFD-fed animals was significantly higher than 
that of LFD-fed animals (Fig 4.1). At the end of the induction of obesity, the 
HFD animals whose BW gain (expressed as percentage of the weight of day 
1) were below the average of BWG% of LFD animals were considered obese-
resistant, and therefore excluded from the study. 
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Fig. 4.1: Induction of obese phenotype. Time course of the body weight gain in rats exposed 
to LFD or HFD for 11 weeks. Data are expressed as means ±SEM. *P<0.05; **P<0.01; 
***P<0.001 vs LFD. 
 
 
4.2.2 Drugs and treatments 
OEA (Sigma-Aldrich) was dissolved in the vehicle (veh; saline/PEG/Tween80, 
90/5/5 v/v/v, 2 ml kg-1), and administered 10 mg kg-1 via i.p. injections for 14 
consecutive days. Both veh and OEA solutions were freshly prepared on each 
test day and administered about 30 min before dark onset. 
 
4.2.3 Chronic treatment 
Starting from the 12th week, all the animals were divided into two main 
experimental groups, named group A and B. All the rats belonging to the A 
group, 40 exposed to the HFD and 24 to the LFD, had free access to food 
throughout the whole experiment, whereas the animals belonging to the B 
group did not have free access to food during the 2 weeks of chronic 
treatment. Moreover, the HFD animals from the A group were divided in two 
subgroups: half of them were given HFD until the end of the experiment, and 
the other half was given LFD in the last two weeks of the experiment. This last 
group was named SHIFT and was introduced in order to mimic the fat and 
calories restriction observed in dieting individuals. In the same way, half of the 
HFD rats of the B group were maintained on HFD until the end of the 
experiment, while the other half became part of the SHIFT group. No changes 
were introduced in the LFD-fed group. 
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During the chronic treatment, all the animals of the A group were treated with 
either veh or OEA (10 mg kg -1, i.p.) and had free access to food, while all the 
animals of the B group (pair-feeding group), were treated only with the veh, 
and received the average of the amount of food consumed by the OEA-
treated animals of the A group in the matching diet group (pHFD, pLFD and 
pSHIFT). This group was introduced to investigate whether the OEA-induced 
weight loss is only due to its effect on the feeding or also to effects on the 
metabolism. 
BW and food and caloric intakes of all animals were monitored 
throughout the whole experiment, both during the induction of obesity and the 
chronic treatment. 
At the end of the experiment, in order to evaluate the effects of chronic 
administration of OEA (10 mg kg-1, i.p.), we evaluated: the energy intake (EI) 
expressed in Kcal of each day of treatment, normalized by the weight of the 
animal; the BW gain expressed as percentage of weight of the last day 
normalized for the weight on day1 of chronic treatment; the BW gain 
expressed as percentage of weight of each day of chronic treatment 
normalized for the weight on day1. 
The EI, expressed in Kcals, was calculated multiplying the grams of 
food consumed by the caloric density of each diet type, and was then 
normalized by the BW of the animal (Kcal/kg). For the behavioral experiment, 
the n= 10-12 per group. 
The detailed timeline of the experiment is depicted in Fig 4.2. 
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Fig. 4.2: Experimental paradigm. The diagram depicts the time course of the experiment, the 
diets and the treatments the animals were exposed to. 
 
 
4.2.4 Terminal experiment 
On the day of the terminal experiment, all food was removed from the cages 1 
h prior to dark onset. All the animals were administered with either veh or 
OEA (mg kg -1, i.p.) 10 minutes before the dark phase, and then had again 
free access to food. One hour after the administration, animals were deeply 
anesthetized with chloral hydrate (Sigma-Aldrich), and sacrificed through 
decapitation. Brains were extracted and immediately snap-frozen in ice-cold 
isopentane (Sigma-Aldrich), and cecal content was collected in sterile 
conditions to avoid any contamination from the experimental environment. 
 
4.2.5 Quantification of total bacteria: qPCR 
The quantification of the total bacteria through quantitative polymerase chain 
reaction (qPCR) was performed in collaboration with Prof. Patrice D. Cani, 
from the Metabolism and Nutrition research group at the Louvain Drug 
Research Institute (LDRI), Université catholique de Louvain (Brussels, 
Belgium). Briefly, the metagenomic DNA from each sample (85-120 mg; n= 3-
6 per group) was extracted using QIAamp Fast DNA Stool Mini Kit (Qiagen, 
Hilden, Germany), following manufacturer’s instruction. Then, the 
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concentration of the DNA was quantified using a Thermo Scientific 
NanoDrop™ 2000/2000c, and each sample was diluted to a concentration of 
10 ng DNA/µl using a Tris-EDTA (TE) buffer. 
The qPCR was performed using the STEPonePLUS Real-Time PCR 
system instrument and software (Applied Biosystems, Foster City, CA, USA), 
using Sybr Green for signal detection. A standard curve was set up with 
seven 5-fold serial dilutions of known amounts of DNA (colony forming units, 
CFU, were used), in order to quantify the number of total bacteria in each 
sample. Data were then expressed as Log10 (CFU/gr of sample). 
The following conditions were used for amplification: an initial holding 
stage of 3 min at 95 °C, then 30 cycles consisting of denaturation at 95 °C for 
15 s, annealing for 20 s, and extension at 72 °C for 10 s. Each sample was 
analyzed in duplicate in the same run. 
A highly preserved sequence of the gene coding for the rRNA 16S was 
used to quantify the total amount of bacteria, using the following primers: 
Rev: ATTACCGCGGCTGCTGG; -Fwd: ACTCCTACGGGAGGCAGCAG. 
 
4.2.6 Pyrosequencing of the barcode rRNA 16s gene 
Pyrosequencing is a method used to analyze a DNA sequence during its 
synthesis, thanks to a charge coupled device able to detect the light signal 
coming from the inorganic pyrophosphate released during DNA elongation. 
Briefly, metagenomic DNA was extracted as described in the previous 
paragraph (n= 4-6 per group), and the highly variable part (V1-V3 region) of 
the rRNA 16S gene was amplified. This region, unlike the one used for the 
quantification of total bacteria, is less conserved, hence it allows to distinguish 
between phyla, classes, and orders. The high-throughput results of the 
sequencing of the amplicons were then analyzed using the Roche FLX 
Genome Sequencer, based on titanium dioxide nanoparticles technology 
(Titanium Chemistry, DNA Vision, Gosselies, Belgium). Data obtained were 
analyzed, in turn, with Quantitative Insights into Microbial Ecology v1.7.0 
(QIIME) pipeline. The abundance of both identified and unidentified taxa, after 
the exclusion of those taxa representing less than 0.01% of the total 
abundance, were converted using the Hellinger method. The principal 
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coordinate analysis (PCoA) was measured using the unweighted UniFrac 
distance, that measures the beta-diversity relying on phylogenetic information 
comparing different microbial communities. Moreover, the operational 
taxonomic units (OTUs) were classified using the uclust consensous 
taxonomic classifier, with the threshold set at 0.97, and consulting the 
Greengenes database. Finally, phylogenetic trees were generated and 
developed using QIIME software v1.7.0 and displayed using iTOL v2.2.2. 
 
4.2.6 RT-qPCR: analysis of gene expression in the brainstem and 
hypothalamus 
The analysis of the alterations of gene expression due to a chronic treatment 
with OEA (10 mg kg-1, i.p.) was carried out through retrotranscription qPCR 
(RT-qPCR), in both the brainstem and hypothalamus isolated from the brains 
previously collected and snap frozen during the terminal experiment (n= 4-5 
per group). Briefly, total RNA was extracted with Trizol (Sigma-Aldrich) and 
chloroform. After centrifugation, isopropanol was added to allow total RNA 
precipitation, followed by washes in EtOH 75%. The pellet obtained was then 
vacuum dried and diluted in nuclease-free water. The concentration of RNA 
was obtained measuring the absorbance at 260 nm wavelength with a 
spectrophotometer, and the purity of the RNA was assessed measuring the 
260 nm/ 280 nm wavelength ratio. 
Then, total RNA was converted into cDNA using RevertAid H Minus 
First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). The 
qPCR was performed using the STEPonePLUS Real-Time PCR system 
instrument and software (Applied Biosystems, Foster City, CA, USA), using 
Sybr Green for signal detection. 
The following conditions were used for amplification: an initial holding 
stage of 10 min at 95 °C, then 50 cycles consisting of denaturation at 95 °C for 
10 s, annealing for 30 s at +57°C, and extension at 72 °C for 30 s. Each 
sample was analyzed in duplicate in the same run. The relative expression of 
the genes of interest (napepld, cfos, PPAR-α in the brainstem, and MC4R in 
the hypothalamus) was normalized to the expression of the GAPDH and 
expressed as 2-ΔΔCt for statistical analysis. 
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4.2.7 Statistical analyses 
Regarding the behavioral experiment, the data obtained from the daily 
monitoring of the BW gain and EI were analyzed with a Two-way ANOVA for 
repeated measures (within the same diet group), setting “treatment” (veh, 
OEA, pair-feeding) and “time” as fixed variables, and the Bonferroni’s test was 
used as post-hoc analysis for multiple comparisons. On the other hand, the 
BW gain between the first and the last day of chronic treatment was analyzed 
by Two-way ANOVA, with “treatment” (veh, OEA, pair-feeding) and “diet” 
(HFD, LFD, SHIFT) as fixed variables, and Tukey’s test was used as post-hoc 
for multiple comparisons. 
Regarding the analyses of the microbiome and gene expression, the 
differences in the number of total bacteria and in the expression of napepld, 
cfos, PPAR-α and MC4R were both analyzed by Two-way ANOVA, with 
“treatment” (veh, OEA, pair-feeding) and “diet” (HFD, LFD, SHIFT) as fixed 
variables, and Tukey’s test was used as post-hoc for multiple comparisons. 
Finally, for the analyses of the pyrosequencing, Student’s t-test was used to 
compare the differences between two groups within the same phylum, order 
or class. 
All the Two-way ANOVA analyses were carried out using SPSS 
Statistics (IBM Corporation, Armonk, NY, USA), while the t-tests were 
performed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, 
USA). 
In all instances, the significance threshold was set at P<0.05. 
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4.3 Results 
4.3.1 OEA decreases energy intake in all diet groups 
In order to evaluate the hypophagic effect due to OEA administration (10 mg 
kg-1, i.p.), the EI (Kcal/kg) was monitored throughout the two weeks of chronic 
treatment. In particular, in LFD animals, the Two-way ANOVA for repeated 
measures analysis showed a significant effect of time (Ftime= 2275.787; df= 
1/35; °°°P<0.001), of treatment (Ftreatment= 26.165; df= 1/35; °°°P<0.001), and 
of interaction between these two factors (Finteraction= 9.222; df= 1/35; 
°°°P<0.001). Moreover, the Bonferroni post-hoc analysis for multiple 
comparisons showed that OEA induces a statistically significant reduction of 
EI from the third day of treatment (LFD V vs LFD O = °P<0.05), and until the 
end of the experiment (°°P<0.01 on the fourth day and °°°P<0.001 from the 
eleventh to the last day) (Fig 4.3A). 
We further analyzed the EI intake of HFD animals. The results 
obtained with the Two-way ANOVA for repeated measures analysis showed a 
significant effect of time (Ftime= 1938.974; df= 1/28; °°°P<0.001), treatment 
(Ftreatment= 8.585; df= 1/28; °°P<0.01) and interaction between these two 
factors (Finteraction= 15.899; df= 1/28; °°°P<0.001). Furthermore, the post hoc 
analysis showed that OEA significantly decreases the EI in HFD animals from 
the eighth day of treatment (HFD V vs HFD O = °P<0.05), and until the end of 
the treatment (°°P<0.01 at days 9 and 10; °°°P<0.001 from the eleventh day 
until the end of the experiment) (Fig. 4.3B). 
Lastly, we analyzed the EI of the SHIFT animals, where the Two-way 
ANOVA for repeated measures analysis showed a significant effect of time 
(Ftime= 869.836; df= 1/26; °°°P<0.001), treatment (Ftreatment= 14.760; df= 1/26; 
°°°P<0.001), and interaction between these two factors (Finteraction= 19.443; df= 
1/26; °°°P<0.001). Moreover, the Bonferroni post hoc analysis for multiple 
comparisons showed that OEA is able to significantly decrease the EI of 
SHIFT animals from day 6 (°P<0.05), and until the end of the treatment 
(°°P<0.01 at the seventh day; °°°P<0.001 from the eighth day until the end of 
the experiment) (Fig. 4.3C). 
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Fig. 4.3: Peripheral OEA administration decreases caloric intake regardless the diet 
regimen. Time course of the caloric intake of animals exposed to LFD (A), HFD (B) or SHIFT 
(C) diet and treated with either vehicle or OEA (10 mg kg-1, i.p.) for fourteen days. Data are 
expressed as mean±SEM. °P<0.05, °°P<0.01; °°°P<0.001 vs veh-treated controls. N= 10-12 
per group.  
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4.3.2 The OEA-induced weight loss is observed in all diet groups, and 
is linked to changes in the metabolism 
In order to evaluate the anti-obesity effects of OEA, we evaluated both the 
cumulative, expressed as the difference between the last and the first day of 
the experiment, and the day-to-day decrease in BW gain. 
Regarding the cumulative BW gain (Fig. 4.4), the results obtained with 
the Two-way ANOVA showed a significant effect of diet and treatment (Fdiet= 
138.960; df= 1/91; ***P<0.001; Ftreatment= 42.696; df= 1/91; ***P<0.001), but 
not of the interaction between these two factors (Finteraction= 0.817; df= 1/91; P= 
0.518). Moreover, the Tukey post hoc analysis for multiple comparisons 
showed that the chronic exposure to HFD induces per se a significant 
increase of BW compared to the chronic exposure to LFD (LFD V vs HFD V = 
*P<0.05). Furthermore, the shift from HFD to LFD induces per se a decrease 
of BW compared to the chronic exposure to HFD or LFD (SHIFT V vs LFD V = 
***P<0.001; SHIFT V vs HFD V = ***P<0.001). In addition, chronic OEA 
administration (10 mg kg-1, i.p.) induced a significant BW loss in all diet groups 
compared to veh-treated controls (veh-treated vs OEA-treated = °°°P<0.001 
in all diet groups). 
Lastly, we investigated whether the OEA-induced weight loss is only 
due to the reduction of the amount of food consumed. By comparing the 
weight loss of OEA-treated and pair-feeding animals in each diet group, we 
observed that OEA-treated animals showed a higher decrease of BW 
compared to pair-feeding animals independently of the diet group 
(^^^P<0.001 HFD O vs pHFD; ^^P<0.01 LFD O vs pLFD; SHIFT O vs 
pSHIFT), suggesting that the anti-obesity effects of OEA are due to effects on 
the metabolism rather than only the reduction of the amount of food 
consumed. 
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Fig. 4.4: OEA decreases the BW gain regardless of diet regimen. BW gain expressed as 
the difference between the first and the last day of treatment, in rats exposed to LFD, HFD o 
SHIFT diet and treated with either vehicle or OEA (10 mg kg-1, i.p.) for 2 weeks. Data are 
expressed as mean±SEM. +P<0.05 LFD veh vs pLFD; °°°P<0.001 veh vs OEA in the same diet 
group; ^^P<0.01, ^^^P<0.001 OEA vs pair-feeding in the same diet group; *P<0.05, **P<0.01, 
***P<0.001 vs other diet regimen in the same treatment group. N= 10-12 per group. 
 
 
Regarding the day-to-day BW gain monitoring, the results of the Two-way 
ANOVA for repeated measures analysis, showed, in LFD animals, a 
significant effect of time (Ftime= 2.479; df= 1/35; *P<0.05), of treatment 
(Ftreatment= 23.393; df= 1/35; ***P<0.001), and of interaction between the two 
factors (Finteraction= 8.173; df= 1/35; ***P<0.001). Moreover, the Bonferroni post 
hoc test for multiple comparisons showed that, from the fifth day of treatment, 
chronic OEA administration is able to significantly decrease the BW of LFD 
animals (LFD V vs LFD O= °°P<0.01 on the fifth day; °°°P<0.001 from the 
sixth day to the end of the treatment (Fig. 4.5A). 
In the same way, the results obtained with the Two-way ANOVA for 
repeated measures showed, in HFD animals, a significant effect of time (Ftime= 
12.719; df= 1/28; ***P<0.001), of treatment (Ftreatment= 8.397; df= 1/28; 
**P<0.01) and of interaction between the two factors (Finteraction= 10.913; df= 
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1/28; ***P<0.001). Furthermore, the Bonferroni post hoc analysis for multiple 
comparisons showed that OEA is able to significantly decrease the BW of 
HFD-fed animals from the sixth day of chronic administration to the end of the 
treatment (HFD V vs HFD O= °°P<0.01 on the sixth day; °°°P<0.001 for the 
remaining days) (Fig. 4.5B). 
The chronic treatment with OEA (10 mg kg-1, i.p.), in addition, is able to 
decrease the BW gain in SHIFT animals. In fact, the results of the Two-way 
ANOVA for repeated measures showed a significant effect of time (Ftime= 
125.040; df= 1/26; ***P<0.001) and of interaction between time and treatment 
(Finteraction= 6.550; df= 1/26; ***P<0.001), but not of treatment alone (Ftreatment= 
2.126; df= 1/26; P=0.141). Moreover, the Bonferroni post hoc test for multiple 
comparisons showed that OEA is able to decrease BW in SHIFT animals from 
the day 11 to the end of the treatment (SHIFT V vs SHIFT O= °°P<0.01 on 
day 11-14) (Fig. 4.5C). 
Interestingly, for all diet groups, the decrease of BW gain in OEA-
treated animals is higher than in pair-feeding animals. In particular, the 
Bonferroni post hoc test for multiple comparisons showed that OEA treatment 
(10 mg kg-1, i.p.) induces, in the LFD group, a significant decrease of BW 
compared to pLFD animals from the seventh day of treatment (LFD O vs 
pLFD= *P<0.05 on day 7; ***P<0.001 from day 8 to the end of the treatment) 
(Fig. 4.5A). 
Regarding HFD animals, the results obtained with the Bonferroni post 
hoc test for multiple comparisons showed that a significant, OEA-induced 
decrease of BW gain, compared to the pHFD group, is observed from the 
ninth day of treatment until the end of the experiment (HFD O vs pHFD= 
**P<0.01 on days 9 and 10; ***P<0.001 from the eleventh day) (Fig. 4.5B). 
Finally, the Bonferroni post hoc test for multiple comparisons showed 
that, in SHIFT animals, OEA induces a significant decrease of BW gain on 
days 11-13 compared to veh-treated animals (SHIFT O vs SHIFT V= 
°°P<0.01 on day 11; °°°P<0.01 on day 12 and 13), and on days 12 and 13 
compared to pSHIFT animals (SHIFT O vs pSHIFT= *P<0.05) (Fig. 4.5C). 
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Fig. 4.5: Peripheral OEA 
administration decreases 
the body weight gain 
regardless of diet regimen. 
Time course of the body 
weight gain of animals 
exposed to LFD (A), HFD 
(B) or SHIFT (C) diet and 
treated with either vehicle or 
OEA (10 mg kg-1, i.p.) for 
fourteen days. Data are 
expressed as mean± SEM. 
°°P<0.01; °°°P<0.001 vs 
veh-treated controls; *P< 
0.05, **P<0.01, ***P<0.001 
vs pair-feeding animals in 
the same diet group. N= 10-
12 per group. 
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4.3.3 Microbiota analysis: total number of bacteria and β-diversity 
Apart from the behavioral analyses, we aimed to investigate whether a 
chronic treatment with OEA (10 mg kg-1, i.p.) could modulate the amount, the 
composition or the beta-diversity of the gut microbiota. Moreover, through the 
sequencing of the barcode genes, we investigated any possible OEA-induced 
changes in the phyla, orders or classes. 
It is already known that the obese phenotype is characterized by lower 
amount and variability of the gut microbiota23. The data obtained show that 
OEA treated animals tend to have a higher number of bacteria in the LFD and 
HFD groups, whereas no differences were observed between the veh-treated 
and the pair feeding animals. Therefore, it could be suggested that this trend 
is induced by the treatment and not by the reduction of food intake (Fig. 4.8). 
In particular, the results of the Two-way ANOVA revealed a significant effect 
of treatment (Ftreatment= 4.138; df= 1/44; *P<0.05), but no significant effect of 
diet or interaction between the two factors (Fdiet= 0.824; df= 1/44; P= 0.44; 
Finteraction= 0.718; df= 1/44; P= 0.585). Moreover, the Tukey post hoc analysis 
for multiple comparisons showed that, in LFD animals, OEA significantly 
increases the number of total bacteria compared to pLFD rats (LFD O vs 
pLFD= °P < 0,05). Interestingly, the same trend is observed in HFD rats, even 
though it does not reach statistical significance (HFD O vs pHFD= P=0.054). 
Lastly, the total amount of bacteria in higher in pSHIFT compared to pHFD 
animals (*P<0,05) (Fig. 4.6). 
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Fig. 4.6: Peripheral OEA administration increases the number of total bacteria compared 
to caloric restriction alone. Number of total bacteria of animals exposed to LFD, HFD or 
SHIFT diet and treated with either vehicle or OEA (10 mg kg-1, i.p.) for fourteen days. Data are 
expressed as mean±SEM. °P<0.05 OEA-treated vs pair-feeding rats; *P<0.05 vs other diet 
regimen in pair-feeding rats. N= 3-6 per group. 
 
 
As for the number of total bacteria, HFD reduces the beta-diversity of the gut 
microbiota. Moreover, from the data obtained from the PCoA, using the 
unweighted UniFrac distance to measure the distance between different taxa, 
show that the chronic treatment with OEA (10 mg kg-1, i.p.), in line with the 
results already showed, increases the beta-diversity of the gut microbiota, in 
all diet groups and, as for the previous results, OEA’s action on beta-diversity 
is not linked only to its hypophagic effects. In particular, taking in 
consideration only the LFD V, HFD V, HFD O, and pHFD groups, a difference 
is observed between the OTUs of veh- and OEA-treated animals in the HFD 
group. In fact, our data show that the exposure to HFD leads to a decrease in 
OTUs, while the OEA treatment reverts this effect (Fig. 4.7). 
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Fig. 4.7: Peripheral OEA administration increases the β-diversity of the gut microbiota. 
Plot of the β-diversity of the gut microbiota of animals exposed to LFD, HFD or SHIFT diet and 
treated with either vehicle or OEA (10 mg kg-1, i.p.) for fourteen days. Data were analyzed using 
the Principal Coordinates Analysis (PCoA), measuring the unweighted UniFrac distance. Each 
dot represents a sample, and the distance between dots represents the difference of the gut 
microbiota. In particular, in the left panel, all the animals exposed to LFD cluster on the left, 
whereas the HFD groups cluster on the right. Moreover, in the right panel, the majority of veh-
treated animals cluster on the upper part of the graph, while the OEA-treated animals cluster on 
the bottom right, and, interestingly, do not overlap with pHFD animals. N= 4-6 per group. 
 
 
4.3.4 Microbiota analysis: relative abundance and the main phyla, 
classes and orders 
After the analysis on the number of total bacteria and the beta-diversity, we 
focused on the variations of the composition of the gut microbiota that could 
be induced by the chronic treatment with OEA (10 mg kg-1, i.p.). 
In particular, the sequencing of the rRNA 16S gene allowed us to 
evaluate the differences in phyla, classes and orders thanks to the QIIME 
software, that separates the microbial communities using the variability that 
characterizes this gene. We analyzed the relative abundance of the major 
phyla (Actinobacteria, Bacteroidetes, Cyanobacteria, Deferribacteres, 
Firmicutes, Proteobacteria, Tenericutes, TM7, and Verrucomicrobia), and the 
major orders and classes belonging to them. However, no statistically 
significant results were obtained by these analyses, exception made for the 
phylum Tenericutes. In fact, the treatment with OEA induced a reduction of 
the abundance of the phylum Tenericutes in HFD animals (HFD V: mean= 
1.552; SEM= 0.361; HFD O: mean= 0.506; SEM= 0.160: *P<0.05) (Fig. 4.9A). 
Moreover, among the classes in this phylum, and OEA-induced reduction of 
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the class Mollicutes has been observed in the HFD group (HFD V: mean= 
1.550; SEM= 0.362; HFD O: mean= 0.483; SEM= 0.158; *P<0.05) (Fig. 4.9B). 
In the orders belonging to this class, the t-test analysis showed an OEA-
induced reduction in the RF9 order in the HFD group (HFD V: mean= 1.523; 
SEM= 0.363; HFD O: mean= 0.370; SEM= 0.164; *P<0.05) (Fig. 4.9C). 
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Fig. 4.9: Peripheral OEAinduces changes in the composition of the gut microbiota. 
Chronic peripheral OEA administration decreases the abundance of the phylum Tenericutes 
(A), and, in particular of the class Mollicutes (B) and the order RF39 (C). Data were obtained 
with the pyrosequencing of the gene encoding for the rRNA 16S. N= 4-6 per group. 
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4.3.5 Effects of OEA on gene expression in the brainstem and 
hypothalamus 
We then investigated the effects of the chronic treatment with OEA (10 mg kg-
1, i.p.) on gene expression in the brainstem and in the hypothalamus, two key 
brain areas in the control of feeding2. In particular, we analyzed the 
expression of PPAR-α, NAPE-PLD and c-fos in the brainstem, and of MC4R 
in the hypothalamus. 
For the brainstem, the Two-way ANOVA analysis revealed a 
significant effect of the diet (Fdiet= 6.233; df= 1/26; **P<0.01), but no significant 
effect of the treatment or interaction between the two factors (Ftreatment= 0.80; 
df= 1/26; P= 0.780; Finteraction= 2.889; df= 1/26; P= 0.078). Moreover, the 
Tukey’s post hoc test for multiple comparisons showed a significant increase 
of PPAR-α expression in OEA-treated HFD animals, compared to both LFD 
and SHIFT animals (HFD O vs LFD O= °°P<0.01; HFD O vs SHIFT O= 
^^P<0.01) (Fig. 4.10A). 
Regarding the expression of the NAPE-PLD, the results of the Two-
way ANOVA showed a significant effect of the diet (Fdiet= 9.306; df= 1/24; 
**P<0.01), but no significant effect of the treatment nor of the interaction 
between the two factors (Ftreatment= 3.055; df= 1/24; P= 0.780; Finteraction= 0.584; 
df= 1/24; P= 0.587). Moreover, the Tukey’s post hoc for multiple comparisons 
revealed that the HFD per se significantly increases the expression of this 
enzyme (HFD V vs LFD V= °P<0.05), and the same difference is maintained 
in OEA-treated animals (HFD O vs LFD O= °P<0.05). In addition, the shift of 
the diet reduces NAPE-PLD mRNA expression in OEA-treated animals (HFD 
O vs SHIFT O= ^^P<0.01) (Fig. 4.10B). 
We then proceeded analyzing c-fos mRNA levels. The results of the 
Two-way ANOVA showed a significant effect of the diet and of the treatment 
(Fdiet= 13.980; df= 1/26; ***P<0.001; Ftreatment= 0.874; df= 1/26; P= 0.360), but 
no significant effect of the interaction between the two factors (Finteraction= 
6.680; df= 1/26; **P<0.01). Furthermore, the Tukey’s post hoc test for multiple 
comparisons revealed that the exposure to HFD significantly increases c-fos 
mRNA expression in OEA-treated rats compared to both LFD and SHIFT 
animals (HFD O vs LFD O= °°°P<0.001; HFD O vs SHIFT O= ^^^P<0.001). 
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Moreover, in HFD animals, OEA increases c-fos mRNA levels compared to 
veh-treated animals (**P<0.01 vs veh in the same diet group) (Fig. 4.10C). 
 
 
Fig. 4.10: Modulation of gene expression in the brainstem after chronic OEA 
administration. Gene expression of PPAR-α (A), NAPE-PLD (B) and c-fos (C) in the 
brainstem of animals exposed to LFD, HFD or SHIFT diet and treated with either vehicle or 
OEA (10 mg kg-1, i.p.) for fourteen days. Data are expressed as mean±SEM. °P<0.05, 
°°P<0.01; °°°P<0.001 vs LFD in the same treatment group; ^^P<0.01; ^^^P<0.001 vs SHIFT in 
the same treatment group; **P<0.01 vs veh-treated controls in the same diet group. N= 4-5 per 
group. 
 
 
In the hypothalamus, we investigated the levels of expression of MC4R. The 
results of the Two-way ANOVA showed a significant effect of the diet and of 
the interaction between the diet and the treatment (Fdiet= 4.317; df= 1/27; 
*P<0.05; Finteraction= 5.362; df= 1/27; *P<0.05), but no significant effect of the 
treatment alone (Ftreatment= 1.691; df= 1/27; P=0.207). Moreover, the Tukey’s 
post hoc test for multiple comparison revealed that the HFD leads to a 
significant increase of this receptor in the OEA-treated group compared to 
LFD animals (HFD O vs LFD O= °°P<0.01). Furthermore, In the HFD animals, 
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OEA induces the expression of MC4R compared to veh-treated rats 
(**P<0.01) (Fig. 4.11). 
 
 
Fig. 4.10: Modulation of gene expression in the hypothalamus after chronic OEA 
administration. Gene expression of MC4R in the hypothalamus of animals exposed to LFD, 
HFD or SHIFT diet and treated with either vehicle or OEA (10 mg kg-1, i.p.) for fourteen days. 
Data are expressed as mean±SEM. °°P < 0.01 vs LFD/SHIFT in the same treatment group; **P 
< 0.01 vs veh-treated controls in the same diet group. N= 4-5 per group. 
 
 
In conclusion, these analyses revealed that both the exposure to HFD and 
OEA treatment (10 mg kg-1, i.p.) play a role in the expression of the genes 
analyzed. These data, together with the ones obtained from the analyses of 
the behavior and of the gut microbiota, support the thesis that OEA does not 
only affect FAO, lipid metabolism24,25 and neurotransmission8,9,11,26,27, but also 
gene expression. 
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4.4 Discussion 
The fight against obesity, considered by many as the epidemic of the 21st 
century, and the lack of a pharmacological treatment proven safe and 
effective28, is one of the main challenges for clinical research. In this scenario, 
a great deal of interest has been gained by OEA, due to its anorexiant 
effect4,8–10,26,29,30. It is known that the excessive consumption of high fat foods 
is responsible of the development of the obese phenotype in both laboratory 
animals and humans, and that a prolonged exposure to HFD (7-14 days) 
decreases the endogenous levels of anorexiant NAEs in the small 
intestine31,32. This effect may, at least in part, promote hyperphagia, 
responsible of the development of obesity. Furthermore, it has been 
demonstrated that the exposure to HFD decreases the synthesis and the 
mobilization of OEA13. 
Based on these premises, the aim of the present work was to analyze 
the effects of the chronic administration of OEA in a rat model of DIO, in which 
the obese phenotype was induced by exposing animals to HFD ad libitum for 
11 weeks. Moreover, the effects of OEA were analyzed in animals that 
underwent a shift of the diet (SHIFT animals) from HFD to LFD ad libitum from 
the first day of treatment, in order to mimic dieting. The data obtained from the 
behavioral analyses confirmed the already known hypophagic effect of 
OEA4,8–10,26,29,30, in all diet groups. Interestingly, in HFD animals, the 
anorexiant effect of OEA appears to be delayed compared to LFD and SHIFT 
groups: the delay of the onset of the hypophagic effect of OEA may be due to 
the disruption of the OEA signaling pathway that occurs upon the exposure to 
HFD, where the synthesis and mobilization of OEA is dampened13. Moreover, 
the data obtained in the present work showed that the hypophagic effect of 
OEA is observable also in SHIFT animals, although, as expected14,33, the 
change of the diet induces per se a reduction in the caloric intake during the 
first days of treatment. Interestingly, the hypophagic effect of OEA, in SHIFT 
animals, is observed earlier compared to HFD animals. This observation led 
us to hypothesize that the shift of the diet may, in part, restore the sensitivity 
to the biological action of OEA, and the imbalance between orexiant and 
anorexiant mediators that is disrupted upon the exposure to HFD34–36. 
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Therefore, novel studies are required to investigate the possible involvement 
of OEA in the secretion and action of other mediators that regulate feeding. 
Recently, it has been reported that NAEs, and OEA in particular modulate the 
secretion of GLP-1, GLP-2 and PYY30 by binding the GPR119 expressed in 
the enteroendocrine L cells37,38. 
We further analyzed the BW gain of the animals in all diet groups, both 
as difference between the first and the last day and as time course. Our data 
demonstrate that OEA is able to decrease BW gain in all diet groups 
compared to veh-treated animals, as expected. In this regard, pair feeding 
groups were introduced in order to investigate whether the effects of OEA on 
BW are only due to the reduction of the food consumed or to effects on the 
metabolism. We found that the BW of OEA-treated animals was significantly 
lower than that of pair-feeding animals in all diet groups. Regarding the day-
to-day monitoring of the BW, we found that the OEA-induced weight loss, as 
for the EI, has a different onset depending on the diet group. In fact, in HFD 
animals, the reduction of the BW gain is delayed compared to the other diet 
groups. This observation further confirms the hypothesis that OEA signaling is 
disrupted by the prolonged exposure to HFD16, that leads to a reduced 
responsivity to its anorexigenic effect39. Regarding the SHIFT animals, the 
OEA-induced reduction of BW, seems to be delayed compared to the onset of 
the effect on the EI. It could be hypothesized that OEA’s effect is dampened 
by the effect that the shift of the diet already has on weight loss. 
These observations highlight how the anti-obesity effects of OEA are 
not only due to the reduction of the food consumed, but also to effects on the 
metabolism. In fact, many lines of evidence report that OEA modulates lipid 
metabolism24,25, mainly through the activation of PPAR-α4. OEA, like other 
PPAR-α agonists, is able to increase fatty acid oxidation (FAO)24, and to 
increase circulating levels of β-hydroxy-butyrate (BHB), a marker of FAO and 
ketogenesis30. Moreover, it has been demonstrated that chronic treatment 
with OEA reduces the levels of circulating lipids and hepatic fat deposition40. 
It is well known that the exposure to HFD decreases the diversity of 
the gut microbiota and the number of total bacteria, increasing the risk of the 
development of obesity41,42. Hence, modulation of the gut microbiota could be 
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a novel approach for the treatment of obesity43. Therefore, in the present 
work, we aimed to evaluate the possible effects of chronic treatment with OEA 
on the gut microbiota, in particular on the number of total bacteria and the β-
diversity. The data obtained in this study show that OEA increases the 
abundance of total bacteria in HFD animals compared to LFD animals. 
Notably, this effect is not only due to the hypophagic effect of OEA, since the 
microbiota abundance in pair-feeding animals is comparable to veh-treated 
rats. As for the number of total bacteria, OEA influences the β-diversity of the 
gut microbiota. In fact, the data obtained from the PCoA analysis show that 
the chronic treatment with OEA modulates the β-diversity in all diet groups. In 
particular, OEA treatment reverts the decrease of OTUs observed by the 
exposure to HFD. Interestingly, this effect is not only due to the reduction of 
food consumption, since the trends of OEA-treated and pair-feeding animals 
are not comparable. These effects are confirmed by very recent finding 
showing the beneficial effects of the subchronic treatment with OEA on gut 
microbiota44. 
Overall, the data obtained with the analysis of the number of total 
bacteria and the β-diversity highlight the impact that the chronic exposure to 
HFD has on the gut microbiota, and how OEA is able to revert this trend, with 
effects that go beyond the sole reduction of food intake. 
Then, through pyrosequencing, we observed changes in the phyla, 
classes and orders of the microbial population. Interestingly, OEA is able to 
induce alterations in particular in the Mollicutes class, belonging to the phylum 
Tenericutes. Interestingly, it has been demonstrated that the class Mollicutes 
is largely influenced by HFD45, even though its role in the development of 
obesity needs to be clarified. 
These observations, in line with previous studies45,46, highlight the 
strong impact that diet has on the gut microbiota, that are at least partially 
reverted by OEA treatment. For the majority of the populations analyzed, the 
OEA-induced changes were not observable in the pair-feeding group, 
suggesting once again the effect that OEA has on the metabolism over the 
effect on feeding. Moreover, these results reflect only the changes induced on 
gut microbiota colonizing in the large intestine. Therefore, OEA-induced 
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changes on the microbiota colonizing the other parts of the intestine17,47 are 
yet to be studied. 
Lastly, we aimed to investigate whether the peripheral administration 
of OEA induces changes in gene expression in brain areas involved in the 
regulation of feeding, the brainstem and the hypothalamus. In fact, through 
the activation of PPAR-α, OEA induces the transcription of target genes in the 
liver and small intestine4. In the brainstem, we found that among OEA-treated 
animals of all diet groups, the exposure to HFD induces the expression of 
PPAR-α. In particular, in OEA-treated animals, the difference between HFD 
and SHIFT animals is possibly due to the interaction between the change of 
the diet and the treatment, since the same trend is not observed in veh-
treated animals. In the same way, HFD is able to increase the expression of 
NAPE-PLD compared to other diet groups, in both veh- and OEA-treated 
animals. As for the PPAR-α, the shift of the diet and the treatment act together 
in order to induce a statistical reduction of the NAPE-PLD, as shown by the 
comparison between HFD O and SHIFT O animals. We further analyzed the 
expression of c-fos in the brainstem. In line with the data obtained with the 
previous analyses, the exposure to the HFD increases the expression of c-fos 
mRNA levels in OEA-treated animals, compared to the other diet groups, 
particularly with the SHIFT group. Moreover, in HFD animals, the treatment 
with OEA increases c-fos mRNA expression compared to veh-treated 
animals. This is in line with previous observations, that demonstrate that OEA 
activates not only the NST and the AP, located in the brainstem, but also the 
PVN and SON in the hypothalamus8,9,29. However, the OEA-induced increase 
of c-fos expression is not observed in LFD animals. This effect may be in 
accordance with our behavioral results: on one hand, in LFD animals, the 
OEA signaling pathway is not disrupted and hence may be exposed to 
tolerance during the chronic treatment with OEA; on the other hand, in HFD 
animals, the sensitivity to OEA is being restored, therefore, in these animals, 
the OEA-induced increase of c-fos expression is still observable. 
Lastly, in the hypothalamus, we analyzed the expression of MC4R. In 
line with the brainstem, the MC4R mRNA levels are increased by HFD in 
OEA-treated animals, compared to the other diet groups, in particular with the 
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SHIFT group that may be the result of physiological riadaptations that occur 
by exposing animals to different diets. In fact, it has been reported that mRNA 
levels of this receptor significantly change among DIO, DR and LFD rats22. 
Overall, our findings show for the first time how the interaction 
between the change of the diet and the treatment with OEA modulate gene 
expression in the brainstem and the hypothalamus. However, these data 
highlight the complex alterations that occur upon the exposure to HFD, 
leading to many questions on the underlying mechanisms. Hence, the 
possible interplay between the diet, the gut microbiota, the gene expression in 
the CNS, and how OEA can modulate these factors requires further studies. 
The data of the present work broaden our knowledge about the 
biological actions of OEA, that, as has been demonstrated, are not due to the 
reduction of food intake alone, but to its action on a variety of levels, from gut 
microbiota to gene expression. 
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Chapter 5: 
General conclusions 
 
Obesity is the world’s most widespread chronic pathological conditions, 
condition that leads to the impairment of the quality of life, and acts as a risk 
factor for the development of other diseases, such as cardiovascular 
diseases, diabetes, and hypertension. Therefore, in the past years, research 
has focused on investigating the mechanisms involved in the control of 
feeding and energy balance, that has led to the discovery of a variety of 
signaling pathways, that are organized in a complex network of 
heterogeneous molecules. 
 It is well known that the metabolites produced by the gut microbiota 
directly influence the activity of the liver, of the central nervous system (CNS), 
of the adipose tissue, of the intestine, and of the skeletal muscle, thus playing 
a crucial role in the regulation of energy homeostasis and in other 
physiological processes. In fact, there is evidence supporting a strong link 
between a dysregulation of the gut microbiota and the onset of pathological 
conditions, such as obesity, type 2 diabetes, and cardiovascular diseases. 
 The increasing incidence of obesity and other eating-related disorders 
highlighted the necessity of a discovery of a novel target for the 
pharmacological treatment of these diseases and their related comorbidities. 
In this scenario, oleoylethanolamide (OEA) has rised a great deal of interest 
due to its effects on feeding: in fact, it is a known pro-satiety factor, leading to 
a reduction of body weight and food intake. 
 In the present work, the mechanism of action, the effects on the CNS, 
and peripheral peripheral organs induced by OEA i.p. administration were 
investigated. In particular, in the 2nd chapter, it has been demonstrated that, in 
contrast with previous findings, vagal afferents are not necessary to convey 
the OEA-induced signal to the CNS. Then, in the 3rd chapter, the effects of the 
peripheral administration of OEA on gene expression in selected brain areas 
and peripheral organs were investigated, and, in line with previous findings, 
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we found that OEA is able to modulate gene expression in almost all the 
areas analyzed. 
 All the results mentioned so far were obtained after an acute 
administration of OEA, from animals fed with standard chow diet. Therefore, 
we aimed to investigate the anti-obesity effects of chronic administration with 
OEA on a rat model of diet-induced obesity (DIO). We investigated, in 
particular, the changes of gene expression and of the gut microbiota, and we 
found that, overall, the chronic administration with OEA induces beneficial 
effects in the DIO rats that go beyond the sole reduction of food intake. 
A schematic representation of the results obtained in the present work are 
represented in Fig. 5.1. 
 Overall, the results of this work show that the anti-obesity effects of 
peripheral OEA administration have an impact on many different levels, from 
behavior to gut microbiota. 
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Fig. 5.1: Schematic representation of the results obtained in the present work. 
Upper panel: After peripheral administration, OEA enters the bloodstream, reaches the CNS, 
and activates several brain areas involved in the control of feeding behavior, such as the NST, 
AP, vTMN and PVN [chapter 2], where it also modulates gene expression [chapter 3], in 
animals exposed to standard chow diet. 
Lower panel: the chronic administration of OEA is able to induce changes in the expression of 
genes involved in the control of feeding behavior in the brainstem and hypothalamus, and in the 
composition, β-diversity, and amount of the bacteria colonizing the gut in animals exposed to 
HFD [chapter 4]. 
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5.1 OEA in clinical practice 
Control of food intake and appetite sensation are considered as effective 
approaches in the control of weight gain1, and several different nutraceutical 
and pharmaceutical compounds have been identified with appetite modulator 
properties, such as n‐3 polyunsaturated fatty acids2 and zinc3. One of the 
pharmaceutical agents that recently attracted more attention is OEA. 
Clinical studies have reported the effects of OEA in the control of 
weight and obesity: in fact, the daily supplementation with 250mg OEA for 60 
days significantly increased the expression of PPARα in 56 obese people 
(BMI= 30-40 kg/m2), who showed also decreased appetite and BMI at the end 
of the study4. Moreover, in another study, it has been shown that the 
supplementation with 120mg epigallocatechin-3-gallate (EGCG) and 170mg 
N-oleyl-phosphatidylethanolamine (NOPE, a precursor for OEA) for 2 months 
resulted in a significant reduction in weight and hip circumference in 38 obese 
people (BMI= 32-41 kg/m2)5. Furthermore, the supplementation with these 
same substances, but at different dosages (50mg EGCG and 85 mg NOPE) 
for 2 months induced an increase of satiety and a decrease of body weight in 
138 healthy overweight people6. However, another study showed no 
significant effects of the daily supplementation with 120 mg NOPE and 105mg 
of EGCG on BMI, body composition, feelings of hunger, or binge eating in 50 
healthy overweight subjects at the end of an 8 weeks-long study7. Inconsistent 
results of clinical studies can be attributed to the different doses of OEA, 
differences in the features of the target groups, sample size, duration of 
supplementation, and type of the supplements (alone or in combination with 
other compounds). 
Recently, the FDA approved a promising OEA supplement (Riduzone), 
that showed encouraging effects in obese people. In fact, supplementation 
with Riduzone (200 mg OEA/capsule) 2–3 times/day for 4–12 weeks 
decreased body mass index about 7–8% in 50 obese people8. 
In conclusion, more future robust human randomized clinical trials are 
surely required to facilitate the development of apposite nutritional and 
pharmacological strategies for the control of appetite in obesity. In this 
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scenario, OEA is one of the novel pharmaceutical bioactive compounds that 
has attracted more attention thanks to its effects on feeding and weight loss. 
In fact, by binding PPARα, GPR119, and TRPV1 receptors, it suppresses 
appetite, and, considering no obvious adverse effects, sufficient efficacy, and 
safety, OEA supplementation can be recommended to manage obesity and 
related abnormalities. 
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2-AG, 2-arachidonoylglycerol 
2-OG, 2-oleoyl-glycerol 
5-HT, serotonin 
ACTH, adrenocorticotropic hormone 
AEA, N-arachidonoylethanolamide (anandamide) 
AgRP, Agouti-related peptide 
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FIAF, fasting-induced adipose factor 
GH, growth hormone 
GHS-R, growth hormone secretagogue receptor 
GI, gastrointestinal 
GIP, gastric inhibitory peptide 
GLP-1, glucagone-like peptide-1 
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JJ, jejunum 
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NAE-PLD, NAPE-specific phospholipase D 
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NAT, N-acyltransferase 
NEFA, non-esterified fatty acids 
NLRPs, NOD receptors containing the pyrin domain 
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NPY, neuropeptide Y 
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PAMP, pathogen-associated molecular patterns 
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PFC, prefrontal cortex 
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TLR4, toll-like receptor 4 
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UCPs, uncoupling proteins 
VLDL, very low-density lipoproteins 
VMH, ventromedial hypothalamus 
vTMN, ventral tuberomammillary nucleus 
WHO, World Health Organization 
α-MSH, alpha melanocyte-stimulating hormone 
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FAO, fatty acid oxidation 
ME, median eminence, 
FAT, FA translocase 
IL-6, interleukin 6 
HFD, high fat diet 
LFD, low-fat diet 
BW, body weight 
EI, energy intake 
qPCR, quantitative polymerase chain reaction 
CFU, colony forming units 
PCoA, principal coordinate analysis 
OTUs, operational taxonomic units 
RT-qPCR, retrotranscription qPCR 
BHB, β-hydroxy-butyrate 
EGCG, epigallocatechin-3-gallate 
 
